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Antipsychotic medications are ubiquitous in the treatment of psychosis. However, relief from
positive symptomatology comes at a price. Extrapyramidal side-effects such as drug-induced
parkinsonism (DIP) are common and superficial similarities between features of
parkinsonism and those of psychosis hinder efforts to calibrate dosages. The boundary
between psychopathology and drug-induced disorder is a major conceptual issue in
psychiatry. Instrumental assessment promises the opportunity to more accurately gauge this
boundary.
Three hypotheses were developed: that instrumentation has a role in the assessment of DIP,
that bradykinesia is the predominant feature of DIP, and that cognitive and subjective
features of parkinsonism are present in DIP. Instrumentation procedures were selected to
objectively assess the three major features of parkinsonism: bradykinesia, rigidity, and
tremor. Subjective ratings of symptomatology associated with psychosis and antipsychotic
medication were taken. All the measures used were evaluated empirically relative to standard
observer rating criteria and the constructs underlying the assessments were examined.
The instrumental assessment techniques demonstrated moderate to high accuracy though
most did not display significant advantages over clinical rating procedures. However, a role
was proposed for performance measures in regular monitoring of bradykinesia. Stronger
support was found for the latter two hypotheses. Results indicated that a greater degree and
prevalence of abnormality relative to the control group was present in bradykinesia than the
other features of parkinsonism. Empirical evidence demonstrated the presence of a cognitive
deficit in behaviour associated with the presence of parkinsonism.
The evidence from the study also bears on issues of drug tolerability. Support was provided
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1.1.1 Conceptions of psychosis
Psychosis has been recognised in human societies for millennia and has been
accounted for in many different ways. In many societies psychosis was explained in
terms of supernatural phenomena such as possession by malevolent spirits or demons
(Zilboorg & Henry, 1941). However, there is evidence that since at least as early as
the Middle Ages psychosis could be regarded in terms of sickness, and thus might be
amenable to medicine rather than exorcism (Allderidge, 1979).
Depressive disorders, often referred to as melancholy, were known to be distinct
from the florid insanity of schizophrenia and mania. Melancholy was thought to
result from a disturbance of the humours, specifically a predominance of black bile.
The first formal account of psychosis was produced by Kraepelin in the 19th century
(see Kraepelin, 1986) who classified the previously uncategorised insane masses into
those suffering schizophrenia (which he termed dementia praecox) and those
suffering affective disorder.
The major psychoses have always been viewed in the context of prevailing theories
of mental function and dysfunction. Different schools of thought have accounted for
psychosis using, among others, biological models, psychodynamic models, and
learning models. In recent years, biological accounts of psychosis have increasingly
taken precedence over other accounts.
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Despite the influence of Kraepelin's classification of psychosis into two forms, the
concept of a single psychosis is an enduring one. Noted formulations of this
hypothesis have been published by Greisinger, who used the term "enheitepsychose"
to identify the concept he described, and Crow (1995).
Crow's account posits a continuum disorder with varying degrees of affective and
cognitive dysfunction. At one end of the continuum lies a disorder characterised by
purely affective disturbance, at the other a disorder characterised by purely cognitive
disturbance. Terms such as schizophrenia and major affective disorder are thus labels
for patients whose condition may be represented as being towards one other end of
the continuum.
Accounts such as these emphasise the considerable overlap between schizophrenia
and major affective disorder in a number of parameters, including clinical
phenomenology, treatment response, outcome measures, and psychosocial
competence. It is true that significant similarities in presentation exist between many
cases of schizophrenia and major affective disorder, that similar if not identical
medication regimes are frequently used to treat schizophrenia and major affective
disorders, that the same rating scales may be used to assess severity of
symptomatology in schizophrenia and major affective disorder, and that social
competence may be similarly impaired in schizophrenia and major affective disorder.
However, most workers now regard the distinction between schizophrenia and
affective disorder as clinically valid.
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1.1.2 Models of symptomatology
Recent research investigations into the aetiology of psychosis have been concerned
primarily with biological correlates of observable features of psychosis, particularly
the negative symptoms of schizophrenia. The distinction between positive and
negative symptoms is a concept used originally in neurology (Berrios, 1985).
Positive symptoms are those abnormal by their presence. In schizophrenia these
include hallucinations, delusions, certain forms of thought disorder, and some bizarre
behaviours (Carpenter et al., 1988). Negative symptoms are those characterised by an
absence of normal function. These may include affective blunting, ideational
constriction, poverty of speech, diminished sense of purpose, and reduce social drive
(Carpenter et al., 1988).
The terms "negative symptoms" and "deficit symptoms" are sometimes used as if
interchangeable though other authors distinguish them in terms of the permanency of
the symptoms (Carpenter et al., 1988; Fenton & McGlashan, 1994). Within this
conception, the term "negative symptoms" is used only as a descriptive term and
does not imply causality. Deficit symptoms are thus characterised as negative
symptoms which are intrinsic to the disease process and are enduring and permanent.
Crow (1980) postulated the existence of two forms of schizophrenia, termed type I
and type II. Patients with type I schizophrenia exhibit normal brain morphology and
display only positive symptoms of schizophrenia. In contrast, patients with type II
schizophrenia exhibit abnormal brain morphology and may display prominent deficit
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symptoms in addition to positive symptoms. Within this account, all patients will
exhibit positive symptoms at some time, though only those with type II
schizophrenia will exhibit deficit symptoms. Although the deficit symptoms of type
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However, other workers have suggested that there may be more than two types of
schizophrenia. Andreasen et al. propose that three types of schizophrenia may be
distinguished (Andreasen et al., 1990). Using the Scale for the Assessment of
Negative Symptoms (SANS; Andreasen, 1983) and the Scale for the Assessment of
Positive Symptoms (SAPS; Andreasen, 1984), patients may be divided into
"positive", "negative", and "mixed" groups dependent upon the form of symptoms
predominating. A similar pattern of results has been found (Kay, 1991) using the
Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987).
Further, cross-sectional analyses of symptom prevalence have suggested that the
delineation of symptomatology into two (positive and negative) categories may be
inadequate. On the basis of factor analysis Liddle (1987) segregated individual
symptoms into three syndromes. The symptoms formed clusters which Liddle termed
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psychomotor poverty, disorganisation, and reality distortion. Other authors have
described four or even five domains of psychopathology (Carpenter et ah, 1988).
1.1.3 Accounts of deficit symptomatology
Despite the above caveats, the concept of deficit symptomatology in psychosis
remains a valid and useful one. Deficit symptomatology has been recognised as a
central component of psychosis since at least the time of Kraepelin (who termed
schizophrenia dementia praecox), and retains a pivotal role in modern conceptions of
schizophrenia such as that of Crow (1980). Within Crow's formulation deficit
symptomatology is regarded as being present only in a proportion of cases of
schizophrenia but progressive and irreversible when present. The severity of deficit
symptomatology is held to be independent of the severity of positive
symptomatology.
However, other authors argue that the severity of positive and negative symptoms are
negatively correlated, and that the positive-negative symptom distinction represents
opposing ends of the symptom continuum (Andreasen and Olsen, 1982).
The independence of positive and deficit symptomatologies is supported by the work
of Carpenter et al., (1988) who make the fundamental distinction previously noted
between primary and secondary negative symptoms. Primary negative symptoms are
persistent and pervasive deficits which are intrinsic features of the illness. In
contrast, secondary negative symptoms are more effervescent state phenomena
present due to factors such as drug effects or a lack of social stimulation.
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Carpenter et al. (1988) state that well-informed physicians are able to reliably
distinguish primary and secondary negative symptoms, enabling the categorisation of
patients into deficit and non-deficit groups. In a later study, the diagnosis procedure
was repeated with a previously categorised group, the authors (Amador et al., 1999)
finding 83% agreement on designation of deficit status, and 88% agreement on the
non-deficit categorisation.
The importance of distinguishing primary and secondary deficit symptoms lies in the
implications for treatment outcome. The presence of primary deficits has been linked
with greater periods of hospitalisation, a poorer employment record, impaired social
functioning, greater severity of overall symptomatology, and lower scores on global
outcome measures, the strongest association being with impaired social functioning
(Fenton & McGlashan, 1994). Further, while primary deficits are enduring features
of the disease process and relatively unresponsive to treatment, secondary deficits
can be alleviated by modification of treatment regimes or provision of greater social
stimulation.
In addition to observer-ratings of the permanency of negative symptoms, a wealth of
evidence has been presented of impairment on common neuropsychological tests. It
is now clear that a constellation of genuine deficits exists in psychosis. In
schizophrenia, impairment has been found in long-term episodic memory (Stip &
Lussier, 1996) and in semantic memory (Frith, 1992); a common theme in these
studies is that access is impaired rather than the stores themselves. Contrary to these
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assertions, evidence has been presented of impairment to memory stores (Pantelis et
al., 1997), though this deficit was less debilitating than the impairment in processes
controlling access to the contents of stores. Extensive evidence also exists of
impairment in short-term memory processes.
Many recent investigations into neuropsychological impairment in schizophrenia
have made use of the working memory model developed by Baddeley (1990). The
proposed system is composed of three elements: the central executive, the
phonological loop, and the visuo-spatial sketchpad. Shallice's Supervisory Attention
System (SAS; Shallice, 1988) is cited as a model which performs the functions of the
central executive and is consistent with existing evidence.
A deficit in executive function is well-established in schizophrenia, impairment
being found on neuropsychological tests such as the Wisconsin Card Sort Test
(WCST, Nelson, 1976; Goldberg et al., 1987), Stroop (Liddle & Morris, 1991),
Tower of London (Pantelis et al., 1997), and Continuous Performance Task (Frith et
al., 1991). Impairment has been demonstrated in both verbal (Fleming et al., 1995)
and spatial (Fleming et al., 1997) short-term memory. Nathaniel-Jones et al. (1996)
suggested that the apparent impairment in executive performance is simply the
product of these sub-system impairments. Though evidence exists of impairment in
both verbal and spatial skills, it has been suggested that relative impairment in verbal
abilities may be characteristic of schizophrenic performance (Goldberg et al., 1993;
Taylor et al., 1981).
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Other authors have hypothesised that the deficit in schizophrenia is not specific to
either the central executive or any of its subsystems (Pantelis et al., 1997; Salame et
al., 1998); they propose that impairment results from a generalised deficit in
processing efficiency, termed bradyphrenia. This form of impairment has been
frequently described in parkinsonism and represents a generalised slowing of
information processing. Parallels are drawn with changes due to ageing, Brebion et
al., (1998) suggesting that "processing speed may be the primary limit to cognitive
performance in schizophrenia as it is in the elderly". However, other evidence
indicates that not all cognitive processes are affected evenly, this being "counter to a
hypothesis that the cognitive dysfunction in schizophrenia is due to a single,
generalised deficit" (Schatz, 1998).
It should be noted that a pattern of differential deficits, performance being relatively
more impaired in some domains than in others forms a strong argument that deficits
are genuine and do not result from factors such as lack of motivation (Gruzelier et
al., 1988). Further, it has also been confirmed that the neuropsychological deficits
found in schizophrenia are independent of medication effects (Pantelis et al., 1997),
and are present in first-episode non-medicated patients (Saykin et al., 1994).
However, there is considerable variation among individual patients: on any given
task, only about half perform in the subnormal range (Stip, 1996).
Evidence of similar impairment exists in the major affective disorders though the
literature is far less comprehensive than that for schizophrenia. This is particularly
true for bipolar disorder; probably due at least in part to the difficulties of testing
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patients in a manic phase. However, there is evidence for impairment in visual-
spatial tasks (Taylor et al., 1981) and in executive function (McGrath et al., 1997).
Amongst depressed patients there is similar evidence for impairment in spatial tasks
(Taylor et al., 1981) and executive function (Austin et al., 1999; Hart et al., 1998).
As in schizophrenia, neuropsychological impairment within major affective disorder
groups (bipolar and unipolar) is apparent in only a limited proportion of the group,
other members of the group performing within the normal range (Goldberg et al.,
1993).
The majority of papers published in this field indicate a pattern of relatively more
severe impairment in verbal abilities in schizophrenia, and relatively more severe
impairment in visual-spatial abilities in major affective disorder (Goldberg et al.,
1993; Taylor et al., 1981), though some investigators did find evidence for the
opposite patterns (Austin et al., 1999; Hart et al., 1998). However, it is worth noting
that in almost all studies directly comparing schizophrenia patients with major
affective disorder patients, the evidence suggests relatively greater overall
impairment in the schizophrenia group (Goldberg et al., 1993; Taylor et al., 1981)
Though there are differences between the patterns of impairment found in
schizophrenia and major affective disorder there are commonalities. Executive
function is impaired in both schizophrenia (Frith et al., 1991; Goldberg et al., 1987;
Liddle & Morris, 1991; Pantelis et al., 1997) and major affective disorder (McGrath
et al., 1997), and significant psychomotor slowing may be present in both
schizophrenia and depressive disorders (Purcell et al., 1997). However, even where
17
there are similarities in performance it should not be assumed that there are common
mechanisms mediating impairment.
The difficulties inherent in studying these issues must not be underestimated. The
existence of efficacious treatment for psychosis provides an ethical imperative to
treat though the use of this treatment may (as discussed later) contaminate the
assessment of the underlying disorder.
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1.2 Antipsychotics
The introduction of effective antipsychotics in the 1950s revolutionised psychiatry.
Other types of drugs have also had a great impact, for instance that of efficacious
antidepressants. However, despite the fact that antipsychotics have promised so
much their use remains plagued with difficulties. These difficulties, combined with
the ubiquity of antipsychotics in psychiatric practice, make the continued study of
antipsychotics both more relevant and more urgent than that of other drugs.
1.2.1 The development of antipsychotics
That there are continuing problems with antipsychotics stems in part from their
empirical development. The first antipsychotic to become publicised was
chlorpromazine which was brought to the world's attention by Henri Laborit, a naval
surgeon. Laborit found that chlorpromazine, investigated as an agent to dampen
autonomic activity during and after surgery, could induce affective and behavioural
changes. Patients were described as being "calm and somnolent, with a relaxed and
detached expression". This "twilight state" of complete equanimity was later termed
"ataraxy", meaning "without anxiety". The state of ataraxy was contrasted with the
effects of existing agents such as morphine or the barbiturates.
Recognition of this, at the time unique, action provided the impetus for the
commercial development and production of chlorpromazine. Within two years,
following the seminal paper of Delay and Deniker (1952), chlorpromazine had
become widely used and was a commercial success. In the following years many
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other antipsychotics were developed. At first these agents were highly derivative of
chlorpromazine but later agents were less closely related. However, all shared the
same goal of reducing the symptoms of psychosis without sedation.
Efficacy of treatment of psychosis can be evaluated in a number of different
domains. The efficacy of antipsychotics is clearly established in terms of their action
on positive features (Cole, 1964). Levels of arousal and anxiety are reduced and
hallucinations and delusions are suppressed. This specific action is the basis for class
membership, distinguishing antipsychotics from tranquillisers, benzodiazepines etc.
However, it is widely stated that around 25-30% of patients do not respond well to
antipsychotic treatment and the true figure may be higher than this (Kane, 1995).
Despite this, the action is sufficiently specific to be used as a criterion for class
membership. Treatment efficacy in other domains is suggestive rather than proven.
In particular, evidence for efficacy in treatment of negative or deficit features is
controversial.
Much recent research effort has been directed to discovering the mechanisms of
antipsychotic efficacy. It is hoped that more efficacious and more tolerable drugs
may arise from a greater understanding of the pathophysiological mechanisms of
psychosis. Existing evidence from both laboratory (Creese et al., 1976) and clinical
(Johnstone et ah, 1978) settings suggests that the efficacy of antipsychotic agents
such as chlorpromazine is related to central blockade of D2 dopamine receptors.
However, these drugs have actions at a huge variety of other receptor sites.
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1.2.2 Extrapyramidal signs
Though alike pharmacologically, the different types of antipsychotics are very varied
chemically. These variations affect factors such as the degree of specificity of action.
This can in turn alter the tolerability of the agent. The most pervasive adverse effects
associated with antipsychotics, extra-pyramidal signs (EPS), have, like the beneficial
effects, been linked with central dopamine blockade. The propensity of
antipsychotics to cause EPS was noted even at their introduction by Delay and
Deniker (1952). However, this action was viewed as unimportant, and a formal
report of the propensity of chlorpromazine to induce EPS was not produced until
1954 (Steck, 1954).
EPS comprise a number of different forms of movement disorder:
All major signs of parkinsonism (bradykinesia, rigidity, tremor) and
Parkinsonism
possibly affective and cognitive changes in mental state.
Involuntary motor activity in which muscle action is sustained at a
point of maximal contraction, frequently resulting in a twisting
distortion of the affected part.
Visible signs of discomfort and unease, difficulty in sitting still.
Subjective symptoms of inner restlessness, anxiety, and disquiet.
Involuntary movements; often predominantly in orofacial regions






Over the period since EPS were first recognised, opinions on their importance have
changed dramatically. At times the development of EPS in a patient has been used as
a means of adjusting the dosage required, the presence of EPS indicating that the
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dose was sufficient to ensure therapeutic efficacy (see Haase, 1985). More recently,
and to the present day, EPS are viewed as undesirable side effects. However, the fact
that these highly prevalent effects are an intrinsic component of the action of
antipsychotics led to the adoption of the term "neuroleptic", or "that which grips the
nerve", as a coverall term for typical antipsychotic agents. Had other suggestions
been adopted these drugs may have been named after their beneficial qualities, as
'ataractics'. The relationship between the beneficial and adverse effects of these
agents is only slightly clearer now.
These disorders are undoubtedly very common. Though a wide range of different
figures have been presented for the prevalence of EPS in differently defined patient
groups, most are in the range 40-85% of typical antipsychotic treated patients
(Casey, 1989).
The different forms of EPS may also be classified by their relationship with
antipsychotic drug treatment (after Owens, 1999).
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The EPS literature is to a large extent dominated by tardive dyskinesia (TD). A
recent search of Medline found 478 papers concerned with tardive dyskinesia while
only 94 concerned with drug-induced parkinsonism (DIP) were published within the
same period of time. This may be due to medico-legal issues, particularly as much of
the work originates from the US. Dystonias are much less studied than other forms of
EPS. This is perhaps due to a widespread belief that they are less common than other
forms of EPS though this may not be so when high potency antipsychotics are used.
Akathisia is perhaps least often the subject of systematic study. This neglect is
possibly due to the difficulties of distinguishing akathisia from psychomotor
agitation occurring as a feature of psychosis. Despite being the first form of EPS to
be identified, DIP has been less studied in recent years. Since its first recognition,
DIP has at different times been viewed as an inevitable consequence of antipsychotic
medication, being a marker of treatment efficacy, or an unfortunate but treatable side
effect unrelated to efficacy.
The concept of a threshold dose for the development of EPS was noted above.
Proponents of this hypothesis stated that a threshold, particular to each individual
patient, existed. Below this threshold lay therapeutic efficacy, above it toxicity,
presenting usually as parkinsonism. Haase proposed that an optimal dose of
antipsychotic for the individual could be determined by increasing dosage slightly
until the first indications of parkinsonism were apparent (the development of
micrographia was to be used as an indicator) and then reducing it slightly.
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Recent use of brain imaging techniques has revived threshold theories of
antipsychotic efficacy. Studies have indicated the existence of a threshold of D2
receptor occupancy in the striatum, above which EPS is apparent (Farde et al., 1992;
Scherer et al., 1994). This implies the presence of a narrow dosage band of
therapeutic efficacy. Below this band dosage is insufficient for treatment to be
effective, above it dosage is sufficient to cause EPS. However, these accounts are yet
to trigger any wholesale revolution in psychiatry.
Though often dismissed as merely troublesome side effects, the boundaries between
EPS and features of psychosis form a major issue in modern psychiatry. In particular,
the relationship between parkinsonism and deficit features of psychosis bears on
issues of diagnosis, medication, drug efficacy, and treatment outcome.
1.2.3 Atypical antipsychotics
Following the evermore widespread adoption of chlorpromazine, other antipsychotic
agents were introduced, all of them derivatives of chlorpromazine, and with similar
modes of action. Other types of antipsychotics were developed too, differing to
greater or lesser extent in properties and actions.
Increasing awareness of the prevalence of EPS drew attention to the lack of
tolerability displayed by all extant antipsychotics. The next wave of drug
development was theory-driven, in contrast to the empirical development of
chlorpromazine. The mesolimbic dopamine system had been identified as the site of
schizophrenic pathophysiology, and the nigrostriatal dopamine system implicated in
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the production of EPS. Dopamine receptors had been recognised as falling into Di
and D2 groups (since further sub-divided into various Drlike and D2-like types), D2
receptors being more common in the mesolimbic dopamine system and Di receptors
being more common in the nigrostriatal system. Thus, drugs were developed with the
attention of focussing on the mesolimbic system, acting more selectively at D2
receptor sites. Sulpiride, a substituted benzamide, and the first antipsychotic to be
labelled "atypical," was one of these.
In this context, "atypical" refers to antipsychotic agents which differ from "typical"
antipsychotics in their having lowered propensity to induce EPS in the presence of
equivalent therapeutic efficacy. Preliminary examination of sulpiride led to the
conclusion that it did indeed have a lower propensity to induce EPS. However, this
optimism was short-lived. Further studies were conducted in which care was taken to
ensure that the sulpiride group received doses of equivalent therapeutic strength to
those received by the comparison group (receiving a typical antipsychotic). The
results of these investigations indicated that the advantages of sulpiride were less
striking than previously thought.
Single system pharmacology is not always viewed as the solution to the problem of
neurological side effects. Less selective drugs, previously derided as "dirty," may
provide more of the benefits promised by so-called "clean" agents. Clozapine in
particular has radically changed perceptions of schizophrenic psychopharmacology.
A dibenzodiazepine, clozapine was developed as an antidepressant and was first
registered in 1960. However, concern grew over its adverse effects on granulocytes
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and it was withdrawn in 1975 following a number of deaths. It has since been re¬
introduced for use in schizophrenia though regular blood testing remains a condition
of its use.
The evidence suggests that clozapine is truly different from typical antipsychotics. In
a large multi-centre trial clozapine was compared with chlorpromazine with
prophylactic antiparkinsonian medication in cases of treatment-resistant
schizophrenia. The results demonstrated a clear advantage for clozapine in terms of
reduction of positive symptomatology and neurologic tolerability. Further studies
have since confirmed that clozapine is not only superior to typical antipsychotics in
selected groups but at least as effective as other agents in non-selected groups of
schizophrenics.
Equally extensive evidence has accumulated of a strikingly low liability to cause
EPS. Clozapine causes little or no dystonia and the respective incidences of akathisia
and DIP are greatly reduced. The risk of tardive dyskinesia is probably also very low
though the evidence for this is less clear.
Clozapine is a drug apart from typical antipsychotics in pharmacological terms too. It
exhibits only low occupancy rates of D2 receptors and its range of actions is broader
even than typical antipsychotics. Affinity for serotonergic receptors is particularly
high. More recent conceptions of dopamine neurophysiology (Jaber et al., 1996) sub¬
divide Di and D2 receptor types into Dj-like and D2-like sub-types. To the extent that
clozapine does act at DA receptor sites, its actions may be at D4 receptors (D2-like)
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which are thought to be localised to the cerebral cortex. However, it is the broad
spectrum of action of clozapine which is assumed to be key to its therapeutic
advantages though the mechanism by which it achieves these benefits is as yet
unclear.
Since the successful re-introduction of clozapine, efforts have been directed at
developing other atypical antipsychotics which may achieve the therapeutic efficacy
and low level of neurological side effects of clozapine without the increased risk of
other adverse effects. To this end a number of other atypical antipsychotics have
been introduced, all of which to some extent achieve their aims. However, many
authors believe that clozapine's propensity to cause neurological side effects is still
uniquely low (Miller et al., 1998).
1.2.4 Subjective experience of antipsychotics
The promise of atypical antipsychotics is of efficacious treatment of positive
symptomatology free from the adverse neurological effects associated with typical
antipsychotics. This freedom may extend beyond the overt physical signs of EPS to
include the negative subjective experiences often associated with typical
antipsychotic medication. These experiences are far from uncommon and may play a
major role in treatment success.
Non-compliance with medication regimes is very high in clinical practice,
particularly amongst outpatients. Assessments of clinically significant non¬
compliance in inpatients range from 7%-57% (Weiden et ah, 1991), and up to 73%
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amongst outpatients over a 2-year follow-up (Serban & Thomas, 1974). Earlier
accounts of non-compliance most commonly attributed it, if not to factors associated
with the illness, then to physical EPS (Van Putten, 1974). More recently the same
author considered that this relationship might be mediated by the subjective
components of EPS (Van Putten & May,1978). Other workers have confirmed this
relationship between negative subjective experiences and non-compliance (Hogan &
Awad, 1992, Awad & Hogan, 1994).
Descriptions of these negative subjective experiences frequently centre around
complaints of feeling "fuzzy, woolly, lacking energy, unable to think clearly, like a
zombie, restless, etc." A number of different terms have been coined for complaints
of restricted cognition and emotion resulting from antipsychotic medication:
"akinetic depression" (Rifkin et al., 1975; Van Putten & May, 1978), "neuroleptic
dysphoria" (Hogan & Awad, 1992, Awad & Hogan, 1994), "neuroleptic-induced
anhedonia" (Wise, 1991). Though these experiences are often subsumed under the
catch-all term "dysphoria", a closer examination of the descriptors used indicates that
the sensations are not common to all patients and that there may be different facets to
the experience.
Some authors argue that the negative experiences may actually constitute depression.
"Pharmacogenic depression" was noted in the German literature during the 1960s
(Bandelow et ah, 1992). Van Putten and May (1978) termed their conception of
antipsychotic-associated dysphoria "akinetic depression", making an explicit link
with DIP. However, it has also been argued that depression seen in schizophrenic
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patients may not be linked with medication. Symptoms of depression may be
accounted for in terms of "reactive depression" to the negative life events of being
diagnosed with a serious mental illness, hospitalisation etc. This account has been
dismissed (Knights & Hirsch, 1981) as "intellectually weak". These authors also
discounted the account of Van Putten and May (1978), having found that depression
persisted after treatment of even very mild signs of EPS. Knights and Hirsch argued
that depression was an intrinsic part of the disease process of schizophrenia. More
recently however, Bandelow et al. (1992) found higher levels of depression in
patients treated with antipsychotics than in non-treated patients, and evidence of an
association between EPS and depression. In light of all these findings it seems
possible that depression may occur both as a component of psychosis and as a
consequence of antipsychotic medication.
Reports of the subjective experience of antipsychotics in normals (Belmaker and
Wald, 1977) are consistent with those of patients. Belmaker and Wald reported
sensations of inner restlessness, anxiety, inability to relax, poor concentration, and
irritability, coincident with a "paralysis of volition" and a lack of physical and
psychic energy. They described a feeling that they felt unable to initiate tasks though
they could perform them if demanded to do so. A 1992 review of literature
concerned with the effects of typical antipsychotics in normals (Hollister, 1992)
found evidence that chlorpromazine and reserpine had been associated with
complaints of restlessness, depression, and feelings of unreality and
depersonalisation. Similar complaints of nerves and apprehension were reported after
a double-blind trial of reserpine.
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The different, and sometimes apparently paradoxical, facets of the negative
subjective experience may reflect different features of physical EPS. Particular
negative experiences have been found to be reliably associated with particular forms
of physical EPS (see table below). In fact, negative subjective response to
antipsychotics early in treatment is predictive of physical forms of EPS later in
treatment (Hogan & Awad, 1992).
Form of EPS Characteristics of associated subjective experience
Dystonia Fear and anxiety (Casey, 1994).
The efficacy of atypical antipsychotics has also been assessed in terms of quality of
life. Quality of life measures are widespread in other areas of medicine but are
underused in psychiatry. Awad and Hogan (1994) argue that quality of life provides
a framework in which many aspects of medication response may be considered.
Relief from schizophrenic symptomatology, side effects, psychosocial factors.
Where quality of life measures have been used they have indicated clear benefits of
atypical antipsychotics over typical drugs. Meltzer (Meltzer et al., 1990) reported the
cases of 38 treatment-resistant schizophrenic patients who were switched to
Akathisia





Lack of physical and psychic energy. Feeling "mummified
and dull" (Van Putten and May, 1978), or "like a zombie"
(Awad, 1993).
30
clozapine treatment. It was found that significant improvements on quality of life
measures (Quality of Life scale; Heinrichs et al., 1984) were apparent after six
months of clozapine treatment. After 12 months of treatment, continued
improvements were seen on this index (Meltzer, 1992). Meltzer stated that these
improvements reflected "highly significant clinical changes that are rarely, if ever,
seen after switching typical neuroleptic drugs in patients who are poor responders to
three or more other typical neuroleptics and in the relatively older schizophrenics
studied here."
Naber (1995) reported the use of a measure of Subjective Well-being under
Neuroleptics (SWN; Naber et al., 1994). This measure is intended to be specific to
the negative effects of typical antipsychotics on quality of life. Naber states that
significant correlations are found between results of this scale and other measures of
quality of life. Scores on this scale were found to be significantly higher in a
clozapine treated group than in a group receiving typical antipsychotics (haloperidol
and flupenthixol), despite the fact that the clozapine group had been negatively
selected for this medication due to therapy resistance or major side effects with
typical antipsychotics.
Despite the influence that negative subjective experiences of antipsychotics may
have on treatment success, they are often ignored. The assessment and identification
of these phenomena is a major obstacle, and misdiagnosis is common. The
superficial similarities between the dysphoria induced by medication and features of
the illness being treated are considerable. There may be significant
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phenomenological overlap between a number of constructs: deficit features of
schizophrenia, psychomotor slowing as a feature of depression, antipsychotic-
induced deficits, parkinsonism. Efforts to disentangle these issues require a full




1.3.1 Features of parkinsonism
This section will cover the features of parkinsonism, noting their properties and the
mechanisms proposed to underlie them. Much of the evidence that will be presented
here derives from studies of Parkinson's disease. Though it would be preferable to
rely only upon evidence derived from DIP, there is a scarcity of work in this
category. Caution must be taken in inferring from one form of parkinsonism to
another.
1.3.1.1 Bradykinesia
Bradykinesia is, in most cases, the most salient feature of parkinsonism, particularly
upper body bradykinesia (Quinn, 1995). Taken literally, bradykinesia means simply
"slowed movement", however it is much more than this. Manifestations of
bradykinesia include diminution or poverty of background motor activity, slowed
execution of movements, difficulties in initiation, increased fatigability, diminishing
amplitude of repetitive movements, impairment in sequencing of movements. This
symptom complex is difficult to describe and define, its expression varying not only
from patient to patient but from day to day within the same patient.
Different authors have used varying terms to refer to bradykinesia. 'Akinesia' is
common, particularly amongst neurologists. However, strictly used the prefix 'a-'
must refer to a total lack of movement rather than the more moderate abnormality of
most cases of parkinsonism. 'Hypokinesia' might appear more appropriate though
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while it has been used by some authors (e.g. Bloxham et al., 1984) for whatever
reason it is not favoured. It has been suggested that 'akinesia' be used to refer to a
poverty of movements produced and 'bradykinesia' be used to refer solely to a
slowing in the execution of movement (Delwaide and Gonce, 1988). Though there is
some evidence to support a distinction of this nature (1.3.1.1.1) this proposal has not
been widely adopted.
1.3.1.1.1 Manifestations of bradykinesia
The most common major manifestations of bradykinesia were noted above. In this
section these manifestations will be more comprehensively described.
Diminution or poverty of background motor activity presents as a lack of normal
non-purposive movements. Adjustments of posture, the continuous non-goal-directed
background motor activity seen in normals, are absent. The patient with
parkinsonism may sit almost immobile. When movements are made the execution is
usually slowed to at least some degree. Though actions may be performed
competently and even accurately, they occur at a slower speed than normal. This has
been demonstrated in tests both of pure movement speed (Evarts et al., 1981) and in
tasks ofmotor control (Meier & Martin, 1970).
Difficulties in initiating movements are common in parkinsonism. The patient may
have an action in mind to perform but is unable to do so. Vaughan (1986) a
Parkinson's disease patient describes both the extent of his disability in normal
activities of daily living (due to an inability to initiate movements) and his ability to
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run for miles once started. Frequently an external stimulus may be necessary to
trigger movements. Sacks (1973) describes devices which have proven effective as
aids to initiate movement: lines on the floor to step over, tiny balls of screwed-up
paper which can be dropped with a minimum of movement to then trigger a much
greater movement. This reliance upon external stimuli to trigger movements, and the
associated lack of self-initiated movements has led to parkinsonian patients being
described as 'environmentally-driven' (Sacks, 1973). However, this term implies not
only an inability to initiate actions held in mind, but a failure to plan self-driven,
'willed' movements. The extent to which this is true will be addressed later (1.3.1.5).
One of the first indications of incipient parkinsonism is often a report of abnormal
tiredness and lassitude. The patient may report that they are easily fatigued and
become rapidly tired. When investigated experimentally, strength may be normal at
first yet rapidly tail off (Onuaguluchi, 1964). Over the course of a time period in
which normal performance remains constant, performance levels amongst
parkinsonian patients decay rapidly. This inability to maintain strength over
relatively short periods of time may play a role in the manner in which the amplitude
of repetitive movements can be seen to diminish.
This particular manifestation of bradykinesia is commonly used as an assessment
technique in clinical practice. The patient is asked to hold their hands outstretched
horizontally in front of their body, and then to repeatedly pronate and supinate the
hands, turning them from palm-down to palm-up. Normals asked to perform this task
do so until instructed to stop. Parkinsonian patients may complete only a few cycles
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before the amplitude of the movements has decreased to nothing and the hands are
still.
Few patients display all of the manifestations of bradykinesia described.
Bradykinesia is a symptom complex that resists precise description and definition.
Not only do some patients not exhibit some of the manifestations, those they do
exhibit may only be apparent in some situations. A comprehensive account of
bradykinesia must describe the situations in which impairment is found and not
found. It must note where impairments thought to be associated can be proven to be
dissociable. And it must attempt to clarify apparently contradictory findings.
Impairments in movement initiation and speed have been long demonstrated, most
often by the use of reaction time tests (Wilson, 1925). Though these two impairments
do show an association, evidence exists that they can occur independently. Later
workers have used a reaction time paradigm which allows the separation of the
latency before the response is initiated from the time taken to complete the response
movement (Evarts et al., 1981). Evarts found that in some trials delayed initiation
was followed by normal speed ofmovement, in others a normal time reaction time to
initiate the movement was followed by an abnormally slow movement time. The
different patterns could be seen in different patients or in the same patient in opposite
arms. This pattern of performance can only be found if the two impairments, a deficit
in initiating movements and a decrease in speed of execution, are mediated by
different mechanisms.
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The demonstrated dissociation between impairments in movement initiation and
speed of execution supports the differential use of the terms 'bradykinesia' and
'akinesia' noted earlier (Delwaide & Gonce, 1988). In fact the authors of the work
(Evarts et al., 1981) use the term bradykinesia to refer solely to the impairment in
speed of execution and not to the impairment in initiation (as indicated by slowed
reaction time). However, as previously stated this practice has not been more widely
adopted.
The above dissociation between performance on measures of movement initiation
and speed of execution is far from the whole story. In a second experiment by the
same authors, performances in simple reaction time (RT) and choice reaction time
(CRT) conditions were compared. In a simple RT condition, the same stimulus is
presented on every trial; the required response is constant too. In the CRT condition,
the stimulus differs from trial to trial; for each stimulus a different response must be
made. It was found that parkinsonian patients were almost unimpaired on CRT
though they had shown a significant deficit on tests of RT (Evarts et al., 1981).
Evarts et al. note that this is opposite to the expected pattern of results, formed on the
basis of similarities between ageing and parkinsonism. Parallels between the effects
of parkinsonism and of ageing are not uncommon (Dobbs et al., 1992). However, this
finding is directly opposite to that found in elderly subjects in whom CRT
performance is relatively more impaired than simple RT performance. In elderly
subjects this is due an increase in initiation time in CRT, attributed to slowed
information processing. Unfortunately the published results of Evarts et al. do not
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allow the contribution of initiation and movement times to reaction time performance
to be investigated in this experiment.
If it were assumed that movement speed was similar in the two conditions (it is
certainly unlikely that movement is quicker in the CRT condition), the results appear
to imply a much quicker speed of information-processing in the CRT condition in the
parkinsonian group than in the control group (Bloxham et al., 1984). Given the
unlikelihood of this explanation, one must conclude that the parkinsonian group are
unimpaired (or relatively so) on CRT but are impaired in the simple RT condition.
Bloxham et al. argued that normals respond more quickly in the RT condition than
CRT because they know what movement will be needed and can pre-program it.
Patients with Parkinson's disease, in contrast, do not make use of this information
and select their response only as the target is seen. Thus, the initiation time deficit in
the simple RT condition is relatively much greater than that in the CRT condition.
An earlier work using a different paradigm (a target-tracking task) found similar
evidence of an inability to make use of prior information in planning movements
(Flowers, 1978). It was demonstrated that parkinsonian patients performed poorly on
a manual tracking task in which the target followed a repetitive (and thus predictable)
path in one dimension. In certain trials, the target changed direction while concealed;
controls could nevertheless predict the target's movement and continue to track it
accurately but the patient group was disadvantaged further. Flowers suggested they
were, "tied more directly to current sensory information, responding to events rather
than anticipating them."
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These findings too have since been clarified further (Bloxham et al., 1984),
elucidating more accurately the situations in which performance is impaired. In the
study of Bloxham et al., patients performed well on a tracking task (even at speeds
too quick for use of visual feedback). This was true for both predictable (normals
known to pre-program movements) and unpredictable tracks (both groups rely on
feedback so prediction and pre-programming are not factors). In order to
accommodate the results of Flowers, Bloxham et al. discussed the concept of
"segmenting" in control of action. In this account, a new unit of movement is
initiated (consciously) at each segmentation point; once initiated, control is automatic
and ballistic. This study differs from that of Flowers in that the movement required is
circular rather than a one-dimensional sweep. Therefore there is no obvious
segmentation. When a new unit of movement must be initiated at the end of each
sweep an impairment is found but a circular task is unaffected by initiation problems.
According to Bloxham et al., patients are able to use prior information to control the
form of a movement but not to initiate or pre-select it (particularly without an
external trigger). A delay in initiation may still occur, but the hypothesis has been
refined to explain a low efficiency of response to prior warnings (i.e. a failure to pre¬
select motor programs).
Perhaps the most notable findings are not the situations in which performance is
impaired but the number of situations in which performance is normal. These
findings have a bearing on determining the mechanisms responsible for bradykinesia.
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1.3.1.1.2 Pathophysiology of bradykinesia
An account of the pathophysiology underlying bradykinesia must explain not only
the performance impairments exhibited by patients but also the situations in which
performance is normal.
That performance can, in some circumstances be normal argues against peripheral
causes, such as factors directly affecting the muscles. It has been demonstrated that
muscle innervation is not dysfunctional in parkinsonism (Dietz et al., 1981). In a
study of gait in parkinsonism, using EMG measures of muscular innervation, it was
found that the muscles are provided with the stimulation to perform actions planned
at a higher level of the motor programming hierarchy. Thus impairment in
performance must result from impairment in central motor control and not peripheral
factors.
It has been stated that evidence for the location of the pathophysiology lacks detail,
though bradykinesia correlates well with striatal dopamine deficit (Delwaide and
Gonce, 1988). However, Marsden (1982) states that dysfunction may be traced to the
basal ganglia, and suggests that Parkinson's disease provides a model of basal
ganglia dysfunction.
1.3.1.2 Rigidity
Hypertonia, or rigidity, is found not only in parkinsonism but as a component of
other disorders too. Three major forms of rigidity have been described: lead-pipe,
clasp-knife, and cogwheel. These are distinguished in clinical practice by manual
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palpation of the limb. Lead-pipe rigidity is felt as a uniform stiffness as the joint is
moved passively. Where rigidity is of the clasp-knife type the limb remains immobile
as increasing force is applied until it relaxes abruptly and offers no resistance to
flexion. Cogwheel rigidity is a form in which passive extension or flexion is felt by
the assessor to be occurring in a series of steps, though a constant force is applied.
The frequency of these steps varies between patients; at higher frequencies it may be
felt as "rippling" (Findley et al., 1981).
1.3.1.2.1 Manifestations of rigidity
Two forms of rigidity are seen in parkinsonism, lead-pipe and cogwheel rigidity. In
addition, the neutral angle at the elbow has been found to be significantly decreased
(Watts et al., 1986). Data for the prevalence of rigidity in parkinsonism are hard to
come by though it is present in most cases of Parkinson's disease and is slightly less
common in DIP. Caligiuri et al. (1989) found clinically apparent rigidity in 42% of
antipsychotic treated patients.
Lead-pipe rigidity is, as described above, a simple increase in resting muscle tone.
Cogwheel rigidity is more complex. The frequency of the "cogs" has been found to
be between 6-6.6Hz and 7.5-9Hz (Findley et al., 1981), at the same frequency as
postural tremor (in the respective patients). Of their 40 patients, 15 (38%) exhibited
cog-wheeling in the 6-6.5Hz range and 18 (45%) exhibited cog-wheeling in the 7.5-
9Hz range.
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1.3.1.2.2 Pathophysiology of rigidity
As with tremor, two major primary causes of extrapyramidal rigidity have been
proposed (Delwaide and Gonce, 1988). Firstly, mediation via spinal mechanisms has
been proposed, citing "discrete troubles found in a few spinal cord reflex pathways",
and a possible role for the tonic stretch reflex which correlates well with rigidity.
Secondly, Delwaide and Gonce describe a possible mechanism involving
hyperactivity in long-loop reflex pathways. However, Watts et al. (1986) found that
rigidity was still present when EMG measures demonstrated that there was no
muscle activity. Rigidity even persists after preparation for surgery when total
muscle relaxants have been administered (Walsh, 1992). It is suggested that this
occurs as a consequence of inactivity due to akinesia (Watts et al., 1986) but
Delwaide and Gonce state that it is unlikely that this mechanism alone can explain
rigidity.
Even less evidence exists to explain the production of cog wheeling. Some authors
have suggested that rigidity overlaid with tremor may be responsible (Lance et al.,
1963; Findley et al., 1981). These assertions were made primarily on the basis of
similarities in frequency of tremor and cog wheeling. However, this hypothesis may
well be an oversimplification (Owens, 1999),
In general, the literature concerning the mechanisms underlying rigidity is far from
extensive; rigidity is often considered solely as a diagnostic marker for parkinsonism.
Delwaide and Gonce (1988) concluded that "a firm conclusion on the mechanisms
responsible for rigidity seems premature".
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1.3.1.3 Tremor
Tremor may be defined as the regular movement of a body part about a fixed point.
Movement occurs in more than one dimension though this may not be apparent to the
naked eye. A degree of tremor, physiologic tremor, is normal and is exhibited by all
humans. Symptomatic tremor may be exhibited as essential tremor, as a feature of
parkinsonism, or in a number of other disorders. Within Parkinson's disease the
prevalence of tremor is high; prevalence of tremor at presentation has been put at
70% (Quinn, 1995). However, tremor is held to be less prevalent in DIP (Ayd, 1961).
Categorisation of tremor is far from simple. It is often described simply in terms of
context: whether it is present at rest, in posture, when the intention to move is
formed, or during the actual performance of the action. Otherwise, it may be
described as being slow or fast, coarse or fine, or of large or small amplitude.
Though it is often stated that large tremors are of low frequency, and small tremors
are of high frequency (Owens, 1999) this is a relationship of association rather than
causation.
The characteristic parkinsonian tremor, as seen in Parkinson's disease, is a slow
resting tremor. The combination of slow tremor with finger flexion gives this tremor
a "pill-rolling" appearance.
1.3.1.3.1 Characterisation of tremor
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Though tremulous movement occurs along more than one dimension, the movement
is predominantly along the vertical axis when the hand is held pronated. For the
purposes of measurement or description the tremor is most commonly considered as
if movement occurs along only one axis (Caligiuri et al., 1989b; Arblaster et al.,
1993). Along this axis, the tremulous movement occurs as a waveform.
Waveforms may be described in terms of their frequency and amplitude. The
frequency represents the rate at which the limb is oscillating. This is expressed in
terms of cycles per second (Hz). The amplitude of the tremor represents the distance
that the tremulous limb moves from the fixed point in space about which it is
moving. An alternative indicator of amplitude is acceleration. This method relies
upon the fact that the acceleration that the limb is undergoing at any point in the
cycle is closely related to its displacement from the neutral fixed point. The
advantage of this is principally in terms of instrumentation factors (many studies use
a means of instrumentation that measures acceleration).
So far so simple. However, it is rare that a tremor forms a regular wave. In almost all
cases, it is a very irregular waveform comprising activity at a number of different
frequencies. Mathematical techniques (FFT; 1.3.2.3) may be used to break down a
sample of an irregular wave into its component parts. In many studies, the peak
frequency of tremor is used as a comparator. The mean peak frequency for one group
may be compared with that for another group (Tyrer et al., 1981), or for the same
group after changes in medication (Pullinger & Tyrer, 1983). Alternatively,
comparisons may be made using the number of cases within a group whose peak
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frequency falls below some threshold (Arblaster et al., 1993). Another method
calculates the amplitude of tremor within frequency bands (Caligiuri et al., 1989b;
Caligiuri et al., 1991; Caligiuri & Lohr, 1993). The amplitude of tremor present
within the frequency bands 3-7 Hz (Caligiuri & Lohr, 1993) or 4-6 Hz (Caligiuri et
al., 1991) has been suggested as an index of the severity of parkinsonian tremor.
1.3.1.3.2 Physiologic tremor
The characteristics of tremor need to be considered for both normal and abnormal
tremors. Normal physiological tremor is of relatively small amplitude and of
individually characteristic frequency though this can be affected by many factors
(stress, food and drink, drugs etc.) Marsden (Marsden et al., 1969) stated that 95% of
normal adults show a single dominant frequency and that the pattern from each
person shows a 'signature' which they found to be constant over three years.
Within a larger time-scale, tremor characteristics are known to change with age.
Specifically, the dominant tremor frequency is known to decrease (or the proportion
of tremor in lower frequency bands increases). Marsden (Marsden et al., 1969) also
found a decrease in the dominant frequency with age from 9Hz at ages 20-40 years
old to 7.7Hz for a group over 60 years old. Similar figures (7Hz for a group under
70; 6Hz for a group over 70) were also found by Wade (Wade et al., 1982). The
differences in the figures found by these two studies can most likely be attributed to
differences in the manner in which tremor was assessed. However, the decrease in
dominant frequency is of similar magnitude.
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1.3.1.3.3 Parkinsonian tremor
The dominant frequencies to be found in Parkinson's disease tremor have also been
investigated. Findley et al. (1981) found a slower (resting) tremor with a frequency
range of 4Hz to 5.3Hz and a fine postural tremor with a range of 5.8Hz to 6.8Hz.
However, the 'resting' tremor could "continue in posture" and the 'postural tremor'
was "sometimes visible at rest".
Tremor in DIP has been comparatively well investigated relative to the other features
of parkinsonism. Arblaster et al. (1993) compared tremor frequencies in
antipsychotic-treated patients with normal controls. Very few controls (3.2%)
showed a dominant frequency below 7Hz but 29% of the patients did in (at least) one
arm. The figure for the patient group could be much higher if a less inclusive entry
condition was used; the group was defined as those who had taken anti-psychotic
drugs for at least one month in the previous year and while DIP is believed to
continue for a period of time after the discontinuation of drug treatment this period
may be less than a year. Despite this, the results demonstrated a lower frequency of
tremor in the patient group that the authors attributed to DIP.
Caligiuri et al. (1991) found that the percentage of overall tremor activity occurring
within the 4-6Hz frequency band is a valid indicator of parkinsonian tremor activity
as assessed by observer ratings. Their results indicated that the tremor found in a
patient group treated with typical antipsychotic medication was more parkinsonian




If the effects on tremor characteristics of treatment with antipsychotic agents are to
be considered, the possible actions of other agents on tremor must be taken into
consideration when selecting patients. In particular, lithium is known to be associated
with tremor.
That a fine tremor may result from lithium therapy is long known (Schou, 1959). It is
a postural tremor, which may be an exaggerated physiologic tremor occurring at
around 8-12 Hz (Hallett, 1986). Lithium tremor can be distinguished from cerebellar
tremors, and from parkinsonian resting tremor. It is not responsive to
antiparkinsonian drug treatment (Schou et al., 1970; Tyrer et ah, 1980). Rather, it
responds to beta-blocking medication, consistent with an attribution to an adrenergic
mechanism. The incidence of symptomatic tremor in patients receiving lithium
therapy has been found to range from 4% to 65% (Gelenberg & Jefferson, 1995).
It is possible to distinguish between the characteristics of tremor in acute lithium
therapy and those after chronic lithium treatment (duration of at least six months;
Pullinger & Tyrer, 1983; Tyrer et ah, 1981). Acute lithium tremor occurs at rest and
in posture. Relative to tremor characteristics before treatment commenced there is
some increase in amplitude though no change in peak frequency (Pullinger & Tyrer,
1983). After longer-term lithium therapy there is a greater increase in amplitude and
also a (small) decrease in peak frequency towards the parkinsonian range (Tyrer et
ah, 1980).
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1.3.1.3.5 Physiology and pathophysiology of tremor
The mechanism that mediates parkinsonian tremor is still unclear and there is little
consensus. In fact, there is not full agreement on the mechanism underlying normal
physiological tremor.
Authors Hypothesised mechanism
Findley et al., 1981 Gamma efferents and alpha motor-neurones have both
been implicated
Lakie, Walsh & Wright, In part due to the mechanical properties of the postural
1986 system
Marsden et al., 1969 No mechanism proposed
Wade et al., 1982 Components from neuromuscular activity, cardio-ballistic
thrust and passive resonance in the tissues of the hand
Though no mechanism was proposed, the results of Marsden et al. (1969), taken
from both arms simultaneously, showed that while the shape of the frequency spectra
from the two arms was very similar there was little coherence and no phase relation.
This indicates that the arms do not share a common source of activation, although the
many factors which affect the arms equally (muscle changes, hormones and other
blood-borne agents, temperature, fatigue) do ensure great similarity in the patterns.
Though the systems causing tremor in the two arms are separate they share the same
environment.
Similarly there is a paucity of evidence concerned with the production of
parkinsonian tremor. Following from suggestions of similarities between the effects
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of ageing and parkinsonism, the mechanisms hypothesised to account for age-related
decreases in tremor frequency may be considered. Arblaster et al. (1993) suggest the
decrease is due to age-related changes in the basal ganglia, specifically decreases in
the dopamine levels, paralleling those seen in parkinsonism. These decreases are not,
in most people, sufficient to lead to parkinsonism but may be sufficient to lower the
dominant frequency of tremor (dopamine levels may decrease to 20% of normal
before parkinsonism is apparent clinically). However, Wade et al. (1982) attributed
the age-associated changes in tremor frequency which they found (7Hz for a group
under 70; 6Hz for a group over 70) to changes in the natural resonant frequency of
the tissues as there was no change in amplitude or spectral pattern. This is consistent
with the attribution of tremor to mechanical properties of the postural system.
Two major causes of parkinsonian tremor have been proposed (Delwaide and Gonce,
1988). The first of these is a supraspinal mechanism in which rhythmic activity in the
thalamus drives contralateral limb tremor. The second is a spinal mechanism with a
role for oscillatory properties of the myotatic arc. Delwaide and Gonce describe a
dual mechanism that uses the concept of long loop reflex pathways to integrate
peripheral influences with a thalamic determination of tremor frequency.
Within the specific context of DIP, an attribution of tremor to extrapyramidal
dopamine-blockade is invariably deemed sufficient (e.g. Caligiuri & Lohr, 1993). A
similar situation is found in the case of lithium tremor. It has been found to be non-
responsive to antiparkinsonian medication (Schou, 1970; Tyrer et al., 1980), though
Tyrer (Tyrer et al., 1981) suggests that it is extra-pyramidal in nature.
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1.3.1.4 Other physical features
Mild postural instability is a common feature of parkinsonism and is commonly used
as a diagnostic technique. However, in some cases, postural instability can be severe.
In these cases there can be an almost total lack of normal reactions to tilting. The
patient fails to react appropriately if tilted and may make little or no effort to prevent
themselves from over-balancing. This impairment is attributed to a failure to make
use of information from vestibular function (Purdon Martin, 1967), though the
vestibular system itself is unimpaired.
The characteristic gait of Parkinson's disease is a stooped, kyphotic, festinating
shuffle. Step length is greatly shortened (Kirollos et al., 1993), stepping occurs more
quickly, and double support time (a measurement of the length of the period during
which both feet are on the ground) is increased. Pendular arm swing is usually
absent. Though a stooped bent posture (a "triple flexion") is common in Parkinson's
disease, an upright poker-back posture with a marching gait may also be seen,
particularly in DIP.
In a study of 130 cases of post-encephalitic parkinsonism, Purdon Martin found
evidence for gait abnormalities in all patients. Within DIP, the most common feature
is the lack of pendular arm swing which may be one of the most sensitive indicators
to incipient parkinsonism (Owens, 1999). It has been suggested that many of the
characteristic abnormalities of parkinsonian gait are secondary to the previously
noted postural instability (Purdon Martin, 1967) .In particular, a failure to control tilt
50
the body sufficiently to produce an adequate step length may lie at the root of
festination. If the body leans forward at an angle appropriate for a normal pace of
locomotion yet step length is insufficient, the rate of stepping must increase to
prevent the patient falling forwards. Purdon Martin localised the source of the
impairments in postural stability and gait to the basal ganglia.
Facial masking is common in all forms of parkinsonism. Normal facial expressions
are absent not through a lack of emotional experience but a bradykinesia in the facial
musculature. However, this feature can be easily confused with the affective
flattening of psychosis in which the physical ability to express is intact though the
emotional range itself is restricted.
Autonomic disturbances including seborrhoea and sialhorrea are found in advanced
cases of parkinsonism though there have been no studies of their prevalence in DIP.
1.3.1.5 Cognitive deficits
Considerable evidence has accumulated for the existence of cognitive deficits in
parkinsonism. These deficits are present in almost all patients and in Parkinson's
disease they are to be distinguished from dementia. Dementia in Parkinson's disease
is much less common than often suggested with a prevalence of 10-15% (Brown &
Marsden, 1984). Although the deficits in non-demented cases are more subtle, there
is evidence that the cognitive decline is progressive. Areas of impairment include
short-term memory and executive function, long-term memory, visuospatial
processing, and sensorimotor dysfunction (Brown & Marsden, 1990).
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As with studies of cognitive impairment in psychosis, much use is made of
Baddeley's model of working memory (Baddeley, 1990; 1.1.3). Impairment has been
demonstrated in all components of working memory, but dysfunction in the central
executive is particularly well established. Impairment has been demonstrated on a
number of different measures of executive function: Wisconsin Card Sort Test
(Gauntlett-Gilbert et al., 1999), Stroop Colour Word Test (Lund Johansen et al.,
1996), Continuous Performance Task (Hart et al., 1998).
Dalrymple-Alford et al., (1994) presented evidence that Parkinson's disease patients
were not impaired in the performance of two tasks separately but were less able than
controls to perform the tasks simultaneously. The authors state that parkinsonian
patients are impaired only when tasks are demanding and effortful, and when they
must rely on internally generated cues to guide attention and behaviour; impairment
is not found when a task requires only automatic responses. They argue that only the
central executive component of Baddeley's model is dysfunctional.
However deficits have also been found in visuo-spatial working memory and verbal
working memory. Owen et al. (1997), found evidence of a systematic decline in
which, "working memory deficits emerge and subsequently progress, according to a
defined sequence." In newly diagnosed Parkinson's disease patients, impairment was
found only in executive function but in more advanced cases, impairment was found
in spatial working memory tasks and finally in visual and verbal working memory
too. The authors argued that the sequence of decline in cognitive abilities, "may be
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linked to the likely spatiotemporal progression of dopamine depletion within the
striatum, in relation to the terminal distribution of its cortical afferents, " i.e. the
deterioration of cognitive performance proceeds from abilities mediated by frontal
cortical regions (executive function) to abilities mediated by slightly more posterior
cortical regions (visuo-spatial working memory and verbal working memory).
Cognitive deficits in Parkinson's disease have frequently been accounted for in terms
of "bradyphrenia" (Naville, 1922). This term denotes slowed cognitive processing, "a
lethargy of the mind distinguished by a lack of interest, initiative, attention,
concentration..." (Wilson, 1947) distinct from the effects of ageing, co-existent
depression, or dementia. Bradyphrenia is sometimes considered "the mental
equivalent of bradykinesia in Parkinson's disease" (Mayeux et al., 1987), a notion
consistent with findings that the presence of cognitive impairment is associated with
greater severity of bradykinesia (Mortimer et al., 1982). Bradyphrenia has been
operationally defined (Brown & Marsden, 1990) as, "a slowing with increasing
cognitive complexity above and beyond that shown by a control group".
Brown & Marsden (1990) reviewed the literature and, arguing that though "apparent
slowing may be found on some tasks... this may imply a deficit relating to the tasks
themselves, rather than reflect a non-specific slowing in cognition," they stated that
an effect of slowness of thought over and above the effects of motor dysfunction on
manual responses had not been demonstrated by any of the studies reviewed.
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Dobbs et al. (1993) stated that the existence of bradyphrenia had been demonstrated
by the standards of Brown & Marsden (1990). In a choice reaction time task, patients
with Parkinson's disease were less efficient in their use of a warning of the response
needed, i.e. they processed information more slowly. Similarly, Cooper et al. (1994)
used a Choice Reaction Time (CRT) paradigm in which task complexity could be
manipulated without changing response requirements; patients with Parkinson's
disease were increasingly impaired as choice complexity increased. However, both
these findings are equally compatible with impairment in specialised sub-systems.
The results of Cooper et al. (1994) are consistent with a hypothesis of impairment in
central executive function and those of Dobbs et al. (1993) are consistent with a
deficit in action planning.
Though accounts postulating specific impairments may reflect the ability of
parkinsonian patients to perform at normal levels in some circumstances, further
parallels with bradykinesia, suggested as a physical model for bradyphrenia, should
be considered. Even severely bradykinetic parkinsonian patients may at times exhibit
normal levels of performance (Sacks, 1973). Thus it may be premature to conclude
that either one of these accounts is wholly correct.
1.3.1.6 Subjective and affective changes
Numerous accounts exist of personality traits said to be characteristic of Parkinson's
disease patients. These traits are believed to predate physical symptoms of
parkinsonism by years or even decades. A review by Todes and Lees (1985) found
consensus in a number of depictions of parkinsonian patients as having in common
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an emotional and attitudinal inflexibility, a lack of affect and a predisposition to
depression. Patients were frequently described as trustworthy, moralistic and diligent
though with considerable suppressed aggressive drive. It should be noted that much
of this work originates from a psychodynamic perspective in which personality
factors may play a role in the aetiology of parkinsonism.
More recent work, from a neurological perspective supports the pre-morbid
personality hypothesis. Ward et al (1984) examined identical twin pairs discordant
for the presence of Parkinson's disease. It was found that the affected twin tended
from early childhood to be less "usually the leader" and "more self-controlled", and a
few years before the onset of the disease had become "less aggressive, quieter and
less confident and light-hearted", than their unaffected twin. It has been suggested
that the parkinsonian personality is indicative of minor changes in the dopamine-
mediated mechanisms which underlie cognitive deficits in later parkinsonism (Lees
& Smith, 1983).
Many of the accounts of a parkinsonian personality note the presence of depression
in a significant proportion of patients (et al., 1980). In fact, the presence of
depression in Parkinson's disease is well established and has been reported in a
number of studies (Mindham, 1970; Tandberg et al., 1996). Prevalence has been
reported as being between 37 and 90% (Santamaria et al., 1986). Significant numbers
of Parkinson's disease patients have been found to have treatment for major
depressive illness before the appearance of motor dysfunction (Shaw et al., 1980). It
has been stated by some authors that this depression is an intrinsic component of
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parkinsonism (Horn, 1974; Hoehn et al., 1976), and by others that it is a reactive
depression secondary to the progressive physical disability of Parkinson's disease
(Mindham et al., 1976).
Taylor et al. (1986) compared a group of depressed Parkinson's disease patients with
a group of endogenous depression patients on a test of short-term memory known to
be sensitive to the presence of primary affective disorder. The Parkinson's disease
group did not show the same deficits found in the affective disorder group though
they did exhibit deficits characteristic of impaired executive function. Taylor et al.
concluded that depression in Parkinson's disease is a reactive depression.
In contrast, Santamaria et al (1986) found that depression in Parkinson's disease was
associated with a younger age of onset, lower severity of motor impairment (as
assessed by observer rating scales), and a positive family history of Parkinson's
disease. The severity of depression was not related to severity of parkinsonism. The
authors argued that depression is an intrinsic component of Parkinson's disease in a
sub-group of patients.
Given the evidence for accounts of both reactive and primary depression in
parkinsonism it may be safest to side with Rabins (1982) who concluded that
depression in parkinsonism may occur as a primary feature in some patients and
secondary to physical disability in others.
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1.3.2 Instrumentation
Instrumentation procedures have been applied to the assessment of all the physical
features of parkinsonism. This section will provide an overview of the methods
investigated, commenting on the properties of the measures and their relative
advantages and disadvantages. As in previous sections, some of the evidence derives
from studies of DIP, some from studies of Parkinson's disease.
1.3.2.1 Bradykinesia
Attempts have been made to instrument most, if not all of the manifestations of
bradykinesia noted earlier (1.3.1.1.1). The most simple methods time the sorts of
tasks usually assessed by simple observation (hand turning, tapping etc). Other
methods use more complex, or more easily standardised procedures.
Tests of grip strength may be provided using a sphygmomanometer cuff
(Onuaguluchi, 1964). This procedure may provide a measure of absolute momentary
strength or of the ability to maintain strength at a particular level over a period of
time, i.e. fatigability. The ability to maintain repetitive movements over a period of
time has been assessed using morse-key tapping. Very simple methods of
instrumentation such as these may be effective in instrumenting very specific
manifestations of bradykinesia but the information they can provide about the overall
severity of the bradykinesia symptom complex is necessarily limited.
Measures of initiation time may be provided by reaction time tests using many
different types of stimuli and response. Stimuli may be visual or "kinaesthetic".
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Responses may be by pressing switches (Ebmeier et al., 1992), twisting a lever
(Evarts et al., 1981), or by touching a computer screen (Riekkinen et al., 1998).
Older studies tended to use custom-designed equipment (Evarts et al., 1981) to take
measures of reaction time but more recent studies (Ebmeier et al.,1992) have utilised
software run on a personal computer. Particularly valuable are methods in which
reaction time and movement time may be separated. These allow the investigator to
identify groups who exhibit difficulties in movement initiation, a slowed speed of
movement, or who exhibit relative increases in choice RT or simple RT (1.3.1.1.).
The advantages of reaction time instrumentation concern primarily the high level of
accuracy in terms of presentation standardisation and performance measurement;
very high test-retest correlations have been found for both simple and choice reaction
time tests (Lowe and Rabbitt, 1998). Also, they provide a measure of pure speed of
movement, uncontaminated by other factors such as motor control.
Other studies have chosen to use fine motor control tasks which provide an
assessment of movement accuracy as well as simple speed of movement. One of the
most simple is the pegboard. The plainest form of pegboard is a board drilled with
holes into which round wooden pegs are to be inserted (Verkerk et al., 1990); in
more complex versions the pegs are keyed identically and must be inserted into the
randomly-oriented holes in the correct orientation (Meier & Martin, 1970). More
complex tasks simulating activities of daily living are also popular, particularly
amongst neurologists. These tests provide an assessment of functional ability
(Jebsen, 1969). As such they have direct relevance to self-care and may be used as an
index of treatment success. The advantages of tasks such as these stem in part from
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their obvious face validity. In addition they require little or no training for the patient
which may help to minimise practice effects. However, the properties of these tests
(reliability, validity) vary greatly and have only been systematically investigated for
a relatively small proportion of them.
Another form of tests which tap motor control abilities comprises pursuit tracking
tasks. In these tasks, the patient uses a joystick to control a trace on an oscilloscope
(Flowers, 1978) or on a computer screen (Bloxham et al., 1984). The task is to
maintain the position of the trace as close to that of a moving target as is possible.
Performance is scored on the basis of time spent on/near the target during the test
period.
The range of instrumentation techniques which have been used to quantify
bradykinesia is wide. It includes procedures which instrument simple speed of
movement, the purest "bradykinesia," procedures which instrument other
manifestations, such as initiation difficulties, or the inability to maintain repetitive
movements, and also more complex batteries of tests which aim to provide a
comprehensive assessment of the consequences of bradykinesia for functional
ability. However, despite the range of techniques used, there has been little
investigation into the validity of the techniques which tends to be assumed rather
than demonstrated. Use of instrumentation methods is sometimes justified on the
basis that they are procedures which detect impairment in parkinsonism rather than
procedures which measure a particular feature of parkinsonism. Few of these
techniques have been used with cases of DIP.
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1.3.2.2 Rigidity
The range of procedures used to instrument rigidity is perhaps less wide than of those
used in the case of bradykinesia. This is probably due more to the much narrower
construct definition of rigidity than to any lack of imagination amongst investigators.
Some of the earliest instrumented methods of assessing rigidity used gravity to drive
the limb(s) in which tone was to be assessed. The Wartenburg test seats the subject
on the edge of a high chair or table with their legs able to swing freely; the physician
lifts the legs to almost horizontal and then lets them drop. The more rigid the
subject's legs, the fewer times they will swing before they come to rest. A computer
has been used to record the number of swings made and the velocity attained (Brown
et al., 1988a & 1988b). The most notable difficulty with this method is for the patient
who must relax sufficiently to allow the legs to swing freely without either
exaggerating or damping the motion. Brown et al. state that either of these situations
may be easily detected from the computer record of the trial.
Rigidity assessment often involves the use of quite large and cumbersome machines
to which the subject must be fastened in order that the limb from which the
measurement is to be made may be passively moved back and forth. Numerous
examples of this kind of work have been published since the 1950s (Long et al.,
1964; Webster 1966; Caligiuri et al., 1989; Caligiuri & Galasko, 1992; Walsh, 1992).
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Most recent studies of rigidity have used the activation paradigm developed by
Webster (1966) to take account of the involvement of higher-level central nervous
system influences in the production of parkinsonian rigidity. Rigidity is assessed in
both "resting" and "activated" conditions and the results compared. In the activated
condition a motor task is performed by the contralateral (i.e. non-test) limb. In
normal subjects, no difference is found between the two measurements but in
parkinsonism stiffness increases in the activated condition. Motor tasks which have
been used successfully include pursuit tracking (Webster, 1966), isometric
contraction (Kirollos et ah, 1996), drawing circles in the air (Caligiuri & Galasko,
1992).
In a number of studies conducted by the same group of workers (Caligiuri et al.,
1989; Caligiuri & Galasko, 1992), "stiffness values are obtained by applying known
displacements and measuring the resultant force". In the study of 1989, stiffness was
tested in the hand. The finger rests in a cradle mounted on a beam. The beam may be
moved, by the experimenter, through a range of 30° (Caligiuri et ah, 1989) or 40°
where possible (Caligiuri & Galasko, 1992). A potentiometer was used to measure
the displacement (in degrees) through which the finger was moved and a strain gauge
mounted on the beam allowed the measurement of the resultant force (in grams).
Stiffness is defined as the ratio of force/displacement. On each trial (a raising and
lowering of the finger) the peak stiffness was obtained using a computer sampling at
a rate of 100 samples/sec. The peak stiffness measures for 20 trials were averaged for
both the resting and activated conditions. The coefficient of stiffness was obtained
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from the ratio of the coefficient in the resting condition to that in the activated
condition.
However, the methodology has serious problems limiting the information which can
be extracted (Walsh, 1992). Measurements of rigidity in which movement is not
continuous will be confounded by the presence of thixotropy in any estimation of
stiffness. Thixotropy is a property seen in materials such as paints and sauces, such
that stiffening occurs when the substance is at rest; the process may be reversed by
agitation. In order to avoid confounding by this phenomenon measurements of
stiffness should not be made from rest.
A later study from the group (Caligiuri & Galasko, 1992), used a series of trials
recorded as one continuous movement, a practice which eliminates the confounding
effect of thixotropy. The influence of thixotropy may be seen in the force and
displacement traces published (fig. 2, page 4). The first (few) cycles of each
condition, performed after a period of rest, show a higher level of resultant force than
in the later cycles. This occurred, in the active condition at least, in the presence of a
lowered figure for displacement. On these first three or four trials, the patient
exhibited greater apparent stiffness than on the later trials; it is likely that this
reflected the influence of thixotropy. However, the authors do not address this effect
and do not specify whether the results of all trials were included in the analysis.
Despite the use of an improved method, the continued use of displacement as the
independent variable causes further methodological difficulties. If the joint is moved
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through a large range of movement, measures of stiffness can be confounded by
differential viscosity at the extremes of movement. Smaller movements avoid this
source of confounding but can only inform about the properties of the joint in a very
limited range.
A further method of rigidity assessment was developed by Kirollos et al. (1996), who
used a motor-powered mechanical device similar to that used by Webster (1966).
Rigidity was assessed at the elbow from the work required to move the forearm
through a fixed angle of 40° at a constant rate of 0.5 Hz. The arm was lightly
strapped to a cradle mounted on a lever attached to the motor. The forearm moved in
a horizontal plane, about a pivotal axis aligned to the elbow joint. Torque was
measured using a semiconductor strain gauge and the angle of displacement using a
potentiometer. The measure of stiffness used was the work required to move the arm
per unit displacement (measured in Nm0"1). Stiffness was compared using the
activated stiffness above baseline.
An alternative method (Walsh, 1992) uses torque applied to the joint as an
independent variable. This evades the confounding influences of thixotropy and
differential viscosity. Positive feedback is added to the motion of the limb, causing
the limb-device combination to oscillate. The man/machine combination forms an
under-damped torsion pendulum, the behaviour of which can be described by an
equation:
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When the motion of the device is tracked, the stiffness in the limb may be calculated
from the frequency of oscillation.
Common themes in almost all the modern methods of rigidity instrumentation is the
controlled movement of the limb under assessment by an external force, the
measurement of forces applied to the limb and movement of the limb, and the use of
the activation paradigm. The methods differ in the means of data analysis, principally
as to whether the independent variable is taken to be displacement (Caligiuri et al.,
1989; Caligiuri & Galasko, 1992), or torque (Walsh, 1992). These differences appear
to be superficial but are central to the validity of the instrumentation procedure.
1.3.2.3 Tremor
Of the different methods which have been used to instrument tremor, by far the
simplest is an objectified form of spirography. The patient is asked to draw a spiral
between printed guidelines and the results are rated for accuracy (Bain et al., 1993);
this form of assessment is, however, rater-subjective rather than truly objective. A
modified method was developed by Verkerk et al. (1990). The time taken to draw the
spiral was used as a score with time added for errors; three seconds for each time a
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guide line was touched, five seconds for each time a line was crossed. As the authors
do not indicate how these penalty times were determined the validity of this method
must be regarded as doubtful at best.
As a means of assessing tremor, spirography appears of little use. Performance will
be greatly affected by bradykinesia, fine motor control ability, and strategy (i.e.
whether the patient aims to complete the spiral as accurately as possible regardless of
the time taken or as quickly as possible despite the increased errors). Spirography
methods may be of use where an assessment of hand function is required; no
information about the properties of the tremor is derived, simply an indication of the
level of impairment caused by the tremor. Other, more complex, methods of
instrumentation provide additional, quantitative data about the properties of the
tremor, most commonly the overall amplitude or information about its frequency
components, e.g. peak frequency.
In recent work, the use of electronic accelerometers is ubiquitous but the literature
contains examples of other methods. Walsh (1996) summarises a method dating from
the nineteenth century, developed by Schaefer, which held the wrist motionless and
transcribed the motion of the hand onto a smoked drum. The results obtained show
an irregular waveform as is obtained with modern methods. However, Walsh
describes the attainment of since replicated results as, at least partially, the product of
good fortune. Another device, designed by Walsh (Lakie, Walsh & Wright, 1986),
was described as a "hanging hand tremorgraph". The wrist was held still by one strap
and the hand attached to an adjustable crank by another strap. The crank was
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connected to an induction generator used as an angular accelerometer. A polygraph
transcribed the signal from the accelerometer and the other data collected, including
EMG.
Electronic accelerometers are now far more common than electro-mechanical
devices. As with all electronic equipment there has been continuous development,
from simple devices consisting of a valve, bridge circuits and a polygraph (Marshall
& Schnieden, 1966), to integrated circuits and the use of computers for data
collection, storage and analysis (Marsden et al., 1969; Homberg et al., 1987;
Caligiuri et al., 1991). The accelerometer detects acceleration in a given plane and
emits a voltage proportional to that acceleration which may be recorded for later
analysis.
To measure tremor in the wrist only, the forearm must be supported, usually with the
hand pronated. The hand may be hanging (for a measurement of resting tremor) or
held out horizontally (for postural tremor). The accelerometer may be attached to the
dorsal surface of the hand, fastened to the middle finger by a velcro strap or gripped
in the fist. Marsden et al. (1969) mounted the accelerometer at the tip of the fingers
but other authors have argued that this may add the effects of tremor in the
interphalangeal joints, confusing the pattern of results, or ignoring important
components of tremor in disease (Wade et al., 1982).
Different studies have also focused on alternative features in the processed data.
Much of the work by Walsh (1996) concentrates on the total movement present in
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the tremor in units of acceleration. However, Arblaster et al. (1993) and most other
authors argue that it is the peak frequency which characterises tremor in
parkinsonism and distinguishes it from other tremors. In addition, there is great
variation in the amplitude of tremor found in healthy adults, with Walsh (1992, 1996)
finding a three-fold variation between some groups and much more between
individuals. Much less variation is found in peak frequency in normal groups
(Marsden et al., 1969).
For the purposes of neurological assessment of disability, tremor frequency is of little
consequence relative to amplitude. However, if the goal is to distinguish
parkinsonian tremor from that due to other causes then an indication of the frequency
components present is essential. This requires the use of a Fast Fourier Transform
procedure to analyse the frequency components of the tremor.
The Fourier transform is a mathematical technique for expressing a(n irregular)
waveform as a weighted sum of sines and cosines (regular waveforms). The Fast
Fourier Transform is an algorithm (a detailed sequence of actions to perform to
accomplish a particular task; named after an Iranian mathematician, Al-Khawarizmi)
for computing the Fourier transform of a set of discrete data values. Given a finite set
of data points, for example a periodic sampling taken from a real-world signal (e.g.
an accelerometer), the FFT expresses the data in terms of its component frequencies.
As methods of instrumenting tremor vary, so do the methods of analysing the data
produced. Though almost all modern studies use FFT procedures to derive the
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amplitude of frequency components present in the tremor, further processing may
proceed in a number of different ways. In many studies, the peak frequency of tremor
is used. The mean peak frequency for one group may be compared with that for
another group (Tyrer et al., 1981), or for the same group after changes in medication
(Pullinger & Tyrer, 1983). Alternatively, comparisons may be made using the
number of cases within a group whose peak frequency falls below some threshold
(Arblaster et al., 1993). Another method calculates the amplitude of tremor within
frequency bands (Caligiuri et al., 1989b; Caligiuri .et al., 1991; Caligiuri & Lohr,
1993). The amplitude of tremor present within the frequency band 3-7 Hz (Caligiuri
& Lohr, 1993) or 4-6 Hz (Caligiuri et al., 1991) has been suggested as an index of
the severity of parkinsonian tremor.
As noted before, accelerometry techniques are ubiquitous amongst modern methods
of tremor assessment, as is the use of computers in data recording and processing,
and FFT algorithms in analysis. These techniques now have well established
properties; test-retest reliability is high (r = .75, p < 0.01; Caligiuri et al., 1989b).
However, there is little concurrence on the position in which tremor should be
measured or on the means by which the results of FFT analysis should be compared.
This latter issue is a problem even between different studies conducted by the same
group (Caligiuri et al., 1991; Caligiuri & Lohr, 1993). There seems little evidence on
which to base a choice between these methods of analysis; they are mostly justified
solely on the basis that tremor in Parkinson's disease is known to have a dominant
frequency of around 4-6 Hz.
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1.3.2.4 Other features
Instrumentation procedures have also been used as measures of gait dysfunction.
Dietz et al. (1981) used a treadmill to keep their subjects stationary during gait
analysis. Potentiometers were placed at the heel and at the ankle to measure changes
in joint angle. The timing of ground contact was measured by separate electrical
switches placed inside the shoes at the ball and heel of the foot. EMG was also taken
from the medial head of gastrocnemius, tibialis anterior and soleus to assess the
timing of muscle activity during gait.
In a number of studies, Dobbs and others (e.g. Kirollos et al., 1993) used a "gait
assessment trolley" which the patient towed behind him. A three metre length of
strong cotton clipped to the heels of the patient's shoes passes around a pulley
attached to a "shaft encoder", mounted on a lightweight trolley. When walking, a
length of cotton is transferred from behind one foot to behind the other; this rotates
the shaft encoder and tows the trolley. The length of cord transferred represents the
distance moved and the direction of encoder rotation indicates which foot has moved.
The trolley is designed to maintain tension in the cotton. A battery-powered infrared
transmitter sends encoded information to a receiver and a chart recorder.
Though highly ingenious, both of these methods, and especially that of Dietz (Dietz
et al., 1981), are time-consuming, expensive and intrusive for the patient.
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1.4 Aims
These hypotheses were formulated from the literature previously reviewed and will
be explained here within the context of the literature. Similar attention will be paid to
methods by which the hypotheses may be evaluated.
1. Instrumentation has a role in the assessment of DIP.
2. Bradykinesia is the predominant feature of DIP.
3. Features of parkinsonism other than the physical ones will be demonstrable in
DIP.
1.4.1 Instrumentation has a role in the assessment of DIP
This assertion is central to the work done, and is the most important of the
hypotheses. It must take precedence over the other hypotheses, here in considering
the means to prove the hypotheses, in the analysis of the data recorded, and in the
discussion of the findings.
In order to demonstrate that instrumentation has a role in the assessment of DIP it is
necessary to demonstrate that instrumentation (or at least the particular methods of
instrumentation evaluated) is an accurate means of assessing parkinsonism. The
methods investigated may be evaluated as measures of a particular feature of
parkinsonism, whether it is bradykinesia (Evarts et al., 1981), rigidity (Caligiuri &
Galasko, 1992), or tremor (Caligiuri & Lohr, 1993), or as markers of the overall
severity of parkinsonism (Arblaster, 1993).
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The properties of the instrumentation methods used must be formally evaluated
against certain criteria. These criteria assess the degree to which measurement occurs
in a systematic and accurate manner. It is the performance of a test against these
criteria which will determine its value.
1.4.1.1 Reliability
Reliability concerns the extent to which a measuring procedure yields the same
results on repeated trials, i.e. the consistency of the procedure (Carmines & Zeller,
1979). This consistency is achieved by the minimisation of chance random error.
However, measurements always contain a certain amount of random error and so an
element of unreliability is unavoidably present. Reliability is thus a matter of degree
rather than all-or-nothing. However, though a high level of reliability is necessary to
a good form of measurement it is not sufficient in itself to recommend a procedure:
validity is essential.
1.4.1.2 Criterion Validity
Validity can be assessed in different forms, most commonly as criterion validity or
construct validity. Criterion validity is concerned with the presence of non-random
error in measures taken, i.e. systematic bias in results. It is assessed with reference to
some other, external, criterion; usually this other criterion is an existing Gold
Standard of assessment for the phenomenon or property under consideration. For
example, an abbreviated assessment procedure may be evaluated relative to a more
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comprehensive form. The degree of criterion validity exhibited by the measure being
evaluated is indicated by the level of correlation with the Gold Standard criterion.
A distinction may be made between concurrent and predictive criterion validity.
Concurrent validity is assessed by the degree correlation between the measure and
the criterion at the same point in time. Predictive validity concerns the ability of the
measure to predict the results of the criterion measure at some future point in time.
Essentially, the logic and procedures are the same for both concurrent and predictive
validity; only the point at which validity is assessed differentiates them.
Criterion validity is expressed using a correlation co-efficient to describe the
relationship between the results of the measure to be assessed and the criterion. An
ideal measure would exhibit a perfect correlation with the criterion (correlation
coefficient r=l). Realistically, a correlation co-efficient of r>0.75 is regarded as a
high degree of correlation and r>0.5 is regarded as moderate. Commonly, the
correlation co-efficient has an associated significance value which indicates the
confidence with which the co-efficient value may be relied upon.
Though not theoretically complex and relatively simple to determine, criterion
validity is wholly dependent upon the validity and reliability of the criterion chosen.
In some circumstances there may be no suitable criterion. Or, one may wish to
validate a measure without reliance upon existing measures. In these circumstances,
construct validity must be investigated.
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1.4.1.3 Construct Validity
Construct validity depends upon the extent to which the performance of a measure
relates to theoretically derived hypotheses concerning the constructs being measured.
This form of validation depends upon the existence of a relatively extensive
theoretical background to the concept being measured.
Establishing construct validity involves three distinct steps. First, the theoretical
relationship between the concepts themselves must be specified. Second, the
empirical relationship between the measures of the concepts must be examined.
Finally, the empirical evidence must be interpreted in terms of how it clarifies the
construct validity of the particular measure.
Unlike criterion validity, construct validity cannot be expressed in a numerical value.
It is for the investigator to interpret the supporting evidence and decide if it is
sufficient to establish the validity of the measure.
If the evidence does not support the validity of the measure, there may be four
possible interpretations (Cronbach & Meehl, 1955). Firstly, and most commonly, it
may be concluded that the measure lacks construct validity, i.e. it does not measure
what it purports to measure (it may measure some other construct, but not the
construct of interest). Secondly, one may question the theoretical framework used to
derive the predictions. Thirdly, the method or procedure used to test the hypotheses
is inappropriate (this may be as simple as the use of an unsuitable statistical
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technique). Finally, there may be a lack of construct validity or reliability in some
other variable(s) in the analysis.
Construct validity demonstration is particularly important when wishing to develop a
more accurate measure than the existing procedures. Criterion validity may be
established against the existing measure as a starting point but the techniques used to
establish validity in the absence of a criterion must be used to demonstrate that
differences between the results of the two measures are due to greater accuracy in the
new measure rather than in the old.
1.4.1.4 Sensitivity and specificity
Sensitivity and specificity describe the ability of a measuring procedure to quantify a
particular property and that property alone. They are assessed relative to an existing
criterion. As such they may be viewed as components in criterion validity. Further,
assessment of these two properties is dependent upon the existence of a valid
criterion for the property in question.
Sensitivity and specificity are often used to evaluate the performance of measures
when the measure is used to divide cases into those which exhibit a particular
property and those which do not, by means of threshold value. Cases which score
above a particular threshold level are labelled positive, and those below the threshold
are labelled negative. Within this context, sensitivity refers to the ability of the
measure to detect genuine positive cases and specificity refers to its ability to avoid
falsely identifying negative cases as positive.
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These two properties may be quantified relative to the performance of a criterion
(Greenhalgh, 1997). Sensitivity is defined as the percentage of genuine cases (as
identified by the criterion) which are identified by the measure. Specificity is the
percentage of cases identified by the measure which are genuine cases (again as
identified by the criterion). These properties are not independent. If the threshold
value is altered this will have opposing effects on the apparent sensitivity and
specificity of the measure.
Using the graph below (Example 1) the relationship between sensitivity and
specificity may be more clearly illustrated. The x-axis represents the results of
assessment using the criterion. The y-axis represents the results of the measure under
assessment. For both the measure and the criterion, cases exhibiting the property are
scored more highly than those that are not. It can be seen that a good but not perfect
degree of correlation exists between the results of the measure and the criterion.
Within the graph, cases which fall in sector A genuinely exhibit the property and are
identified as doing so by the measure being assessed. Those which fall in sector B
also exhibit the property but are not identified as doing so by the measure. Sector C
contains those cases which are correctly identified by the measure as not exhibiting
the property. Cases falling in sector D do not exhibit the property but are wrongly
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By shifting the threshold at which the measure identifies positive and negative cases,
the sensitivity and specificity may be manipulated (though the criterion validity of
the measure has not changed). If the threshold of the measure is increased the
number of cases identified by the measure is decreased. There are fewer cases in
sectors A and D and a greater number of cases in sectors B and C. Fewer cases are
correctly identified but the number of false positives is reduced. Specificity has been
increased but sensitivity is reduced.
If the threshold of the measure is decreased the number of cases identified by the
measure increases. There are more cases in sectors A and D and fewer cases in
sectors B and C. A greater proportion of genuine cases are correctly identified but
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there are more false positives. Sensitivity is increased at the expense of reduced
specificity.
The optimum threshold level for a measure is dependent upon its intended purpose
and the circumstances in which it is to be used. If it is desirable that all cases
exhibiting the property are identified and the presence of some false positives is not
important, high sensitivity is paramount and a low threshold value should be used. If,
however, it is important to avoid false positives, specificity should be maximised by
the use of a raised threshold.
Example 2 uses the same results as the earlier illustration but the positive/negative
threshold on the new measure is lower. The small number of cases in sector C
indicates how few of the cases identified as positive by the criterion were not
identified by the new measure. In contrast, a great number of cases were detected by
the new measure which were not identified by the criterion. This pattern of results
may signify greater sensitivity in the new measure relative to the criterion, or less
specificity. In order to determine which of these two explanations is more
satisfactory the investigator must use the techniques detailed earlier for the
demonstration of construct validity. This recourse to the theoretical framework will
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1.4.1.5 Summary of test properties
The test properties described here are essential qualities for any measuring
procedure. Use of a measure is only justified if it can be demonstrated that the
measure exhibits high levels of reliability, validity, and sensitivity and specificity.
The analysis techniques can enable the quantification of the extent to which a
procedure fulfills these criteria. However, it must be noted that the criterion validity
(and sensitivity and specificity) of a measure can only be established to the extent
that the criterion has validity. Thus, the success of the enterprise is dependent upon
the choice of a suitable criterion. This is dependent not only upon the property to be
measured but the use to which the measure will be put.
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1.4.1.6 Other considerations
The instrumentation methods will be investigated first as measures of particular
features of parkinsonism, and then as markers of the overall severity of parkinsonism
(where the literature suggests this is appropriate). This latter form of assessment
relates most particularly to accelerometry assessment of tremor which has been
described as providing an "early warning" of the development of sub-clinical
parkinsonism (Arblaster et al., 1993).
However, demonstrating that instrumental measures provide a valid means of
assessment of parkinsonism is not sufficient to demonstrate the existence of a role.
The other characteristics of the measures must be assessed to determine whether they
have some advantage over the observer ratings used in clinical practice. An
advantage may be shown in terms of being a better, more accurate, measure of
parkinsonism. Or the instrumentation may be easier to use for the investigator, less
time-consuming for the patient and the investigator, less intrusive for the patient, less
demanding of the investigator (in terms of experience, training and skill level
required). It is hoped that instrumentation may allow the relatively unskilled
investigator to quickly produce accurate, reliable and valid assessments of severity of
parkinsonism without confounding by inter-rater differences.
1.4.2 Bradykinesia is the predominant feature of DIP
It is stated that bradykinesia (particularly upper-body bradykinesia) is the cardinal
feature of parkinsonism (Quinn, 1995). Though there is an absence of comparative
studies, clinical impression strongly suggests that this is the case. In other words, that
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rigidity and tremor are of lower prevalence than bradykinesia and/or that rigidity and
tremor are of lower relative severity than bradykinesia. Clinical impression also
suggests that bradykinesia is the dominating symptomatology in DIP to an even
greater extent than in Parkinson's disease.
A demonstration that one feature is of greater severity than another, or of greater
prevalence is deceptively complex. It is necessary to determine on what grounds this
increased severity or prevalence is to be assessed. Perhaps the simplest method is to
consider which items on the observer rating scales make most contribution to overall
score variance. If total scores are more influenced by bradykinesia item scores than
say, tremor scores, one could conclude that bradykinesia has a more central role in
symptomatology than tremor. However, to a large extent, this analysis would rely
upon the construction of the scale to provide equal weight to each feature of
parkinsonism. Use of a scale which gave undue to significance to ratings of a
particular feature would confound efforts to assess the contribution of that feature
and other features to overall severity of parkinsonism (this point will be revisited
later 2.3.1).
In the previous section, the intention to assess instrumentation methods as markers of
overall severity of parkinsonism (using whole-scale observer ratings of parkinsonism
as criteria) was noted. The results of this form of evaluation may provide evidence to
indicate the predominating form of symptomatology. An advantage of this method is
that the observer ratings are used as whole scale assessments of parkinsonism, as
they were designed to be used. If a particular instrumentation procedure can be
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identified as being the best indicator of overall severity of parkinsonism, it could be
concluded that the feature assessed predominated in the patient group used.
However, it is also possible that a particular method may show greatest value as a
measure of overall parkinsonism simply because the other instrumentation
procedures do not measure the features of parkinsonism they are intended to
measure. The greater accuracy of one form of measurement would not be valid
evidence that the feature so measured was the predominant form of symptomatology.
Possibly the simplest method, and one which may avoid many of the difficulties
noted above is to consider the numbers of patients who are outside the normal range
on measures of each feature. This analysis may be completed principally using the
instrumentation methods. Results from the control group can be used to determine a
normal range of scores for each method of instrumentation, and then the numbers or
proportions of patients who fall outside the normal range for each feature of
parkinsonism assessed may be calculated. Alternatively, a similar method may be
used using the observer ratings with which the rating criteria may be used to
determine a normal range.
While it is hoped that the instrumentation methods may have a role in answering
questions of this nature, perhaps by providing enhanced sensitivity of measurement,
they cannot be used in this fashion unless their validity as measures of the features of
parkinsonism has been satisfactorily demonstrated (see hypothesis 1).
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1.4.3 Cognitive and subjective features of parkinsonism are present in DIP
Cognitive deficits and other subjective features such as changes in personality have
been documented in Parkinson's disease. However, evidence of the existence of
these phenomena in DIP is limited. It is hypothesised that these phenomena do exist
in DIP and that their existence may be demonstrated. Again, this aim is deceptively
complex. The principal difficulty is the extent of the superficial similarities between
features of parkinsonism and deficit symptoms of psychosis. This phenomenal
overlap between psychosis and parkinsonism was described earlier but includes
cognitive deficits, psychomotor slowing, and can include motor abnormalities.
In circumstances such as this, longitudinal experimental designs are frequently used.
It is often possible to assume that features which emerge after commencement of
treatment are the result of treatment, in this case that they would be parkinsonian in
nature. However, the fact that psychotic symptomatology is not stable over time
makes it an intricate matter to determine that changes in deficit severity are due to
treatment factors. An alternative method is to use a cross-sectional experimental
design to consider the presence of cognitive deficits across a patient group.
In order to demonstrate that deficits found are features of DIP rather than the
underlying psychosis it is necessary to demonstrate an association between the
presence of the deficits and the presence of other features of parkinsonism. Within
Parkinson's disease, associations have been demonstrated between cognitive deficits
and bradykinesia (Mortimer et al., 1982). If the presence of a particular cognitive
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deficit is associated with the severity of bradykinesia, it can be concluded that the
deficit in question is a feature of parkinsonism rather than of the illness being treated.
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2 Methodology
This section will consider the measures selected for evaluation, the observer-ratings
to be used as criteria, and the statistical techniques to be used to analyse the data.
2.1 Measures
The measures selected will be described in the context of the features of which they
are intended to provide an assessment.
2.1.1 Bradykinesia - Jebsen Hand Function Test
Two methods were chosen to instrument bradykinesia: the Jebsen hand function test
(Jebsen et al., 1969) and the CANTAB reaction time test. The two procedures are
dissimilar in structure and administration, being designed to measure different
aspects of bradykinesia.
The Jebsen hand function test is a comprehensive battery of fine motor control tasks.
The battery was intended for both clinical and research use as an assessment of
functional capability and treatment efficacy. It is suitable for measuring a broad
spectrum of manual function in different populations.
The authors originally used the test with seven tasks: (1) writing; (2) turning over
cards; (3) picking up small common objects and placing in a container; (4) stacking
checkers (draughts pieces); (5) simulated feeding; (6) moving large light objects
(empty large tins); (7) moving large heavy objects (full tins). All tasks are assessed
purely on the basis of time taken to complete the task.
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The Jebsen test has many qualities to recommend its use. Primarily it is a test of
functional ability, tapping the impaired performance in activities of daily living
which is distressing to patients and has negative consequences for treatment success.
In particular, the simulated feeding task instruments the patient's ability to perform a
primary task of self-care. The variety of tasks in the test are sensitive to performance
in many facets of motor function. Strength, speed of movement and accuracy are all
required to perform the tasks swiftly.
The Jebsen test exhibits good psychometric properties of validity and reliability. The
use of common household objects and the inclusion of tasks very obviously related to
normal activities lends the Jebsen test a high degree of face validity. Further, the
authors have demonstrated that it also exhibits a high degree of test-retest reliability
(r = 0.60 to 0.99; Jebsen et al., 1969). Further, practice effects are negligible, perhaps
a benefit of the use of everyday objects in simple tasks.
The study of the Jebsen group indicates that tasks 2-7 exhibit very similar properties,
including a similar range of scores. However, task 1 shows a much higher rate of
failure to complete, with a proportion of higher scores tending to be much more
extreme than on the other items. While this may indicate a higher level of sensitivity
to motor control dysfunction in the writing task, it may indicate that the task does not
sit well with the other tasks.
Writing is known to be very sensitive to parkinsonism, and micrographia is often
cited as an early marker of incipient parkinsonism (1.2.2). However, assessment of
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writing performance is usually on the basis of observer-rated changes in size and
quality of writing. It is the size and steadiness of the writing rather than the speed
which it is produced which marks parkinsonism. There is little indication in the
literature as to what extent writing speed is indicative of bradykinesia rather than
non-medication factors such as cognitive impairment or educational level. Further, it
is changes in the writing relative to previous assessments, rather than properties of
the writing at any one time, which are used as indicators of dysfunction.
A pilot study here found very high levels of failure to complete task 1 (particularly
with the non-dominant hand) and it was omitted from the battery for the study proper
as it detracted from the integrity (and construct validity) of the battery as a whole.
Following the omission of task 1, six tasks from the Jebsen test were included in the
assessment of bradykinesia. All tasks were performed with each hand separately, and
timed.
1. Card turning using 3"x 5" cards (simulated page turning). Five cards are placed
in a horizontal row, 2" apart, oriented vertically on the desk in front of the
subject. Timing is from the word "Go" until the last card is turned over. No
accuracy of placement after turning is required.
2. Picking up small common objects. A large empty tin is placed in front of the
subject, 5" from the front of the desk. The objects (2 paper clips, 2 pennies, 2
bottle tops) are placed in a row alongside the can. Timing is from "Go" until the
last object strikes the inside of the can.
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3. Simulated feeding. Five kidney beans are placed on the board (a large wooden
board, secured to the desk, with an upright central piece of plywood (2" high)
glued to it), touching the upright and 2" apart. An empty tin is placed in front of
the subject, and a teaspoon is provided. Timing is from "Go" until the last bean
touches the inside of the can.
4. Checkers. Four draughts pieces were placed in front of and touching the board.
The pieces are to be stacked one on top of another. Timing is from "Go" until the
4th piece makes contact with the 3rd.
5. Large light objects. Five empty 400g size tins were placed in front of the board,
2" apart with open end facing down. The tins are to be moved to stand on the
board. Timing is from "Go" until the last tin is released.
6. Large heavy objects. The task is as the previous task but cans are full (400g
weight).
Total time taken to complete all tasks in the battery with both hands was calculated.
In the Jebsen study, it was necessary to calculate time taken for the dominant and
non-dominant hands separately as one patient group participating in the study was a
hemiparesis group. However, this consideration is not relevant to this study. The use
of a combined time for the two hands may be justified on the grounds that the
observer-rating criteria to be used for bradykinesia do not differentiate between the
two hands (in contrast to those of rigidity and tremor), being ratings of overall speed
of movement. The use of a combined total for all six tasks is intended to produce a
comprehensive combined assessment of overall upper-body bradykinesia. Similar
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properties were demonstrated for the tasks which all proved sensitive to impaired
motor performance (Jebsen et al., 1969).
2.1.2 Bradykinesia - CANTAB
The CANTAB (Cambridge Neuropsychological Tests, Automated Battery) is a PC
software package which contains a number of common neuropsychological tests, of
which the reaction time test was selected. Stimuli are presented visually on the
screen and responses are via a press-plate and a touch-sensitive screen. On all tests,
feedback is provided to the subject immediately after each trial.
The CANTAB reaction time task contains both simple reaction time and choice
reaction time conditions. In both conditions, the subject responds by touching the
computer screen. In the simple reaction time condition a circle is presented in the
middle of the screen (always in the same position); the subject is asked to touch the
centre of the circle as quickly as they can after a dot appears in the circle. In the
choice reaction time condition five circles are presented on the screen (again, always
in the same position); the subject is asked to touch the centre of the circle in which
the dot appears. A press-pad is used in some sections of the task, the hand resting
upon the plate until the stimulus appears. The use of the press-plate enables the
separation of reaction latency and movement latency. Reaction latency includes time
to view and process the stimulus information, and plan and initiate the response.
Movement latency is solely the time taken to move the hand from the press-plate to
the screen. The separate recording of reaction and movement latencies means that a
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differentiation may be made between patients who are slow to move and those who
may be unimpaired in movement speed but are slow to initiate their movements.
The reaction time test is presented in five sections, of which three are forms of
simple reaction time, and two are forms of choice reaction time:
1. subject must touch a circle on the screen when a yellow dot appears in the centre
of the circle;
2. as previous stage, but dot may appear in one of five circles;
3. press-pad must be held down until dot appears, subject does not need to touch the
screen;
4. press-pad is to be held until dot appears, and then screen touched (single circle);
5. as previous stage, but with five circles.
The first three of these function primarily as practice stages for the responses
required in the final two sections.
Being administered by computer, the CANTAB has certain valuable properties.
Presentation of stimuli is more consistent from patient to patient than can be
achieved by a human investigator. Response latencies are measured with great
accuracy. Finally, the administration of the test is simpler and quicker for the
investigator.
The use of the CANTAB with the patient groups involved in this study is well
established, its use having been validated in varied contexts and with different
groups: schizophrenia (Pantelis et al., 1997), depression (Purcell et al., 1997),
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Parkinson's disease (Riekkinen et al., 1998), tests of drug effects (Elliott et al.,
1997).
The purpose of including the CANTAB reaction time task in addition to the Jebsen
test is, in part, to provide a more pure assessment of motor speed. The Jebsen test
demands the performance of complex sequences of controlled movements. In
contrast, the CANTAB movement latency provides an uncontaminated measure of
speed of movement after the response has been initiated. The capacity to analyse
initiation latency distinct from movement speed is also valuable. Further, the
CANTAB also allows the calculation of a motor planning latency which may be used
as a marker of cognitive slowing (2.1.5).
2.1.3 Rigidity
Rigidity is to be assessed using a positive feedback device previously used by Walsh
(1992). As with most other forms of automated rigidity assessment this device is
used to examine the relationship between the force applied to the limb and the
resultant motion of the limb.
The positive feedback device consists of a printed motor mounted with the axle
positioned vertically. A metal beam is fastened perpendicular to the axle. Mounted
on the beam is a padded cradle in which the subject's forearm rests. The arm is held
in place with velcro straps. The axis of movement at the subject's elbow is positioned
concentric with the axle of the motor.
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The velocity through which the lever is moving is monitored by the device. When
motion is detected, a force is applied to the lever in the same direction as the
movement. The torque generated by the motor causes the limb to move until its
momentum is restrained by stretching the tissues of the joint about which motion is
occurring and a rebound occurs. As soon as the velocity reverses, the current in the
motor (and hence the torque) reverses, pushing the limb backwards until it is again
checked by elasticity. Once again the current reverses, accelerating the limb in the
opposite direction. With sufficient gain in the loop the oscillations will become self-
sustaining for as long as the system is energised.
The output from the device consists of three signals conveying displacement of the
lever (and attached limb), velocity of the lever and torque applied to the lever. These
signals are to be recorded on computer using custom software. Recording will begin
once the motion of the lever has settled to a regular pattern of oscillation. Samples
are to be of a minimum of ten cycles of oscillation.
The software used presents the data as graphs of displacement, velocity and applied
torque against time. Accurate values for any point on the graphs may be produced.
This information will be used to calculate the mean cycle length of oscillation (in
seconds) for each sample. From this the frequency of oscillation may be derived.
It is possible, using the formula noted earlier (1.3.2.2), to calculate a raw stiffness
value from the frequency of oscillation. However, it is argued (Caligiuri & Galasko,
1992; Webster, 1966) that an activation ratio is a more valid method of quantifying
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parkinsonian rigidity. The ratio represents the effect of activation on stiffness and is
calculated from the ratio of activated stiffness to resting stiffness. Because the ratio is
derived by comparing data from one condition to another within the same patient, the
effect of inertia on stiffness is cancelled out. This method is simpler for the
investigator and less intrusive for the patient.
The positive feedback method has great advantages over other methods of rigidity
quantification. Principally, the use of torque as the independent variable avoids
confounding by thixotropy and differential viscosity. These phenomena affect, to
some degree, most other instrumental procedures. Further, the relatively small
influence of the investigator on the procedure (in other methods the force applied to
the limb is produced by the investigator rather than by a motor) is also beneficial in
ensuring validity.
2.1.4 Tremor
The instrumentation method selected to quantify tremor is an accelerometer
procedure similar to that used in numerous other studies (Arblaster et al., 1993;
Caligiuri et ah, 1991; Caligiuri & Lohr, 1993; Pullinger & Tyrer, 1983; Tyrer et ah,
1981). The accelerometer to be used (model no. ICS 3022-0022-N) is approximately
lcm square and 3mm deep; it is fastened to the finger by a velcro strap. The output
signal is proportional to the acceleration undergone. The raw data is to be recorded
and stored on computer. Variables representing the amplitude and frequency
composition of the tremor may be calculated.
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Samples of tremor will be recorded from both hands, of both resting and postural
tremor. In both conditions, the patient will be seated with the hand pronated and the
forearm supported on a cushioned rest. Cushioning is necessary to ensure against the
presence of artefacts due to pulses in the forearm causing movement in the hand.
Resting tremor is to be recorded with the hand hanging limp; postural tremor is to be
recorded with the hand extended. All samples will be of at least 15 seconds in length,
and will be recorded after the hand has settled into position.
Data will be analysed using three 5-second epochs taken from the sample. A Fast
Fourier Transform will be performed on the data to determine the relative
contribution of different frequency components in the sample to total amplitude. The
software to be used presents this information on a frequency spectrum and as a
measure of amplitude for each frequency component. Using the three analysed
epochs, mean tremor amplitude in two frequency ranges will be calculated These
ranges are 3.0-7.0 Hz (low frequency parkinsonian tremor) and 7.0-13.0 Hz (high
frequency normal tremor). Comparisons may be made using total tremor amplitude,
amplitude in the low and high frequency bands, and the ratio between high and low
frequency amplitudes.
The use of accelerometry in tremor instrumentation is now long established and well
validated. The same may be said for the use of FFT procedures to analyse the
frequency composition of tremor. In this study, the values chosen both for the FFT
procedure and the calculation of representative values are well supported by the
literature.
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The 5-second epoch to be used for FFT analysis was judged sufficient to ensure the
validity of the analysis, given the frequency ranges to be assessed. An average of
three epochs is to be taken as a precaution against the presence of artefacts in the
record. The frequency ranges (3.0-7.0 Hz and 7.0-13.0 Hz) are chosen on the basis of
existing work in this field. The literature provides evidence that tremor may be
defined as activity occurring above a 3.0 Hz cut-off (Caligiuri et al., 1991). Many
authors use a 4.0 Hz cut-off but a lower threshold may be more inclusive of
extremely slow tremors. The 13.0 Hz upper limit is also common, it being stated that
normal human tremor above this level is unusual (Marsden et al., 1969). The use of a
cut-off value of 7.0 Hz between the two frequency ranges is also supported, a similar
value being used by other authors (Arblaster et al., 1993; Caligiuri & Lohr, 1993).
2.1.5 Motor Planning Impairment
The indicator of cognitive impairment to be used is the motor planning variable
calculated from the CANTAB reaction time test data. Though it is derived from
results in the simple and choice reaction time conditions, the impairment is
independent of motor response speed and slowed initiation.
The failure of some parkinsonian patients to make use of prior information
concerning movement form has been noted earlier (Bloxham et al., 1984; 1.3.1.1.1).
This can be illustrated in terms of the reaction time paradigm. In the simple reaction
time condition the form of the response to be made is known before the stimulus is
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presented, as the response is always the same. In the choice reaction time condition
the form of the response cannot be known until the stimulus is presented.
Normal subjects make use of prior of their prior knowledge of response form in the
simple condition and pre-plan their response. Their response time is thus shorter in
the simple condition than the choice condition. In contrast, patients with
parkinsonism often fail to make use of prior knowledge. The effect on their
performance is that response times are lengthened to a greater extent in the simple
reaction time condition than the choice condition. It is this relative impairment in the
simple reaction time condition (and relative lack of impairment in the choice
condition) which characterises the motor planning impairment. This characteristic
pattern of performance may be exhibited as impairment in the choice condition and
greater impairment in the simple condition or as impairment only in the simple
condition.
Within the CANTAB reaction time test setting, a variable to indicate the extent of the
motor planning latency (a component of the reaction latency) can be derived by
subtracting the simple reaction latency from the choice reaction latency. The
common components of the two latencies (time to view the stimulus, process the fact
of its presence, and to initiate a response) are cancelled out, leaving only the extra
time taken to prepare a motor plan in the choice condition. In subjects who do not
make use of prior knowledge of the form of response needed this figure should be
zero (though in practice it is unlikely to be).
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An advantage of this procedure, over other methods of detecting cognitive
impairment is that the motor planning variable may be calculated from data already
collected. This removes the need for patients to complete any further tests.
2.1.6 Subjective Features - SWN
Two subject-rated scales have been selected. The SWN (Subjective Well-being under
Neuroleptics; Naber et al., 1994) is a recently developed scale intended to be
sensitive to the negative subjective effects of typical antipsychotics. It was originally
developed in German but is now available in an English translation. No evidence has
yet been published of the use of this version. Also to be used are three simple visual
analogue scales. These form simple assessments of subjective sensations of slowing,
sedation, and restlessness.
The SWN has been shown to distinguish the effects of typical antipsychotics from
those of atypical agents, and to be predictive of future non-compliance with
medication (Naber, 1995). The scale comprises 42 multiple-choice items, with five
possible responses for each item. It is intended that the total score of the scale is
used, in line with Naber (1995). However the authors also state that factor analysis
demonstrates that the items form five sub-factors (emotional regulation, self-control,
mental functioning, social integration, physical functioning) and one extra item
which does not cluster with any others.
The SWN scale has been selected for the opportunity that it may provide to identify
reliably those patients who have negative experiences of typical antipsychotics,
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distinguishing them from those who may have a superficially similar appearance due
to features of their illness.
2.1.7 Subjective Features - Visual Analogue Scales
The visual analogue scales have been devised specifically for this study. They
comprise three 10cm lines, labelled as follows:
Scale Maximum Minimum
Slowing
I feel so slowed down it's like
carrying a weight on my back
My movements don't feel at all
slow
Sedation
I feel so sedated I can't keep
my eyes open
I don't feel sedated at all
Restlessness
I feel so fidgety and restless I
can't sit still at all
I don't feel fidgety or restless at
all
The form of response is to mark a cross on the line at the point felt to most accurately
represent the patient's subjective state. The response is scored by measuring the
position of the cross from the maximum point on the scale. Thus for all three scales a
minimum score (representing normality) rates 10.0 cm and a maximum score
(representing extreme abnormality) rates 0.0 cm.
Use of visual analogue scales is well established in many situations in which they
provide reliable and valid measures of subjective sensations (criterion validity has
been demonstrated relative to objective measures of related features). The benefits of
scales such as these derive principally from their ease of use. Visual analogue scales
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are quick and simple to administer, and are easily understood by the patient. This
rapidity of response may in itself help to increase the validity of the scales by




2.2.1 Jebsen Hand Function Test
In addition to the standard instructions below, patients were encouraged to treat the
test as a game which challenged them to complete the tasks as quickly as possible.
2.2.1.1 Card turning
For the left hand: "Place your left hand on the table please. When I say 'Go', use
your left hand to turn these cards over one at a time as quickly as you can, beginning
with this one (indicate card to extreme right). You may turn them over in any way
that you wish and they need not be in a neat pattern when you finish. Do you
understand? Ready? Go."
For the right hand: "Now the same thing with the right hand beginning with this one
(indicate extreme left card). Ready? Go."
2.2.1.2 Small common objects
For the left hand: "Place your left hand on the table please. When I say 'Go', use
your left hand to pick up these objects one at a time and place them in the can as fast
as you can beginning with this one (indicate paper clip on the extreme left). Do you
understand? Ready? Go."
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For the right hand: "Now the same thing with the right hand beginning here (indicate
paper clip now on the extreme right). Ready? Go."
2.2.1.3 Simulated feeding
For the left hand: "Take the teaspoon in your left hand please. When I say 'Go', use
your left hand to pick up these beans one at a time with the teaspoon and place them
in the can as fast as you can beginning with this one (indicate bean on the extreme
left). Do you understand? Ready? Go."
For the right hand: "Now the same thing with the right hand beginning here (indicate
bean on the extreme right). Ready? Go."
2.2.1.4 Checkers
For the left hand: "Place your left hand on the table please. When I say 'Go', use
your left hand to stack these checkers on the board in front of you as fast as you can
like this, one on top of the other (demonstrate). You may begin with any checker. Do
you understand? Ready? Go."
For the right hand: "Now the same thing with the right hand. Ready? Go."
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2.2.1.5 Large light objects
For the left hand: "Place your left hand on the table please. When I say 'Go', use
your left hand to stand these cans on the board in front of you, like this
(demonstrate). Begin with this one (indicate can on extreme left). Do you
understand? Ready? Go."
For the right hand: "Now the same thing with the right hand beginning here (indicate
extreme right can). Ready? Go."
2.2.1.6 Large heavy objects
For the left hand: "Now do the same thing with these heavier cans. Place your left
hand on the table. When I say 'Go', use your left hand to stand the cans on the board
in front of you, like this. Begin with this one (indicate can on extreme left). Do you
understand? Ready? Go."
For the right hand: "Now the same thing with the right hand beginning here (indicate
extreme right can). Ready? Go."
2.2.2 CANTAB
In addition to the verbal instructions below, diagrams of the stimuli were produced.
These illustrations of the circle with a dot in the centre and the five circles, could be
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shown and explained before the trial commenced, benefiting patients who found the
verbal instructions too abstract if given before the start of the test and too quick if
given after the test had started.
2.2.2.1 Pointing to the circle
"A yellow spot will appear inside the circle. Touch the circle as soon as you can after
the spot appears."
If the subject points TOO SOON prompt "Try to wait until the spot appears"
If the subject points TOO LATE prompt "Try and point a little quicker".
2.2.2.2 Five choice pointing
"Now we are going on to pointing with five choices. The spot may appear in any of
the five circles. Point to the circle where you saw the spot appear. Point as soon as
you can after you see the spot."
2.2.2.3 Single choice release
"The yellow spot will appear inside the circle soon after you press the pad. Let go of
the pad as soon as you can after you see the spot. Don't let go of the pad until after
you see the spot appear."
Prompts: "Try no to let go of the pad until after you see the spot."
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2.2.2.4 Single choice release and point
"From now on, when you let go of the pad, touch the circle as soon as you can.
Remember not to let go of the pad before you see the spot, but this time remember
you have to touch the circle."
2.2.2.5 Five choice release and point
"Now we are going to give you five circles again. Remember, touch the circle where
you saw the spot as soon as you can, but don't let go of the pad until you see the
spot."
A slight modification was made to the instructions to read "...touch the 'centre' of the
circle..." following the case of one patient who interpreted the instruction to "touch
the circle" in an over-literal fashion, touching the line forming the perimeter of the
circle rather than its centre.
2.2.3 Rigidity
The rigidity instrumentation required little to no conscious effort on the part of the
patient. Instructions for this procedure were not formalised. The patient was simply
asked to relax as fully as possible and let the machine do the work of moving their
arm rather than trying to 'help' it.
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2.2.4 Tremor
Like the rigidity assessment procedure, this form of instrumentation demanded little
effort from the patient. For each section the hand position needed was explained and
if necessary demonstrated. The patient was asked to hold their hand in the position
demonstrated, either extended (in the resting tremor assessment) or hanging limp (in




The criteria to be used in the evaluation of the instrumental measures are all
commonly used and well-established rating scales. Most are observer-ratings, one is
a self-report scale.
2.3.1 Extrapyramidal Symptom Rating Scale
Designed using extensive input from neurology, the Extrapyramidal Symptom
Rating Scale (ESRS; Chouinard et al., 1980) is a highly comprehensive rating of
extrapyramidal symptomatology with very good psychometric properties. The
parkinsonism section of this scale is a comprehensive assessment of parkinsonian
features. Separate items for the severity of all major signs are included, including
bradykinesia, and rigidity and tremor by different body areas. All items are rated on a
scale of 0-6 (generally "normal" to "extremely severe" though extensive rating
guidelines are provided).
The ESRS has advantages over other commonly used scales (e.g. Simpson & Angus,
1970). The tremor items use a novel feature, the score being influenced on a dual-
axis basis by the extent to which tremor is present as well as the amplitude of the
tremor. Bradykinesia is made distinct from gait problems (and facial masking),
which may in part result from bradykinesia but should not be used as the sole
indicator of bradykinesia. Further, similar weight is given to all the major features of
parkinsonism (bradykinesia, rigidity, tremor), and correspondingly less weight is
placed upon minor features such as facial masking.
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Analysis may use a total of all items, a group of bradykinesia-related items (nos. 1, 2,
and 4), and some individual items (tremor and rigidity in the arms, bradykinesia, and
akathisia).
2.3.2 Abnormal Involuntary Movement Scale
The Abnormal Involuntary Movement Scale (AIMS; Guy, 1976) is an observer-rated
assessment of dyskinesias. Items are included for the severity of movements in a
number of different body areas (grouped in "facial and oral", "extremities", and
"truncal" categories). Further items provide global scores for the overall severity of
abnormal movements, incapacitation due to abnormal movements, and patient's
awareness of abnormal movements. All items are rated on a 0-4 basis, these scores
representing "normal", "minimal", "mild", "moderate", and "severe" degrees of
dysfunction. The three global impression items and a total of all movement items
may be used in analysis.
2.3.3 Targeting Abnormal Kinetic Effects scale
An observer-rated assessment of parkinsonian side effects (TAKE; Wojcik et al.,
1980), designed as a companion to the AIMS scale The format of the TAKE parallels
that of the AIMS, consisting of five items for individual features (bradykinesia,
rigidity, tremor, autonomic nervous system (ANS) effects, akathisia) and three global
scores for overall severity of side effects, incapacitation due to side effects, and
patient's awareness of side effects. Like the AIMS, all items are rated on a 0-4 basis,
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these scores representing "normal", "minimal", "mild", "moderate", and "severe"
degrees of dysfunction. Analysis may be conducted using all individual item scores
and/or a total of items 1-5.
2.3.4 Positive And Negative Syndrome Scale
This scale is an observer-rating assessment of psychiatric symptomatology (PANSS;
Kay et al., 1987), most commonly used for schizophrenic patients. Items fall into
three sub-scales (positive and negative symptomatology, and general
psychopathology). Analysis may use the total overall score of all three sub-scales,
the totals for the three sub-scales, a composite score (negative symptomatology -
positive symptomatology), and some individual items.
2.3.5 Montgomery-Asberg Depression Rating Scale
The Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery &
Asberg, 1979) is an observer-scored rating of depression. The MADRS was derived
from a comprehensive observer-rating of psychopathology, the Comprehensive
Psychopathological Rating Scale (CPRS; Asberg et al., 1978), by selecting the items
most sensitive to changes in depressive symptomatology.
When analysing the results of the MADRS, total score is most commonly used. Two
groups of items may also be used in this study. The first comprises items which may
overlap descriptively with features of extrapyramidal side effects. This "EPS-like"
group of items allows the investigation of possible conceptual contamination; it
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comprises items 3, 6, 7, and 8. The second group is comprised of all other items (nos.
1, 2, 4, 5, 9, and 10).
2.3.6 Beck Depression Inventory
The Beck Depression Inventory (BDI; Beck et al., 1961) is a very commonly used
self-report scale for depression which has been well-validated in psychiatric
populations. The BDI comprises 21 items which are rated on a 0-3 basis, the patient
being asked to choose which of four statements best describes the way they have
been feeling during the previous week. A simple total score will be used for analysis.
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2.4 Statistical analysis procedures
2.4.1 ANOVA
Analysis of variance and associated post-hoc tests (Bonferroni and LSD) are used for
the comparison of means of different groups where the number of groups is three or
more. ANOVA tests to determine if the different experimental groups are likely to
represent samples from the same population. Post-hoc tests to perform multiple
comparisons allow the location of significant differences to be determined, i.e. which
groups differ significantly from each other. The Bonferroni post-hoc test is the more
conservative of the two. A significance level of p < 0.05 was considered significant
and a level of p < 0.01 very significant.
2.4.2 T-test
Student's t-test likewise calculates the likelihood that two sample means tested
represent the same population. Levene's test for equality of variances was performed
with all t-tests, a probability of p < 0.05 indicated that the assumption of equality of
variance had been violated. As with ANOVA, a significance level of p < 0.05 was
considered significant and a level of p < 0.01 very significant.
2.4.3 Non-parametric ANOVA
The Kruskal-Wallis test is a distribution-free form of analysis of variance, i.e. it may
be used for data which cannot conform to a normal population curve (when data
values must be integers). As with the other tests for group differences, a significance
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level of p < 0.05 was considered significant and a level of p < 0.01 very significant.
Lieberman's index analysis was used as a non-parametric post-hoc test to determine
the location of significant between-group differences.
2.4.4 Parametric correlation co-efficient
The Pearson's correlation co-efficient is calculated as an indicator of the strength and
significance of a relationship between two variables. Relationships where r > +0.8 or
r < -0.8 can be considered strong, those where r is between -0.5 and -0.8 or between
0.5 and 0.8 are classed as being of moderate strength, and those where r is between -
0.5 and 0.5 are classed as weak. As with the tests of differences, a significance level
of p < 0.05 was considered significant and a level of p < 0.01 very significant.
2.4.5 Nonparametric correlation co-efficient
The Spearman's ranked correlation co-efficient is a non-parametric equivalent of the
Pearson's measure. This coefficient will identify non-linear relationships which may
be missed by the Pearson coefficient, and may also be used with non-continuous
variables. As with the Pearson coefficient, relationships where r > +0.8 or r < -0.8
can be considered strong, those where r is between -0.5 and -0.8 or between 0.5 and
0.8 are classed as being of moderate strength, and those where r is between -0.5 and
0.5 are classed as weak. Once again, a significance level of p < 0.05 was considered
significant and a level of p < 0.01 very significant.
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2.5 Demographic characteristics
The following tables contain the demographic data for the patient group and the
control group. The information covers age, gender, diagnosis, and medication status.
2.5.1 Patient group case characteristics
Case Age Gender Diagnosis Medication Code
AD 28 M Schizophrenia Depixol 80mg weekly 2
AG 50 F Schizophrenia Risperidone 4mg nocte
Changed to
Quetiapine 100 + 150
4












BW 47 M Bipolar
Disorder
Lithium lOOOmg
Thioridazine 25 mane + 100 nocte
3
CM 48 F Depression Nefazodone 200mg BD
Mirtazapine 15-30mg
7









DC 52 F Depression Imipramine 175mg nocte 6
DCL 23 M Schizophrenia Clozapine 750 OD
Hyoscine
5










GC 26 M Schizophrenia Clozapine 300 mg OD
Paroxetine 20 OD
5
GG 20 M Schizophrenia Amitriptyline 200 mg nocte 6





HH 34 F Bipolar
Disorder
Amitriptyline 125mg nocte




HM 41 F Schizophrenia Clopixol 400 2/52










JG 38 F Depression Chlorpromazine 75-100mg
Paroxetine 30mg
3








JK 45 F Depression Amitriptyline 125mg nocte 6
JM 33 M Schizophrenia Clozapine 200 nocte 5
JMK 48 M Depression Seroxat
Trazadone 100 nocte
7
JR 58 M Bipolar
Disorder
Haloperidol 5 BD 1
JS 28 M OCD Olanzapine 20mg 4










LS 32 F Schizophrenia Olanzapine 15mg 4
MB 40 M Schizophrenia Depixol 30 mg 3/52 2
MD 22 M Schizophrenia Trifluoperazine 25mg 2
MH 59 F Depression Lithium 600mg nocte
Imipramine lOOmg nocte
6
MT 17 M Schizophrenia Trifluoperazine 20mg
Procyclidine 5 BD
2
MWB 41 M Schizophrenia Clozapine 750mg OD 5





PMG 53 M Schizophrenia Clozapine 350 mg OD 5




RF 31 F Schizophrenia Chlorpromazine 50mg (for 5 days
only)
1
SM 24 M Schizophrenia Clopixol 200mg weekly 2
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Zopiclone 7.5
SP 22 M Schizophrenia Risperidone 2mg OD 4
SPA 25 M Schizophrenia Clozapine 325mg OD
Seroxat 30 OD
5
TIH 33 M Schizophrenia Clopixol 100 weekly
Chlorpromazine 100 nocte
2





The following codes were used to describe medication status for defining patient
medication groups:
0 - Control
1 - Minimal exposure to psychotropic medication
2 - Typical antipsychotics (high potency)
3 - Typical antipsychotics (low potency)
4 - Atypical antipsychotics (other than clozapine)
5 - Atypical antipsychotics (clozapine)
6 - Antidepressants (tri-cyclic)
7 - Antidepressants (SSRI)





















This section will present and compare the demographic characteristics of the control
group and the different patient groups identified. The analysis will first consider the
control group and the overall patient group, then consider the patient medication
groups which will be used.









Patient 25 17 42
Control 8 9 17







Control 24 45 31.625
2.5.3.4 Patient medication group numbers
The first sub-division of the patient group is into those receiving antipsychotic
















Antipsychotic 20 11 31
Typical 12 6 18
Atypical 8 5 13
Non-antipsychotic 6 11
Antidepressants 5 4 7
Minimal exposure 3 2 4
2




Antipsychotic 17 53 32.94
Typical 17 47 32.39
Atypical 22 53 33.69
Non-antipsychotic 20 59 45.18
Antidepressants 20 59 46.29
Minimal exposure 31 58 43.25
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2.5.3.7 Antipsychotic medication group numbers
The antipsychotic group may be further sub-divided by separating the typical
antipsychotics group into those who are receiving high- or low-potency antipsychotic
agents and by separating the atypical antipsychotics group into those who are
receiving clozapine and those who are receiving other agents. The resulting sub¬












2.5.4.1 Patient and control group
No difference in gender composition (Chi sq. = 0.764, df = 1). Similarly no
differences in age (Kruskal Wallis test, Chi sq. = 1.8, df =1). The control group is
very similar to the overall patient group in terms of gender composition and average
age.
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2.5.4.2 Patient medication groups
Differences are found in gender composition (Chi sq. = 15.434, df = 3, p < 0.01) and
in age (Kruskal Wallis test, Chi sq. = 13.612, df = 6, p < 0.05). Though the overall
patient group is similar to the control group, the age and gender distribution in the
patient group is not consistent within the different medication groups.
2.5.5 Multiple drug therapy
Data were also collected describing the prevalence of multiple drug therapy in this
patient cohort. The following table illustrates the prevalence of multiple drug therapy
in some of the patient medication groups participating in the study. The distinction
between high and low potency typical antipsychotic agents is not used in most










1 17% - 50% 43%
2 25% 33% 50% 43%
3 25% 50% - 14%
>3 33% 17% - -
Supplementary medications in the typical anti-psychotic groups include additional
typical antipsychotics, lithium carbonate, tricyclic antidepressants, SSRIs,
carbamazepine, and anti-parkinsonian agents (procyclidine). Even in the clozapine
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group, half of the group were receiving supplementary medication including SSRIs,
other antidepressants, and even a small regular dose of a typical antipsychotic.
2.5.6 Summary
The control group is a suitable comparison group for the patient group in this study,
being non-significantly different in gender and age composition. Though there are
differences between the patient medication groups these likely reflect differences in
the diagnostic composition of the medication groups. Multiple drug therapy is
common in all the patient medication groups. Though this prescribing practice is




This section contains the evaluation of the measures used in this study and, following
this, a consideration of any other significant results.
3.1 Bradykinesia - Jebsen hand function test
3.1.1 Observer ratings of bradykinesia
Observer ratings of bradykinesia are taken from the TAKE and ESRS scales. The
TAKE item is a global assessment of bradykinesia, including manifestations of
bradykinesia such as gait difficulties, lack of pendular arm swing and facial masking.
The ESRS bradykinesia item is an assessment of "pure" bradykinesia, comprising
speed of movement and initiation difficulties. Also used is the group of bradykinesia-
related items from the ESRS scale.
3.1.1.1 Descriptive statistics for the TAKE bradykinesia item scores in the patient
group only




42 0 4 0
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3.1.1.3 TAKE bradykinesia item score frequencies for the patient group only









3.1.1.4 Summary of TAKE bradykinesia item scores
Though a small number of patients were rated as exhibiting severe levels of
bradykinesia, the vast majority exhibited minimal or no bradykinesia. Over 50% of
patients were rated normal, and two thirds were rated as normal or minimal
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bradykinesia. The median score was zero. The scores do not exhibit a normal
distribution.
3.1.1.5 Descriptive statistics for the ESRS bradykinesia item scores in the patient
group




42 0 4 0













3.1.1.8 Summary of ESRS bradykinesia item scores for the patient group
The ratings made using the ESRS bradykinesia. item exhibit an even greater
preponderance of low scores than do those made using the TAKE bradykinesia item.
Over two thirds (69%) of patients were rated as exhibiting no bradykinesia on this
item, and the highest score used was four (of a maximum six). The median score was
zero again. The scores on this item display a similar non-normal distribution pattern
to those on the TAKE bradykinesia item.
3.1.1.9 Descriptive statistics for the group of ESRS bradykinesia-related items
scores in the patient group only





42 0 11 1
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3.1.1.10 Bar-graph of score frequencies for the group of ESRS bradykinesia-related
items
ESRS Group of bradykinesia-related items















3.1.1.12 Summary of ESRS group of bradykinesia-related items scores
As with the other ratings of bradykinesia, scores on this criterion were mostly low.
The maximum rating given was 11, and the median was only 1. The distribution of
scores is also similar to the other bradykinesia criteria.
3.1.2 Instrumentation
The results of the Jebsen Hand Function Test are presented here for the patient group
only.
3.1.2.1 Jebsen hand function test total time descriptive data from the patient group
N Minimum Maximum Mean SD
Jebsen total
time
40 54.76 107.37 74.9667 12.5430











3.1.2.3 Summary of the Jebsen hand function test results
The results from the Jebsen test exhibit significant clustering towards the lower end
of the total time range. The lack of a normal distribution parallels the pattern of
scores found in the observer-rating criteria.
3.1.3 Evaluation of the Jebsen hand function test as a measure of bradykinesia
relative to the TAKE bradykinesia item criterion
3.1.3.1 Correlations between TAKE bradykinesia item and Jebsen total time
N Coefficient Significance
40 0.325 0.020
Scatter plots of the relationship between Jebsen total time and TAKE bradykinesia
item are displayed in section 3.1.3.6.
3.1.3.2 Identification of a bradykinetic group using the observer-rating criterion







3.1.3.3 Identification of a bradykinetic group using Jebsen test
The inclusion/exclusion threshold for the Jebsen test groups was set at 2SDs above
the mean of the control group.





17 45.15 75.53 60.3871 6.6229 73.6329
3.1.3.4 Scatterplot of Jebsen total time results in the patient group with group









3.1.3.5 Frequency data for Jebsen test identified groups
Jebsen total time Frequency Percent
<2SDs above control 21 50.0
group mean
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3.1.3.8 Summary of the evaluation of the Jebsen hand function test using the TAKE
bradykinesia item criterion
The correlation between the Jebsen test results and the TAKE bradykinesia item
criterion is of only weak to moderate strength but is statistically significant (p =
0.020). The instrumentation group inclusion threshold at 2SDs above the mean of the
control group provided comparison groups of roughly equal sizes (though the group
identified as bradykinetic by the Jebsen test was slightly larger than that identified by
the TAKE bradykinesia item criterion). The majority of patients were rated as non-
bradykinetic by both the observer-rating and the Jebsen test. In this evaluation the
sensitivity of the Jebsen test was reasonably good though the specificity was poor.
The poor specificity resulted from the relatively high number of false positive cases
identified by the Jebsen test.
3.1.4 Evaluation of the Jebsen hand function test as a measure of bradykinesia
using the ESRS bradykinesia item criterion





A scatterplot of Jebsen total time against ESRS bradykinesia item may be seen below
in section 3.1.4.4.
3.1.4.2 Identification of a bradykinetic group using the ESRS observer-rating
criterion







The same Jebsen test identified groups were used as in the previous comparisons
(3.1.3.3).
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3.1.4.6 Summary of the evaluation of the Jebsen hand function test using the ESRS
bradykinesia item criterion
The correlation between the Jebsen test and the ESRS bradykinesia item criterion is
weak and only trends towards significance. The groups identified by the measure and
the criterion are less similar in size than in the previous comparison, due to the small
numbers of patients identified as bradykinetic by the ESRS bradykinesia item
criterion. As before, both the measure and the criterion identify the majority of
patients as non-bradykinetic. Relative to this criterion, the sensitivity of the measure
is good, but specificity is low.
3.1.5 Evaluation of the Jebsen hand function test using the group of ESRS
bradykinesia-related items criterion
3.1.5.1 Correlation between Jebsen total time and score on group of ESRS
bradykinesia-related items
One-tailed significance is quoted.
N Coefficient Significance
40 0.361 0.011
Scatterplot illustrated below (3.1.5.4)
3.1.5.2 Identification of a bradykinetic group using the observer-rating criterion








The same Jebsen-identified group were used as in previous comparisons (3.1.3.3).
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3.1.5.6 Summary of the evaluation of the Jebsen hand function test using the ESRS
group of bradykinesia-related items criterion
The strongest association between the Jebsen test and an observer-rating was found
with this criterion. It is of moderate strength and a high level of significance.
However, the observer-rating and Jebsen test identified groups are not very equal in
size, though the majority of patients are identified as non-bradykinetic by both the
measure and the criterion. Although the sensitivity of the measure is very high
specificity is low.
3.1.6 Summary
Observer-ratings of bradykinesia are low in the patient group. Most patients are rated
normal, those exhibiting bradykinesia are mostly rated as exhibiting only minimal or
mild abnormality. The correlations between the objective measures and the ratings
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criteria are mostly weak but statistically significant. The sensitivity of the
as markers of bradykinesia is moderate to good but the specificity is low.
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3.2 Bradykinesia - CANTAB reaction time test
3.2.1 Results of CANTAB instrumentation
Results are presented for the patient group only.
3.2.1.1 CANTAB reaction time test descriptive data for patient group only
N Minimum Maximum Mean SD
Simple RT
total time
40 547 1317 783.65 180.73
Choice RT
total time
40 450 1261 783.07 169.45
N Minimum Maximum Mean SD
Simple RT
movement 40 285 806 453.95 130.55
latency
Choice RT
movement 40 294 809 446.80 128.00
latency
3.2.1.2 Scatterplots of CANTAB reaction time test variables for the patient group
only
3.2.1.2.1 Simple RT total time
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Patient group only

























































3.2.1.3 Summary of CANTAB reaction time test results
The pattern of results from the CANTAB reaction time variables is superficially very
similar to those from the Jebsen hand function test, and the observer-ratings of
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bradykinesia. The majority of patients exhibit relatively low total times and the
distribution of times is non-normal.
3.2.2 Evaluation of the CANTAB reaction time test variables as measures of
bradykinesia relative to the TAKE bradykinesia item criterion
Total reaction time and movement latency variables from both simple and choice RT
conditions are to be used as measures.
3.2.2.1 Correlation between the CANTAB reaction time variables and the TAKE
bradykinesia item (one-tailed significance)
Correlation with TAKE
bradykinesia item



















3.2.2.2 The TAKE bradykinesia item groups were selected using the same inclusion







3.2.2.3 CANTAB reaction time test groups identified using these data from the
control group only (threshold set at 1SD above control group mean)





17 511 933 710.94 130.97 841.91
Choice RT
total time








17 290 567 414.82 86.30 501.12
3.2.2.4 Scatterplots of patient group data with group thresholds marked












































































3.2.2.5 Frequency data for groups identified using CANTAB reaction time test
variables
3.2.2.5.1 Simple RT total time
Simple RT total time Frequency Percent
<1SD above control group 28 70.0
mean
>1SD above control group 12 30.0
mean
Total 40 100.0
3.2.2.5.2 Choice RT total time
Choice RT total time Frequency Percent
<1SD above control group 30 75.0
mean
>1SD above control group 10 25.0
mean
Total 40 100.0




<1SD above control group 28 70.0
mean








<1SD above control group 29 72.5
mean
>1SD above control group 11 27.5
mean
Total 40 100.0
3.2.2.6 Sensitivity and specificity analysis of the CANTAB reaction time test
variables using the TAKE bradykinesia item criterion














































3.2.2.7 Summary of the evaluation of the CANTAB reaction time test variables
using the TAKE bradykinesia item criterion
The correlation between the criterion and simple reaction time is statistically
significant but weak. The same is true of the correlations between the criterion and
the movement latencies in both the simple and choice reaction time conditions.
However, the association between the criterion and total reaction time in the choice
condition is very weak and non-significant. In all four analyses, the groups defined
by the measure were of similar size to those identified by the criterion. Sensitivity
and specificity were moderate in most cases. However, the two choice reaction time
variables, especially total choice reaction time, demonstrated relatively higher
specificity and lower sensitivity.
3.2.3 Evaluation of the CANTAB reaction time variables relative to the ESRS
bradykinesia item criterion
3.2.3.1 Correlation between the CANTAB reaction time variables and the ESRS
bradykinesia item
Correlation with ESRS





Correlation with ESRS Simple RT movement Choice RT movement
bradykinesia item latency latency
Coefficient 0.314 0.187
Significance 0.024 0.124
3.2.3.2 Frequency scores for normal and bradykinetic groups identified using the







Group numbers are as before (3.2.2.3):
Simple RT total: 12 above, 28 below
Choice RT total: 10 above, 30 below
Simple RT movement: 12 above, 28 below
Choice RT movement: 11 above, 29 below
3.2.3.4 Sensitivity and specificity analysis for the evaluation of the CANTAB
reaction time variables using the ESRS bradykinesia item criterion













































3.2.3.5 Summary of the evaluation of the CANTAB reaction time variables using
the ESRS bradykinesia item criterion
The correlations between the CANTAB reaction time variables and the ESRS
bradykinesia item are weaker than those using the TAKE bradykinesia item criterion.
Both simple reaction time and the SRT movement latency correlate significantly with
the criterion; the relationship is of weak to moderate strength. Neither of the choice
reaction time variables correlate significantly with the criterion. The groups
identified by the measure are of similar size to those identified by the criterion. In all
cases, sensitivity is of moderate strength but specificity is low.
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3.2.4 Evaluation of the CANTAB reaction time variable using the group of ESRS
bradykinesia-related items criterion
The CANTAB variables were also evaluated using the group of ESRS bradykinesia-
related items as the criterion.
3.2.4.1 Correlation between the CANTAB reaction time variables and the criterion
Correlation with ESRS





















The instrumentation group numbers are as before (3.2.2.3):
Simple RT total: 12 above, 28 below
Choice RT total: 10 above, 30 below
Simple RT movement: 12 above, 28 below
Choice RT movement: 11 above, 29 below
3.2.4.4 Results of sensitivity and specificity analysis of the CANTAB reaction time
variables using the ESRS group of bradykinesia-related items criterion


















































3.2.4.5 Summary of the evaluation of the CANTAB reaction time variables using
the ESRS group of bradykinesia-related items criterion
The relationships between the CANTAB variables and the criterion are weak; all but
that involving the choice reaction time variable are statistically significant. The
groups identified by the criterion and the measures are of similar size. In the simple
reaction time condition sensitivity is reasonably good though specificity is poor. In
the choice reaction time condition sensitivity is lower though specificity is
correspondingly higher.
3.2.5 Summary
The correlations between the CANTAB reaction time test variables and the
bradykinesia criteria are weak to moderate in strength but statistically significant. As




Observer-ratings of rigidity were made as part of the TAKE and ESRS scales. The
TAKE item is an overall assessment for the whole body. The ESRS uses individual
items for each limb; those for the upper two limbs are used in this analysis.
3.3.1 Observer ratings of rigidity
Ratings of rigidity are taken from the TAKE and ESRS scales. The TAKE item is a
global assessment of overall rigidity. The two ESRS items used are separate items
for the right and left upper limbs assessed independently.
3.3.1.1 Descriptive data for TAKE rigidity item scores in the patient group
Minimum Maximum Median
TAKE rigidity 0 3 0












None/Normal Minimal Mild Moderate
TAKE Rigidity
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3.3.1.4 Summary of TAKE rigidity item results
Scores on this rating item are generally low. The highest score given is three
(moderate rigidity) and over 50% of patients assessed were rated as exhibiting no
rigidity. The scores do not exhibit a normal distribution.
3.3.1.5 Descriptive data for the ESRS rigidity (R) item
Minimum Maximum Median
ESRS rigidity (R) 0 4 1
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3.3.1.8 Summary of ESRS rigidity (R) ratings
Scores awarded on this rating are low. The maximum awarded was four (of a
maximum of six). As with the TAKE rigidity item, over 50% of patients were rated
as not exhibiting rigidity. The distribution of scores is again non-normal.
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3.3.1.9 Descriptive data for the ESRS rigidity (L) item
Minimum Maximum Median
ESRS rigidity (L) 0 5 0
3.3.1.10 Bar graph of ESRS rigidity (L)
ESRS rigidity (L)
0 12 3 5
ESRS rigidity (L)










3.3.1.12 Summary of ESRS rigidity (L) scores
Ratings on this item are similar to those on the other rigidity items. Scores are
generally low: the maximum awarded was five and the median is zero. The scores
are not normally distributed.
3.3.2 Instrumentation
This section comprises the results of the rigidity instrumentation in the patient group
and the evaluation of the rigidity instrumentation using the observer-rating criteria.
3.3.2.1 Descriptive statistics for mean activation ratio in patient group




32 0.92 1.22 1.0562 6.051x10-2
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3.3.2.3 Descriptive statistics for activation ratio (R) in patient group
N Minimum Maximum Mean SD
Activation
ratio (R)
























3.3.2.5 Descriptive statistics for activation ratio (L) in patient group
N Minimum Maximum Mean SD
Activation
ratio (L)
32 0.89 1.26 1.0401 7.228x10-2
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3.3.2.6 Scatterplot of activation ratio (L) in patient group
Patient group only
3.3.2.7 Summary of rigidity instrumentation results
As with the observer-ratings of rigidity, there is a predominance of low results on the
rigidity instrumentation. However, there are outliers at the low end of the range of
results as well as the top.
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3.3.3 Evaluation of the mean activation ratio as a measure of rigidity severity
relative to the TAKE rigidity item criterion
3.3.3.1 Scatterplot of mean activation ratio against TAKE rigidity in the patient





















3.3.3.3 Identification of the observer-rating groups
The inclusion threshold for the observer-rating groups was set at two (mild rigidity).
Frequency Percent




3.3.3.4 Characteristics of the control group




A threshold of 1SD above the mean of the control group was used to identify a group
exhibiting rigidity.
3.3.3.5 Scatterplot of mean activation ratio patient group data with group threshold
(mean of the control group +1SD) marked
Patient group only
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3.3.3.6 Frequency characteristics of the instrumentation-defined groups (mean
activation ratio)
Group Number Percent
Less than 1SD above 19 59.4
control group mean
More than 1SD above 13 40.6
control group mean
Total 32 100.0















3.3.3.9 Summary of the evaluation of the mean activation ratio using the TAKE
rigidity criterion
The correlation between the measure and the criterion is of weak to moderate
strength and statistically significant. The measure and criterion identified groups are
of similar sizes. The sensitivity of the measure is very good but specificity is poor;
more cases were falsely identified by the measure as rigid than were correctly
identified.
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3.3.4 Evaluation of the activation ratio (R) using the ESRS rigidity (R) criterion
3.3.4.1 Scatterplot of activation ratio (R) against ESRS rigidity (R) with linear best
fit line marked
sss
-1 0 1 2 3 4 5
ESRS rigidity (R)




3.3.4.3 Groups were identified using the ESRS rigidity (R) observer-rating criterion
Frequency Percent




3.3.4.4 Groups were identified using a threshold of 1SD above mean of control
group
Mean SD Mean +1SD
Activation ratio (R) 1.0394 4.270x10-2 1.08210













3.3.4.6 Frequency data for activation ratio (R) groups
Group Number Percent
Less than 1SD above 24 70.6
control group mean




3.3.4.7 Scatterplot of activation ratio (R) against ESRS rigidity (R) with group
thresholds marked
ESRS rigidity (R)













3.3.4.9 Summary of the evaluation of the activation ratio (R) using the ESRS
rigidity (R) criterion
The correlation between the activation ratio (R) and the ESRS rigidity (R) criterion
was of moderate strength but only trends towards statistical significance. The
instrumentation and observer-rating groups are of similar sizes. Sensitivity is very
high and specificity is also good.
3.3.5 Evaluation of activation ratio (L) against ESRS rigidity (L)



















3.3.5.3 Observer-rating groups were identified using the ESRS rigidity (L) item
Frequency Percent
Normal/Minimal rigidity 25 78
Rigid 7 22
Total 32 100
3.3.5.4 Instrumentation groups were identified using a threshold of 1SD above the
mean of the control group
Mean SD Mean +1SD
Activation ratio (L) 1.0083 6.526x10-2 1.07356
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3.3.5.6 Frequency data for the activation ratio (L) groups
Group Number Percent
Less than 1SD above 20 62.5
control group mean












































3.3.5.9 Summary of the evaluation of the activation ratio (L) using the ESRS
rigidity (L) item
The correlation between the measure and the criterion was of weak to moderate
strength but non-significant. The observer-rating and instrumentation groups are of
very similar size. Sensitivity is good but specificity is poor.
3.3.6 Summary
Observer-ratings of rigidity indicate that clinically significant levels of rigidity were
rare in this patient group. No cases of severe rigidity were found and few reached
even mild level. The correlations between the activation ratio and the ratings criteria
were weak to moderate; only that for the mean activation ratio reaches significance.
As a marker of rigidity the activation ratio exhibits a high level of sensitivity but its
specificity is low to moderate.
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3.4 Tremor - postural tremor amplitude
3.4.1 Observer-ratings of tremor
Observer ratings of tremor are taken from the TAKE and ESRS rating scales. These
ratings are intended to be overall ratings of tremor but generally form assessments of
postural tremor amplitude. The TAKE item is a global assessment of tremor severity.
The two ESRS items are for the two upper limbs assessed independently (the novel
scoring guidelines for the ESRS items were discussed earlier, 2.3.1).
3.4.1.1 Descriptive data for TAKE tremor in the patient group
Minimum Maximum Median
TAKE tremor 0 4 2
3.4.1.2 Bar graph of TAKE tremor scores
TAKE Tremor item
None/Normal Minimal Mild Moderate Severe
TAKE Tremor item
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3.4.1.4 Summary of TAKE tremor item scores
The pattern of scores on this rating is very different from the other features
previously considered. The majority of patients (69%) exhibit symptomatic tremor
rated mild or greater. Severe tremor is rare (2.4%) but only 16.7% of patients do not
exhibit greater than normal levels of tremor.
3.4.1.5 Descriptive data for ESRS tremor (RH) scores in the patient group only
Minimum Maximum Median
ESRS tremor (RH) 0 6 3
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3.4.1.6 Bar graph of ESRS tremor (RH) scores
ESRS Tremor (Right upper limb)
0 1 2 3 4 5 6
ESRS Tremor (Right upper limb)










3.4.1.8 Summary of ESRS tremor (RH) scores
Though the rating scheme for the ESRS tremor items differs from that used for the
TAKE tremor item, the pattern of scores is superficially very similar. Severe tremor
is rare but most patients do exhibit some level of symptomatic tremor.
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3.4.1.9 Descriptive data for ESRS tremor (LH) scores
Minimum Maximum Median
ESRS tremor (LH) 0 6 3
3.4.1.10 Bar graph of ESRS tremor (LH) scores
ESRS Tremor (Left upper limb)
ESRS Tremor (Left upper limb)











3.4.1.12 Summary of ESRS tremor (LH) scores
The ESRS tremor ratings for the left hand closely parallel those for the right hand:
there are no apparent asymmetries. Again, severe tremor is rare but some level of
symptomatic tremor is very common.
3.4.2 Instrumentation
Postural tremor amplitude was used as the primary comparative variable. Within the
patient group this feature showed the following results
3.4.2.1 Mean postural tremor amplitude descriptive statistics for the patient group
only




33.34 448.80 162.47 104.64
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3.4.2.3 Postural tremor amplitude (RH) descriptive statistics for the patient group
only




32.29 576.74 160.73 109.77
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3.4.2.5 Postural tremor amplitude (LH) descriptive statistics for the patient group
only




30.31 538.23 164.21 131.19
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3.4.2.7 Summary of postural tremor amplitude results
All three variables indicate that a moderate degree of tremor is very common. Where
tremor is severe it may be of very great amplitude but this is relatively rare. The
instrumented results are superficially consistent with the observer-ratings.
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3.4.3 Evaluation of the postural tremor amplitude variable as a measure of tremor
severity using the TAKE tremor variable criterion























3.4.3.3 Frequency characteristics of observer-rating identified groups (using a
threshold score of 2 or greater)
Number Percent




3.4.3.4 Instrumentation groups were identified using a threshold of 1SD above the
control group mean




3.4.3.5 Scatterplot of mean postural tremor amplitude with the threshold value
























3.4.3.6 Frequency data for the patient groups identified using the instrumented
mean postural tremor amplitude variable
Number Percent
Less than 1SD above 19 45.2
control group mean




3.4.3.7 Scatterplot of mean postural tremor amplitude against TAKE tremor item



















3.4.3.9 Summary of the evaluation of mean postural tremor amplitude using the
TAKE tremor item
The correlation between the measure and the criterion is of moderate strength and
trends towards significance. The measure and criterion groups are of similar sizes.
Sensitivity is good and specificity is very good. However, some patients rated as
exhibiting tremor were not identified as tremulous by the measure.
3.4.4 Evaluation of the postural tremor amplitude variable (RH) using the ESRS
tremor (RH) item criterion

















ESRS Tremor (Right upper limb)
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3.4.4.2 Correlation of the postural tremor amplitude variable (RH) against ESRS
tremor (RH)relationship (two-tailed significance)
N Coefficient Significance
42 0.292 0.061
3.4.4.3 Frequency data for the observer-rating (ESRS tremor (RH)) identified
groups (inclusion threshold of 2)
Number Percent
None/Minimal tremor 18 42.9
Tremulous 24 57.1
Total 42 100.0
3.4.4.4 Groups were identified using the postural tremor amplitude (RH) variable
with a threshold value of 1SD above the mean of the control group





3.4.4.5 Scatterplot of postural tremor amplitude (RH) with threshold value (1SD





















3.4.4.6 Frequency data for groups identified using postural tremor amplitude (RH)
Number Percent
Less than 1SD above 22 52.4
control group mean































ESRS Tremor (Right upper limb)












3.4.4.9 Summary of the evaluation of postural tremor amplitude (RH) using the
ESRS tremor (RH) item
Correlation between the measure and the criterion is moderate and trends towards
significance. The criterion and measure group sizes are less similar than those used
in the previous comparison (mean postural tremor amplitude and TAKE tremor
item). Sensitivity is moderate but specificity is good. However, a notable number of
cases positively identified by the criterion were not detected by the measure.
3.4.5 Evaluation of the instrumented postural tremor amplitude (LH) variable using
the ESRS tremor (LH) observer-rating as criterion

















ESRS Tremor (Left upper limb)
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3.4.5.2 Correlation of instrumented postural tremor amplitude (LH) with ESRS
observer-rating of tremor severity (LH) (two-tailed significance)
N Coefficient Significance
42 0.336 0.030
3.4.5.3 Frequency data for the groups identified by the criterion (ESRS tremor item
for the LH with an inclusion threshold value of 2 or greater)
Number Percent
None/Minimal tremor 19 45.2
Tremulous 23 54.8
Total 42 100.0
3.4.5.4 Groups were identified using the instrumented variable postural tremor
amplitude with a threshold value of 1SD above the control group mean





3.4.5.5 Scatterplot of postural tremor amplitude (LH) in the patient group with the

















3.4.5.6 Frequency data for the patient groups identified using-instrumented postural
tremor amplitude (LH)
Number Percent
Less than 1SD above 20 47.6
control group mean




3.4.5.7 Scatterplot of postural tremor amplitude (LH) against ESRS tremor severity




















ESRS Tremor (Left upper limb)












3.4.5.9 Summary of the evaluation of postural tremor amplitude (LH) using the
ESRS tremor (LH) item
Correlation between the measure and the criterion is of moderate strength and
statistically significant. The group sizes are similar. Both sensitivity and specificity
are high.
3.4.6 Summary
Observer-ratings of tremor indicated that symptomatic tremor was very common in
the patient group though it was rarely of more than mild to moderate severity. Only
weak to moderate correlations were found between postural tremor amplitude and the
rating criteria; not all of the correlations reach significance though all trended
towards significance. In contrast, the sensitivity and specificity of the variable as a
marker of tremor were both high.
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3.5 Tremor - resting tremor frequency ratio
The frequency ratio calculated from the FFT analysis results provided a variable
which has been proposed as a marker of parkinsonism. For this evaluation the
instrumentation measure will be the frequency ratio described earlier (2.1.4). The
criteria will be overall ratings of parkinsonism: the overall severity item from the
TAKE scale and ESRS total score.
3.5.1 Scatterplot of mean tremor frequency ratio against TAKE overall severity
TAKE Overall severity




















3.5.4 Correlation between mean tremor frequency ratio and ESRS total score
N Coefficient Significance
42 -0.223 NS
3.5.5 Effect of Lithium tremor on analysis of tremor as a marker of parkinsonism
The negative correlations between tremor frequency ratio and the criteria indicate
that the proportion of low frequency tremor (relative to overall total tremor activity)
is lower in those rated as having more severe parkinsonism. Further, both
correlations are non-significant.
However, in the light of the known influence of lithium therapy on tremor









ratio vs. ESRS total
score
31 -0.313 NS
Following the exclusion of lithium-treated patients, the results are little changed. The
correlations remain negative; though very slightly weaker, the correlation between
mean frequency ratio and ESRS total score now trends towards significance (p =
0.863).
3.5.6 Summary
The resting tremor frequency ratio showed no relationship to ratings of the global
severity of parkinsonism.
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3.6 Motor Planning Impairment
The calculation of a measure of motor planning time variable was described earlier
(2.1.5). This variable may be used to identify a group who exhibit a deficit in motor
planning. The members of this group are those patients who do not show the normal
increase in reaction latency in the CRT condition over the SRT condition, i.e. their
motor planning latency appears to be shorter than that of the control group.
With the aim of ensuring group comparability, only patients receiving antipsychotic
medication were included in this analysis. From these patients, two groups were
identified: a deficit group in whom motor planning time is more than 1SD below the
mean of the control group, and a non-deficit group in whom motor planning time is
not shorter than that of the control group.
3.6.1 Reaction latencies in the deficit and non-deficit patient groups
The following error bar graph demonstrates that mean reaction latency in the deficit
group is increased over the non-deficit group in the SRT condition but not in the
CRT condition. The difference between the groups in the SRT condition is
statistically significant (p = 0.012).
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3.6.2 Comparison of the deficit and non-deficit groups using observer-ratings
The deficit and non-deficit patient groups were compared using the observer-rating
criteria. Median scores in the two groups and the significance levels of any
differences are found are presented below. In all cases, severity is greater in the
deficit group than the non-deficit group.
Item Significance
TAKE:
Bradykinesia p = 0.018
Rigidity p = 0.005
Total of items 1-5 p = 0.007
ESRS:
Group of bradykinesia-related items p = 0.052
Total (tremor excluded) p = 0.006
Trends were found towards findings of greater negative symptomatology and
observer-rated depression in the deficit group.
Another notable finding is the lack of significant difference between the two groups
using the total score of the ESRS scale (p>0.05) . It is only when the tremor items are
excluded that the difference reaches significance. Removing the tremor item from the
TAKE total of items 1-5 (i.e. considering items 1,2,4 and 5 only) increases the
significance of the difference between the two groups (p = 0.007 to 0.002).
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3.6.3 Comparison of the deficit and non-deficit patient groups and the control
group using objective measures of bradykinesia
Noting the evidence reviewed previously of an association between non-physical
features of parkinsonism, particularly motor control impairments, and bradykinesia,
the motor planning deficit and non-deficit groups were compared with each other and
with the control group using the objective measures of bradykinesia (Jebsen Hand
Function Test and CANTAB reaction time test).
3.6.3.1 Jebsen Hand Function Test - results of ANOVA and post-hoc tests
An overall effect of group was found on Jebsen total time (p = 0.000).
Control Non-deficit
Deficit p = 0.000 NS (p = 0.053 by LSD)
Non-deficit p = 0.003
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3.6.3.2 Error bars of 95% confidence intervals for group means of Jebsen results
Control Deficit Non-deficit
Motor Planning
3.6.3.3 CANTAB SRT movement latency - results ofANOVA and post-hoc tests
An overall effect of motor planning group was found on CANTAB SRT movement
latency (p = 0.000).
Control Non-deficit
Deficit p = 0.002 p = 0.000
Non-deficit NS
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3.6.3.5 CANTAB CRT movement latency - results of ANOVA and post-hoc tests
An overall effect of motor planning group was found CANTAB CRT movement
latency (p = 0.013).
Control Non-deficit
Deficit p = 0.032 p = 0.019
Non-deficit NS
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3.6.3.6 Error bars of 95% confidence intervals for group means of CANTAB CRT
movement latency results
$
N = 17 11 19
Control Deficit Non-deficit
Motor Planning
3.6.3.7 Summary of the comparison of motor planning groups using objective
measures of bradykinesia
All three instrumented bradykinesia variables exhibit a significant effect of motor
planning group. In all cases, the deficit group is slower than the control group. The
non-deficit patient group is slower than the controls on the Jebsen test but not on the
two CANTAB movement latency variables. The deficit and non-deficit patient
groups differ on SRT and CRT movement latency, the deficit group being slower. A


















3.6.4 Comparison of the deficit and non-deficit patient groups and the control
group using other objective measures
The deficit and non-deficit patient groups were also compared with each other and
with the control group using measures of tremor and rigidity. The variables used
were the mean resting tremor frequency ratio and the mean rigidity activation ratio.
In both the cases the deficit and non-deficit groups did not differ significantly.
3.6.5 Summary
The presence has been demonstrated of an impairment in motor planning in a
proportion of antipsychotic treated patients. This impairment is associated with
increased severity of bradykinesia.
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3.7 Subjective experience
This section comprises the analysis of results from the SWN and visual analogue
scales, and an investigation of the validity of the scales.
3.7.1 SWN scale
3.7.1.1 Correlations between the sub-scales and the total score
SWN sub-scale r P
Emotional regulation 0.897 0.000
Self-control 0.900 0.000
Mental functioning 0.917 0.000
Social integration 0.908 0.000
Physical functioning 0.929 0.000
The extremely high strength of all correlations indicates that there is a great degree
of correlation between all the sub-scales. Therefore it was decided to continue the
analysis using only the total score.
3.7.1.2 Comparisons between treatment groups
The literature suggests that the SWN is sensitive to the subjective effects of
antipsychotic medication. The total score was used in the following comparisons:
patient group vs. control group, antipsychotic treated patients vs. non-antipsychotic
treated patients, typical antipsychotic treated patients vs. atypical antipsychotic
treated patients.
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3.7.1.2.1 Patient group vs. control group
Minimum Maximum Median
Patient group 27 176 120
Control group 109 185 173
The difference between the groups is highly significant (p = 0.000).









The groups do not differ significantly.




antipsychotic 60 165 114
treated
Atypical
antipsychotic 56 176 128
treated
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The groups do not differ significantly.
3.7.1.3 Correlations with BDI
The lack of discriminatory power indicated by the previous analysis may signify a
lack of sensitivity in the SWN, i.e. that the SWN is a poor measure, or that the SWN
is a measure of some phenomenon other than that which it purports to measure. The
relationship between the SWN results and those of the BDI was examined.
Coefficient Significance
SWN total -0.808 0.000
This relationship holds true for all the groups examined above though it is weaker in
















It should be noted that this high degree of correlation holds true for all the sub-scales

















Self-control r =-0.741 r =-0.550 r =-0.865
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A very high degree of correlation exists between all the sub-scales of the SWN and
the total score. The high degree of covariance between the scales makes it
appropriate to use only the total score for analysis. Comparison of different groups
indicates that subjective well-being is lower in the patient group than the control
group. However, no differences were found between antipsychotic and non-
antipsychotic patients or between typical antipsychotic and atypical antipsychotic
treated patients. A very high degree of correlation was found between scores on the
SWN and BDI scales, suggesting that the construct tapped by the SWN is very
similar to that measured by the BDI.
3.7.2 Visual analogue scales
Three visual analogue scales were used, for subjective sensations of sedation,
slowing, and restlessness respectively.
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3.7.2.1 Results of the visual analogue scales in the patient group only
Minimum Maximum Mean
Sedation 0.00 10.00 7.10
Slowing 1.10 10.00 6.55
Restlessness 1.00 10.00 7.19
Results on all three scales demonstrate a wide range of scores between the minimum
and maximum points on the scales. In each case the mean score is towards the
unimpaired end of the scale. The scores are not normally distributed.
3.7.2.2 Evaluation of the visual analogue scales as measures of the objective signs
of parkinsonism





















3.7.2.2.6 Correlation between the slowing scale and the Jebsen Hand Function Test
objective measure of slowing
N Coefficient Significance
40 -0.111 0.495
3.7.2.2.7 Summary of the visual analogue scales as measures of objective signs
The visual analogue scales for slowing and restlessness perform very poorly as
indicators of objective signs of the features they purport to measure. This finding
may indicate that the scales are inaccurate measures. Alternatively it may indicate
that the phenomena measured by the visual analogue scales exhibit little association
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with observer ratings (or objective measures) of slowing, sedation or restlessness,
respectively. In other words that they do not measure the features they are intended
to measure.
3.7.2.3 Associations between the visual analogue scales and other measures of
subjective state
It is known that psychomotor slowing may be a feature of depression, and that
feelings of restlessness may also feature in depression and anxiety so the relationship
between the visual analogue scales and the BDI criterion was investigated.
3.7.2.3.1 Descriptive data for the BDI criterion
Minimum Maximum Median
BDI 0 51 9
3.7.2.3.2 Correlation between the visual analogue scales and the BDI criterion
The results obtained using all three visual analogue scales were compared with those


















3.7.2.3.3 Associations between the visual analogue scales
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On the basis of the strength of correlation between all three visual analogue scales



















3.7.2.3.4 Summary of the evaluation of the visual analogue scales
Strong and highly significant correlations are found between the three visual
analogue scales and the BDI. The association is strongest for the slowing scale and
weakest for the sedation scale. The correlations tend to be stronger when all cases are
considered than when the patient group only is considered. The consistently low
scores on all three visual analogue scales and on the BDI in the control group may
tend to falsely inflate the strength of correlation though the associations appear
robust.
3.7.2.4 Visual analogue scales as measures of medication effects
The effects of treatment group on subjective ratings of sedation, slowing and
restlessness were examined.
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3.7.2.4.1 Medication effects on subjective sedation
Using analysis of variance, ratings of sedation were higher in the overall patient
group (p = 0.001) and in most patient medication groups than in the control group.
The patient medication groups did not differ significantly from each other.
3.7.2.4.2 Medication effects on subjective slowing
Results from the slowing scale were very similar to those from the sedation scale,
ratings of slowing being higher in the overall patient group (p = 0.001) and in most
patient medication groups than in the control group. The patient medication groups
did not differ from each other.
3.7.2.4.3 Medication effects on subjective restlessness
The results from the restlessness scale differed from those of the other two visual
analogue scales. Though the overall patient group differed from the control group (p
= 0.000), this was not true of all the patient medication groups. Ratings of
restlessness in the clozapine group were not higher than those in the control group,
and were significantly lower than those in the typical antipsychotics group (p =
0.004). The other patient medication groups did not differ from each other.
3.7.2.4.4 Error bars for group means of subjective restlessness in medication groups
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Control New Generation Anti-depressant
Std anti-psychotic Clozapine
Medication
3.7.2.4.5 Summary of the visual analogue scales as measures ofmedication effects
Mean ratings of sedation, slowing, and restlessness are higher in the patient group
than in the control group. On the sedation and slowing scales no differences between
patient medication groups were found. However, ratings of restlessness in the
clozapine group do not differ from the control group and are significantly lower than
in the typical antipsychotics group.
3.7.3 Summary
The results from the visual analogue scales indicate that subjective sensations of
slowing and restlessness show little association with observer-ratings or instrumented
measures of objective slowing. In contrast, subjective slowing was associated with
depression. All patients exhibited elevated levels of subjective slowing and sedation
relative to the control group. All patients except the clozapine treated medication
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group exhibited elevated levels of subjective restlessness relative to the control
group; levels of restlessness in the clozapine group were significantly lower than in
the typical antipsychotic group.
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3.8 Single case serial assessment
One patient (AG) was evaluated on six occasions over five months. During this
period medication was altered (drug changed from risperidone to quetiapine and then
dosage of quetiapine reduced) with the aim of reducing levels of parkinsonism. At
each visit a full clinical assessment was performed and the instrumentation was used
to produce an objective assessment of parkinsonism. Subjective rating scales were
not used at all visits due to time constraints.
The use of a longitudinal design may allow the instrumentation to be assessed
without the confounding effects that individual differences may have when a cross-
sectional design is used. To this end, many of the correlations between clinical rating
criteria and instrumentation measures which were calculated in previous sections
using cross-sectional data from a group of patients will be calculated using the
longitudinal follow-up data from this series of visits.
3.8.1 Bradykinesia
3.8.1.1 Correlation coefficients for the relationships between clinical rating criteria
and instrumental measures
r P
Jebsen vs. TAKE 0.728 0.087
bradykinesia item












CRT vs. ESRS group of
bradykinesia related items
0.183 0.005
Very strong and highly significant correlations are found between Jebsen total time
and the ESRS group of bradykinesia related items, between SRT and both the TAKE
bradykinesia item and the ESRS group of bradykinesia related items, and between
CRT and the ESRS group of bradykinesia related items.




ESRS group of bradykinesia related items
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3.8.1.3 Scatterplot of Jebsen time against TAKE bradykinesia item
TAKE Bradykinesia
The correlations between the rating criteria and the measures of bradykinesia are
stronger in the serial assessment than in the cross-sectional analysis. Though the
number of observations was small, the significance levels were still high.
3.8.2 Rigidity
Very weak and non-significant correlations are found between the activation ratio
and the rating criteria. This is true for both the mean activation ratio using the TAKE
rigidity item and the individual arm activation ratios using the ESRS upper limb
rigidity items. The correlations are of similar strength to those found in the earlier
cross-sectional analysis, though with the limited number of observations these levels
of correlation are non-significant.
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3.8.3 Tremor
The pattern of associations found (and not found) in the cross-sectional analysis are




(RH) vs. ESRS tremor 0.670 0.131
(RH)
Postural tremor amplitude
(LH) vs. ESRS tremor 0.828 0.032
(LH)
As in the cross-sectional analysis, resting tremor frequency ratio is not a valid
indicator of parkinsonism. However, an unexpected relationship was found between
overall severity of parkinsonism and tremor characteristics. In this patient, severity of
parkinsonism was inversely related to postural tremor amplitude (r = 0.900, p =
0.009).
No changes in tremor frequency composition associated with changes in severity of
parkinsonism were found. Rather, tremor amplitude in the low and high frequency
bands tended to correlate. This was particularly in true in posture (right hand r =
0.848, p = 0.026; left hand r = 0.864, p = 0.033) though the relationship neared
significance at rest too (right hand r = 0.750, p = 0.086; left hand r = 0.695, p =
0.125).
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3.8.4 Motor planning impairment
Motor planning time exhibits a tendency to increase during the course of the follow-
up, indicating a reduction in parkinsonism. However, the result from visit six does
not fit this pattern. If the observations from this visit are excluded from the analysis,
then the motor planning variable tends to show a correlation with both the visit order
and with total Jebsen time (that with visit is positive, and that with Jebsen time
negative).
r P
Motor planning vs. visit






As the subjective ratings were not used at all visits there are too few observations for
meaningful analysis.
3.8.6 Summary
The relationships between instrumental measures and clinical ratings of bradykinesia
were much stronger than those found in the cross-sectional analysis. Despite the
small number of observations some associations, particularly that between Jebsen
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time and the ESRS group of bradykinesia related items, reached a high level of
significance. The associations between measures and ratings of rigidity were non¬
significant. Though weak in strength the coefficients were of similar magnitude to
those found in the cross-sectional analysis. The tremor results also closely parallel
those found in the cross-sectional analysis. No evidence was found of a parkinsonian
slow resting tremor. Tremor frequency composition remained relatively constant at
all visits, with amplitude in both frequency ranges increasing as the severity of
parkinsonism decreased. Motor planning time was found to increase during course of
the follow-up. This change, indicative of decreasing parkinsonism, is associated with
declines in ESRS total score and objectively assessed bradykinesia.
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3.9 Medication-associated tremor characteristics
Clinical ratings of tremor indicate the presence of increased tremor amplitude in a
majority of patients relative to the control group. However, these ratings are limited
in the information they provide. In particular, they do not distinguish tremors with
different frequency compositions.
Previous sections (3.4 and 3.5) have considered the results from the tremor
instrumentation as they may be used to evaluate the instrumentation procedures.
These data may also provide information concerning the characteristics of the
tremors associated with different forms of medication. This section considers the
tremor characteristics of the different patient medication groups in terms of the
amplitudes of postural and resting tremor in low and high frequency ranges.
It should be noted that in all the comparisons, the variance of the patient medication
groups is high. This, with the very small numbers in some groups ensures that many
effects of group do not reach statistical significance, and that the likelihood of type II
errors (rejection of positive finding) is elevated.
3.9.1 Lithium tremor
Increased amplitude of high frequency tremor is recognised as a side-effect of
lithium treatment. The first comparisons used three groups: Lithium-treated patient
group, non-Lithium treated patient group, control group.
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3.9.1.1 Postural tremor (R)
A significant effect of group was found in the 7.0-13.0 Hz range (p = 0.038).
Amplitude was greatest in the lithium group in all cases. The lithium and control
groups differed significantly (p = 0.039).














N = 17 33 11
Control Non-Li treated Lithium treated
Lithium treatment
3.9.1.1.2 Post hoc comparisons for group mean postural tremor amplitude (R)
7.0-13.0 Hz
Lithium vs. non-Lithium patients NS






3.9.1.2 Postural tremor (L)
The effect of group was significant in the 7.0-13.0 Hz (p = 0.001) range, and there
was a trend towards significance in the 3.0-7.0 Hz (p = 0.059) range; greater
amplitude was found in the lithium group. Amplitude was greater in the lithium
group than the control group in both high (p = 0.001) and low (p = 0.059) frequency
ranges; it was greater in the lithium group than in the non-lithium patient group in the
high frequency range (p = 0.031) only.











Control Non-Li treated Lithium treated
Lithium treatment
3.9.1.2.2 Post hoc comparisons for group mean postural tremor amplitude (L)
3.0-7.0 Hz 7.0-13.0 Hz
Lithium vs. non-Lithium NS p = 0.031
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patients
Lithium vs. Control group p = 0.059 p = 0.001
3.9.1.3 Resting tremor (R)
No significant effects of medication group were found in any of the variables tested.
3.9.1.4 Resting tremor (L)
Significantly greater amplitude was found in the lithium group than in the other
groups in both low frequency and high frequency ranges (both p = 0.000).


















Non-Li treated Lithium treated
Lithium treatment
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N = 17 33 11
Control Non-Li treated Lithium treated
Lithium treatment
3.9.1.4.3 Post hoc comparisons for group mean resting tremor amplitude (L)
3.0-7.0 Hz 7.0-13.0 Hz
Lithium vs. non-lithium
patients
p = 0.002 p = 0.001
Lithium vs. Control group p = 0.000 p = 0.001
3.9.1.5 Summary of lithium tremor characteristics
Lithium treatment is associated with a significant increase in tremor magnitude. This
increase was found in postural tremor in both hands, and at rest in the left hand only.
The increase is present predominantly in the higher frequency range (7.0-13.0 Hz)








3.9.2 Other patient medication groups
Comparisons of the tremor characteristics in patient medication groups were made
after the exclusion of all patients receiving lithium.
3.9.2.1 Postural tremor (R)
Significant effects of medication group were found in both low and high frequency
ranges: 3.0-7.0 Hz (p = 0.006), 7.0-13.0 Hz (p = 0.036). In all comparisons amplitude
is greatest in the clozapine group. The clozapine group differed significantly from the
control group in both frequency ranges. The results showed trends towards greater
amplitude in the clozapine group relative to the other patient medication groups in
the 3.0-7.0 Hz frequency range.




17 13 4 8 5
Control New Generation Anti-depressant
Std anti-psychotic Clozapine
Medication
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3.9.2.1.3 Post hoc comparisons for medication group mean postural tremor
amplitude (R)
3.0-7.0 Hz 7.0-13.0 Hz
Clozapine group vs.
control group
p = 0.003 p = 0.023
Clozapine group vs.
typical antipsychotic group
NS (p = 0.092) NS
Clozapine group vs. New
Generation group
NS (p - 0.080) NS
Clozapine group vs.
antidepressant group
NS (p = 0.162) NS
The clozapine group exhibits low frequency tremor of greater amplitude than any of
the other groups. Overall tremor amplitude in this group is greater than in the control
group and tends to be greater than in the other antipsychotic groups.
3.9.2.2 Postural tremor (L)
Significant effects of group on tremor amplitude were found in both frequency
ranges: 3.0-7.0 Hz (p = 0.000) and 7.0-13.0 Hz (p = 0.000). In both ranges the
clozapine group exhibited significantly greater tremor amplitude than all other
groups.

















17 13 4 8 5
Control New Generation Anti-depressant
Std anti-psychotic Clozapine
Medication
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3.9.2.2.3 Post hoc comparisons for medication group mean postural tremor
amplitude (L)
3.0-7.0 Hz 7.0-13.0 Hz
Clozapine group vs.
control group
p = 0.000 p = 0.000
Clozapine group vs.
typical antipsychotic group
p = 0.000 p = 0.001
Clozapine group vs. New
Generation group
p = 0.003 p = 0.007
Clozapine group vs.
antidepressant group
p - 0.001 p = 0.001
3.9.2.3 Resting tremor (R)
None of the effects of medication group on resting tremor amplitude (R) found
reached significance, however some showed trends towards significance. Differences
were found, in the high frequency range, between the antidepressant group and the
clozapine, typical antipsychotic, and control groups; amplitude was greater in the
antidepressant group in all comparisons.













N = 17 13 4 8 5
Control New Generation Anti-depressant
Std anti-psychotic Clozapine
Medication
3.9.2.3.2 Post hoc comparisons for medication group mean resting tremor amplitude
(R)
7.0-13.0 Hz range
Antidepressant group vs. clozapine group NS (p = 0.084)
Antidepressant group vs. typical
antipsychotic group
NS (p = 0.178)
Antidepressant group vs. control group NS (p = 0.056)
3.9.2.4 Resting tremor (L)
A significant effect of medication group on resting tremor amplitude (L) was found
in the high frequency range (p = 0.024). Amplitude was highest in the antidepressant
group, the group mean showing trends towards significant differences with the
control group and the clozapine group.
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Control New Generation Anti-depressant
Std anti-psychotic Clozapine
Medication
3.9.2.4.2 Post hoc comparisons for medication group mean resting tremor amplitude
(R)
7.0-13.0 Hz range
Antidepressant group vs. control group NS (p = 0.076)
Antidepressant group vs. typical
antipsychotic group
NS (p = 0.135)
Antidepressant group vs. clozapine group NS (p = 0.061)
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3.9.2.5 Proportion of low frequency resting tremor
When frequency ratios were examined directly, effects of medication group were
found only in resting tremor in the left hand. In this comparison, proportion of low
frequency tremor is higher in the clozapine group than in the antidepressant group
and the typical antipsychotic group. There is a slight trend towards a lowered
proportion of low frequency tremor in the typical antipsychotic group relative to the
control group.











Control New Generation Anti-depressant
Std anti-psychotic Clozapine
Medication
3.9.2.5.2 Post hoc comparisons for the proportion of low frequency resting tremor
(L)
Low frequency resting tremor
Typical antipsychotic group vs. control NS (p = 0.176)
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group
Clozapine group vs. typical antipsychotic
group
p = 0.002
Clozapine group vs. antidepressant group p-0.038
3.9.3 Summary of medication-associated tremors
3.9.3.1 Typical antipsychotic group
The typical antipsychotic group did not exhibit any significant differences in tremor
properties relative to the control group. There is a trend towards a lowered proportion
of low frequency resting tremor in the left hand though this apparent finding may
actually reflect a non-significant increase in high frequency activity in this condition.
The error bars appear to indicate that high frequency postural tremor amplitude may
be slightly increased though this was not statistically significant.
3.9.3.2 Lithium
Lithium treatment is associated with a significant increase in tremor amplitude. This
increase was found in postural tremor in both hands, and at rest in the left hand only.
The increase is present predominantly in the high frequency range though there is
evidence of an increase in magnitude in the lower range.
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3.9.3.3 Clozapine group
Postural tremor amplitude was increased; the elevation was seen in both the low and
high frequency ranges in the left hand, but only in the low frequency range in the
right hand. Weaker evidence was found of increased resting tremor amplitude. There
is also some evidence of a relatively increased proportion of low frequency activity
in resting tremor.
3.9.3.4 Antidepressant group
Relative to the control group, resting tremor in the antidepressant group was
increased in amplitude; this increase occurred predominantly in the high frequency
range. However, patient numbers in this medication group were very small so the
results cannot be regarded as wholly reliable.
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3.10 Other patient medication group comparisons
In the previous section the tremor instrumentation was used in the comparison of the
patient medication groups with the control group. This section reports the results of
using the other measures (instrumental measures and subjective ratings) to compare
the same groups. A large number of comparisons were made in this investigation.
However, the majority of findings were of non-significant differences. Only those
findings which were felt to be of interest are reported. These include those in which
significant differences were found between patient medication groups, and those in
which patient groups did not differ from the control group.
3.10.1 Bradykinesia - Jebsen hand function test
3.10.1.1 Group mean total score
Group Mean SD
Control 60.39 6.95
Typical antipsychotic 75.37 11.94




There was an overall highly significant effect of medication group (p = 0.000) on
Jebsen test total time. Post-hoc comparisons reveal that total time was significantly
higher than in the control group in the typical antipsychotic, New Generation
238
antipsychotic, and antidepressant patient groups. The clozapine group was not
significantly slower than the control group.
3.10.1.3 Error bars for medication group mean Jebsen test total time
Control New Generation Anti-depressant
Std anti-psychotic Clozapine
Medication
3.10.1.4 Comparison of medication groups using observer ratings of bradykinesia
In a further effort to evaluate the accuracy of the Jebsen test, the comparison of
medication groups was repeated using observer-ratings of bradykinesia. As ratings
were not performed in the control group it was decided for the purposes of this
analysis to attribute ratings of zero on all items to all members of the control group.
Single item ratings of bradykinesia (TAKE and ESRS bradykinesia items) did not
demonstrate significant overall effects of medication group. However, a significant
effect was seen on ratings using the ESRS group of bradykinesia-related items (p <
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0.05). A multiple comparisons procedure revealed that the only significant between-
groups difference was between the typical antipsychotic group and the control group.
As with the results of the Jebsen test the clozapine group was not found to be slowed
relative to the control group.
3.10.1.5 Summary
When the Jebsen test is evaluated against observer-ratings of bradykinesia on its
ability to detect effects of medication group on bradykinesia it exhibits greater
accuracy than single-item ratings taken from both the TAKE and ESRS scales.
Accuracy is comparable to that obtained by using the group of bradykinesia-related
items from the ESRS scale.
3.10.2 Subjective sensations of restlessness
A significant effect of medication group was found on subjective ratings of
sensations of restlessness.
3.10.2.1 Group mean ratings of restlessness














The overall effect of medication group was highly significant (p = 0.000 by
ANOVA). Using post-hoc tests, subjective ratings of restlessness were significantly
higher (indicated by lower scores) in both the typical antipsychotic and
antidepressant groups than the control group (p = 0.000 and p = 0.031, respectively).
Ratings of restlessness were higher in the typical antipsychotic group than in the
clozapine group (p = 0.004); ratings in the clozapine group did not differ from those
in the control group.
3.10.2.3 Error bars for medication group mean ratings of sensations of restlessness





The two notable comparisons described here both concerned the clozapine group
contrasted with the typical antipsychotic group. In the first, the clozapine group was
found to be not significantly slowed relative to the control group. All other patient
medication groups were significantly slower than the control group. In the second,
mean ratings of restlessness were found to be lower in the clozapine group than in
the typical antipsychotic group; ratings in the clozapine group did not differ from
those in the control group. Other comparisons made,, such as those using the rigidity
instrumentation did not demonstrate any noteworthy results.
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4 Discussion
This section will assess the evidence within the context of the hypotheses presented
at the end of the introduction (1.4):
1. Instrumentation has a role in the assessment of DIP
2. Bradykinesia is the predominant feature of DIP
3. Cognitive and subjective features of parkinsonism are present in DIP.
4.1 Instrumentation has a role in the assessment of DIP
The methods by which this hypothesis may be demonstrated were discussed earlier
(1.4). It is necessary to show that the measures are accurate, and that they are valid
measures of the features they purport to measure. Validity may be demonstrated
relative to existing criteria (observer-ratings in this case) or by reference to
theoretical constructs. To define a role for instrumentation, these measures must
demonstrate not only validity as a means of assessment, but some advantage over
observer-rating methods.
The instrumentation methods will first be considered individually, as assessors of
particular features of parkinsonism. The validity of the measures will be considered
relative to both the observer-rating criteria and the theoretical constructs underlying
the procedures. Finally, the role of instrumentation may be considered independently
of specific methods.
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4.1.1 Jebsen Hand Function Test
This section will commence with an evaluation of the properties of the Jebsen Hand
Function Test. Face validity of the Jebsen test, as of all performance measures, is
high: the test appears to be a measure of movement speed and motor control.
However, though total time taken to complete the Jebsen test correlates significantly
with observer-rating criteria for bradykinesia (TAKE bradykinesia item, ESRS
bradykinesia item, ESRS group of bradykinesia-related items), the association is of
only moderate strength. It should be noted that in the single-case study, the degree of
association found over a number of assessment visits was much greater than in the
overall cross-sectional study. The sensitivity of the Jebsen test as a marker of
bradykinesia was good to very good, being highest with the ESRS group of
bradykinesia-related items. However specificity was low, being lowest with the
ESRS group of bradykinesia-related items. This demonstration of criterion validity
indicates that the Jebsen test functions as a measure of bradykinesia, though overall
accuracy is not particularly high. As discussed in the introduction (1.4.1.3), an
apparently lower level of accuracy in the measure than the criteria may indicate that
the level of accuracy in the measure is actually higher than in the criterion.
In a supplementary evaluation of the Jebsen test, the ability of the test to distinguish
medication groups was contrasted with that of the observer-ratings (3.10.1.4). The
Jebsen test identified differences between medication groups not detected by single-
item ratings of bradykinesia from the TAKE or ESRS scales. The accuracy of the
Jebsen test was comparable to that obtained using the ESRS group of bradykinesia-
related items.
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It is necessary to address the relatively low degree of correlation between the Jebsen
test and the observer-rating criteria. This finding may be accounted for by an
examination of the constructs tapped by the measure and the criteria respectively. All
of the criteria scores represent ratings of the degree of abnormality present in the
patient on a particular axis at the time of assessment. In this case, this is an
assessment of the severity of bradykinesia relative to a baseline (i.e. non-
bradykinetic) state of normality for that particular patient. The rating is thus
independent of individual differences in baseline speed of movement. However, the
Jebsen test results represent a measurement of absolute speed of movement; this
figure is not a measure of slowing as it cannot take into account the individual's
baseline state. Logically, it would be expected that absolute speed of movement and
degree of bradykinesia would correlate positively, but that the relationship would not
be one of perfect correlation when the data are taken from a group of patients. In
contrast, the two variables should correlate perfectly (or almost so) if all the data are
from a single patient. In this situation, the single case study, the results from the
Jebsen test do form an assessment of the degree of slowing relative to other visits,
and the correlation coefficients for the relationships between the Jebsen test results
and the observer-rating criteria are extremely high.
Thus it may be argued that the construct tapped by the Jebsen test (and by inference
other performance measures too) is bradykinesia only in the case of a series of
follow-up assessments of the same patient. In a one-off assessment the construct
tapped is not bradykinesia, though it is closely related to bradykinesia.
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The advantages of the Jebsen test over observer-ratings arise principally from its
truly objective nature which removes any variation in assessments due to inter-rater
differences. This characteristic contrasts with the observer-ratings which incorporate
a degree of subjectivity into the assessments, despite the use of rating guidelines, and
can only be valid when performed by a trained and experienced assessor. Further, the
test demands little of the assessor conducting the measurements other than the ability
to set up the apparatus, provide instructions and operate a stopwatch.
The results of the Jebsen test require little data analysis and are simple to interpret.
However, the Jebsen test does require a fairly cumbersome array of equipment.
Though the apparatus used is cheap and easily obtained, it is hardly portable. A
further criticism of the Jebsen test is the time taken to complete the full battery of
tasks, resulting primarily from the number of tasks included. The time taken may be
excessive for inclusion of the test in regular assessments of extrapyramidal status,
particularly in light of the fact that that assessment of bradykinesia forms only one
part of an assessment of extrapyramidal status, itself only one component of a
comprehensive clinical examination.
The construct tapped by the Jebsen test was discussed above in the context of the
relationship between the Jebsen test results and the observer ratings of bradykinesia.
This analysis indicated that the Jebsen test does provide a direct indicator of
bradykinesia in serial follow-up assessments within a single patient, and an indirect
indicator of bradykinesia when used for one-off assessments. It is also worth
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considering the literature concerned with the bradykinesia construct. It is asserted
that upper-body bradykinesia is the cardinal sign of parkinsonism (Quinn, 1995).
This implies that the principal indicator of parkinsonism should be an assessment of
upper-body bradykinesia. The use of a performance measure of upper-body
bradykinesia such as the Jebsen test is consistent with this argument.
4.1.2 CANTAB
The properties of the CANTAB reaction time test as a measurement of reaction time
are well established, and reaction time tests have been previously used as indicators
of bradykinesia (Evarts et al., 1981). However, no evidence has been published of the
CANTAB test itself being used in this fashion.
Examination of the relationships between the CANTAB variables used (SRT total
time and movement latency, CRT total time and movement latency) and the
observer-rating criteria for bradykinesia indicates a consistent pattern of results
within the CANTAB variables. The SRT variables exhibit a moderate strength of
correlation with the criteria, but the CRT variables are only weakly related to them.
The sensitivity and specificity characteristics of the CANTAB tests as markers of
bradykinesia reveal a similar level of overall accuracy to the Jebsen test in the CRT
variables and a slightly higher level of overall performance in the SRT variables. In
comparison with the Jebsen test, sensitivity is lower and specificity higher.
The issues discussed in the previous section concerning the construct validity of
instrumental measures as markers of absolute speed of movement when contrasted
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with observer-ratings of the degree of abnormality present are pertinent to the
CANTAB instrumentation too. However, it is likely that these issues affect the
simple and choice RT conditions equally, and this account does not explain the fact
that the CRT results show a lower degree of correlation with the observer-ratings of
bradykinesia than do the SRT results.
The CANTAB reaction time test shares many of the benefits of the Jebsen hand
function test. The results are truly objective, removing any influence of rater error;
the test is simple to administer; most patients found it easy to comply with. However
there is the same reliance upon cumbersome equipment, though this time it is rather
more expensive. Further, the CANTAB is similarly time-consuming for regular use.
Though the CANTAB provides, like the Jebsen, a measure of bradykinesia, the
construct tapped is slightly different. The CANTAB movement latency provides a
measure of pure speed of movement, and the reaction latency a measure of speed of
motor planning and movement initiation. It is notable that all CANTAB variables
(SRT reaction latency, SRT movement latency, CRT reaction latency, CRT
movement latency) correlate very highly.
The movement latencies can be contrasted with the Jebsen variable which is a
measure of overall performance including aspects of motor control and movement
initiation. Though movement initiation is a factor in the CANTAB reaction latencies,
there is an external trigger for these movements. In contrast, performance of the tasks
in the Jebsen test requires a complex sequence of self-initiated goal-directed
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movements. The CANTAB assessment may be viewed as assessing only a limited
part of the bradykinesia complex.
4.1.3 Bradykinesia
It was noted earlier that it is not sufficient to demonstrate merely that the
instrumental measures provide a valid means of assessing parkinsonism. The
instrumentation must display advantages over clinical ratings. If not in terms of
accuracy then in some other frame of reference, perhaps ease of use for the assessor,
or by being less time-consuming. The advantages may be limited to certain situations
or particular types of assessment but must be specified.
From the introduction (1.3.1.3.3) it was suggested that some instrumental measures
may provide a sensitive means of detecting the early onset of EPS, by virtue of
increased accuracy over observer ratings. The evidence presented does indicate that
performance measures of movement speed can provide a highly accurate means of
assessing the severity of bradykinesia within the individual. Further, the Jebsen test
proved capable of identifying a clozapine treatment group which was not
significantly slowed relative to the control group though all other patient groups
were. This will be discussed in greater depth (4.5.2).
Though the procedures provide a valid means of assessing bradykinesia, they exhibit
significant weaknesses. The measures do not display very high levels of sensitivity or
specificity relative to the observer-rating criteria, and are not capable of functioning
as one-off indicators of the presence of parkinsonism within the individual. Rather,
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variations in baseline movement speed within normal and patient populations mask
the minimal changes in performance due to very mild or sub-clinical bradykinesia.
Of greater promise is the very high level of validity demonstrated by the
bradykinesia instrumentation in the single case study assessment. When all the
observations made came from a single individual the level of correlation between the
measures and the criteria was extremely high. This suggests that the benefit of
bradykinesia instrumentation may be as an appropriate procedure for repeated
assessments in the follow-up of individual patients on a longitudinal basis rather than
for screening for the presence of bradykinesia within groups of patients.
Performance measures may thus be a means for monitoring the development and
progression of bradykinesia without the need for a comprehensive examination by a
doctor. They are relatively simple to administer and provide a truly objective
assessment of the degree of slowing in the individual relative to a pre-treatment
baseline measurement. The influence of inter-or intra-rater variability is wholly
removed. Further, the assessment may be performed with the same level of accuracy
and reliability without the need for a trained and experienced rater.
Within the individual, the Jebsen test proved sensitive to minor changes in condition,
and it is likely that this property is not exclusive to this one particular performance
measure. Though it was used in this study, the Jebsen test may not be the most
practical measure for use in this fashion The criticisms made earlier, of both the
Jebsen and CANTAB procedures, that they depend upon cumbersome, and in the
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case of the CANTAB test expensive, equipment do not necessarily apply to all
performance tests. Numerous performance measures appear in the literature, many of
which use small portable pieces of equipment such as pegboards (1.3.2.1). It seems
likely that many if not all of these measures may provide the same information
gained from the Jebsen and CANTAB tests with a similar degree of accuracy. These
measures may also be less time-consuming and thus more suitable for repeated
assessments. Many of these measures could be adapted to incorporate integral
automated timing devices to remove another source of confounding.
The importance of monitoring the development of bradykinesia, perhaps more so
than other features of parkinsonism, is the subject of the other hypotheses and is
discussed in depth (4.6).
4.1.4 Positive feedback device
The activation ratio variable derived from the results of the positive feedback device
was found to correlate with the observer-rating criteria, though the association was of
only moderate strength. The relationship was statistically significant for the mean
activation ratio (TAKE rigidity criterion) though it was non-significant when the
arms were considered separately (ESRS upper-limb rigidity criteria). As an indicator
of the presence of rigidity, the activation ratio exhibited good levels of sensitivity
and specificity, especially for the right arm alone.
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The lack of significant correlation between the activation ratio and the ESRS rigidity
item criteria raises doubts about the validity of the procedure. However, sensitivity
and specificity were of a good level, suggesting that though the correlation
coefficient was low, the activation ratio did provide a valid marker of rigidity.
A benefit of the activation ratio becomes apparent when the properties of the rigidity
construct are contrasted with those of the constructs tapped by the instrumental
measures of bradykinesia previously considered (4.1.1 - 4.1.2). It was noted that
performance measures such as the Jebsen test provide an assessment of speed of
movement rather than of slowing, i.e. of absolute performance rather than of the
degree of abnormality. As discussed in the introduction (1.3.2.2), the activation ratio
represents the degree to which stiffness in the arm increases when a reinforcing
technique is used to elicit rigidity. The technique thus controls for baseline
differences in rigidity; these may derive from baseline differences in muscle volume.
Though the activation ratio may demonstrate construct validity in this fashion there
are difficulties with the stated construct used in the determination of the clinical
rating criteria. It is assumed, as with all rating criteria, that the criterion comprises an
assessment of the degree of abnormality present. However, the stated construct
allowed for both increases in resting rigidity and increases in the degree to which
activation increased rigidity. Within this concept, an increase in resting stiffness
indicates a more severe degree of rigidity than if the rigidity is only apparent when
elicited by reinforcement techniques. The rater (DGCO) stated that he was unaware
of findings in the literature demonstrating baseline differences in resting rigidity due
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to the gender of the patient (Walsh, 1992) though he would expect greater rigidity in
a heavily muscled individual than one more slightly built. Stated in this fashion the
clinical rating appears vulnerable to confounding by differences in muscle volume.
However, average ratings of rigidity in male and female patients did not differ,
suggesting that baseline differences in rigidity resulting from muscle volume were
sufficiently accommodated.
The major benefits of the positive feedback device are those common to all
instrumental methods of assessment: the assessment is objective and rater-
independent. However, as a technique its uses are limited. The equipment used is
specialised and cumbersome; the positive feedback device itself is the size of a small
table and very heavy. Adjustment to the height of the individual patient is tricky and
can be time-consuming. For smaller patients, placing the forearm in the cradle with
the elbow concentric to the axle required an awkward stretch. Further equipment is
needed to record the output from the device, and once data is recorded, it must be
analysed to derive the activation ratio.
The problems with the rigidity instrumentation procedure are not limited to those of
the device itself, the principal difficulty is one of compliance. This was not a matter
of patients being unwilling to comply with the demands of the assessment, rather that
some patients (and some controls too) found it impossible to relax their arm
sufficiently to form part of the "torsion pendulum" combination with the rigidity
device. This difficulty was most prominent in the activated condition, particularly
with the "circle drawing" activation technique. Complying with the demands of the
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assessment in this condition was described as being akin to patting one's head at the
same time as rubbing the stomach.
The difficulties in finding a suitable reinforcement procedure were noted previously
(1.3.2.2). In preliminary trials, it seemed that the different techniques produced
varying degrees of activation. These could be ranked from least to greatest degree of
activation as follows: very simple verbal tasks (e.g. reciting the days of the week or
months of the year in reverse order), more difficult verbal tasks (e.g. serial sevens -
counting downwards from 100 in sevens), gripping a rubber ball with the
contralateral arm, drawing circles in the air with the contralateral arm.
The degree to which a verbal task counts as difficult rather than simple is greatly
dependent upon the individual. If the task is too simple it is an inadequate stressor
and will have little or no reinforcing effect. In contrast, the circle drawing task
proved almost too effective, preventing some patients (who had already had a
measurement of resting stiffness taken) from complying with this part of the
assessment. Maintaining a grip on a rubber ball was found to have an effective
reinforcement effect without being detrimental to compliance.
Some patients, perhaps among those who found it difficult to comply with the
demands of the device, were also noted to be "helping" the device to move their arm.
This could be detected by examining the torque trace on the record; an excess of
movement in the absence of a significant torque output indicated that the work was
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being done by the patient rather than the machine! Though this may be detected, it is
another obstacle to obtaining a valid instrumented assessment of rigidity.
In spite of the operational difficulties, the positive feedback device provides a
reasonably sensitive and specific indicator of the presence of rigidity. However there
are difficulties with patient compliance with the procedure and with the equipment.
4.1.5 Rigidity
The demonstration that the positive feedback device may provide a valid marker of
rigidity is not sufficient to demonstrate a role for instrumentation in the assessment
of parkinsonism. It is necessary to consider other factors relating to the role of
instrumentation in the assessment of rigidity, such as the need or otherwise for
greater accuracy than can be obtained using observer-ratings. Though the relative
importance of different features in DIP is the subject of the next hypothesis, it also
has a bearing on this issue.
Observer rating criteria indicated that severe rigidity was rare in this patient group
(3.3.1). The results of the instrumentation too, indicated that only a small proportion
of the patient group were more than 1SD above the mean of the control group. Even
using this threshold, set to ensure a relatively large "rigid" group, the numbers of
patients identified as exhibiting a significant degree of rigidity was small. It is also
the case that few patients complain of rigidity, in the way that they do of gross
tremors, for example. Further, rigidity does not impair normal activities of daily
living in the manner that bradykinesia or tremor may. Finally, in considering
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hypothesis two it may become apparent that highly accurate measurement of rigidity
is less important than that of other features of parkinsonism.
Though instrumentation may have accuracy and objectivity to recommend it, there is
evidence for the reliability and validity of clinical ratings, demonstrating the high
level of agreement found between experienced raters. And, when other rigidity
instrumentation procedures from the literature are considered construct validity is
often lacking (1.3.2.2), and all the procedures reviewed are dependent upon
cumbersome and usually expensive equipment. Even if instrumentation has greater
accuracy than clinical rating, the disadvantages of instrumentation outweigh any
benefit.
In terms of practical utility in clinical practice, there is little reason to believe that
possible gains in accuracy or objectivity over clinical ratings outweigh the
considerable difficulties inherent in instrumental assessment of rigidity. Even in
research settings, the benefits may not be sufficient to justify its use on a regular
basis.
4.1.6 Postural tremor amplitude
Two forms of tremor analysis were used, producing two tremor variables: postural
tremor amplitude and resting tremor frequency ratio. These variables and the
procedures by which they were derived are to be evaluated separately.
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The results analysis of the data from the tremor instrumentation found only weak to
moderate correlations between postural tremor amplitude and clinical rating criteria
(TAKE tremor item, ESRS right and left hand tremor items). Only the relationship
between postural tremor amplitude in the left hand and the corresponding ESRS
tremor item reaches statistical significance. In contrast, the sensitivity and specificity
of this variable as an indicator of symptomatic tremor are both good, especially when
mean postural tremor amplitude is evaluated using the TAKE tremor item. Overall,
the accuracy of the assessment of postural tremor amplitude is good.
However, though this procedure is an accurate and valid measure of tremor
amplitude, it is necessary to address the construct validity of this form of assessment.
In particular, it is essential to examine what it is about tremor which is important to
measure and what a tremor of abnormal amplitude signifies, whether it is an
indicator of parkinsonism, a predictor of a poorer outcome, or something unrelated to
any of these factors.
Severe tremor is a problem for patients; it can hinder fine motor control, affecting
basic activities of daily living. Further, a very visible tremor may be highly
embarrassing and have adverse effects on social competence. Less severe tremor is
usually well tolerated if it is associated with otherwise effective and tolerable
therapy.
In neurology there is an emphasis, in all domains of symptomatology, on the
practical consequences of dysfunction. Thus tremor is considered only as it impinges
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on daily life. Assessment of tremor may be via clinical ratings, but assessments of
the consequences of the tremor may be made. If an objective assessment of tremor is
to be made very simple techniques are most commonly be used. A typical procedure
is to measure the volume of liquid spilled when lifting a glass of water which has
been filled to the brim.
The evidence from this study does not indicate that increased tremor amplitude is
related to any other important indicators. Amongst the patient group as a whole, the
greatest individual tremor amplitudes were found in the clozapine group, a group of
patients who were notably non-symptomatic on measures of other features of
parkinsonism. The great variations in baseline tremor amplitude found in the normal
population must also be noted. Tremor amplitude varies greatly between individuals,
and from day to day within the individual. It is only when it reaches extreme levels
that it is regarded as noteworthy. Further, in the single case study, tremor amplitude
increased as levels of other features of parkinsonism, particularly bradykinesia
decreased.
The instrumentation has advantages over observer-ratings in its objectivity and
accuracy. It is simple to use and the analysis process may be configured to produce a
single figure for overall tremor amplitude. In this study the analysis software ran on a
standard PC. Alternatively a more simple hard-wired device could perform the same
algorithms. This would be both cheaper than a dedicated PC (though the software
can run on any PC) and more compact.
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4.1.7 Resting tremor frequency ratio
The evaluation of the tremor frequency ratio variable indicated a level of accuracy
very different to that found with the postural tremor amplitude. The resting tremor
frequency ratio did not provide an indicator of the presence of parkinsonism. In fact,
what correlation there was (non-significant and very weak) between the frequency
ratio and the ratings of global parkinsonism was negative.
On the basis of observation there was little evidence of slow resting tremor in the
patients tested. Clinical experience also suggests that a slow resting tremor is
uncommon in the wider population of psychiatric patients receiving antipsychotic
medication. However, it is necessary to consider whether there was a failure of the
quantification procedures used.
The equipment used for this procedure was the same as that used for the
instrumentation of postural tremor amplitude. The results from tremor amplitude
analysis were consistent with ratings of tremor severity. It is possible to be confident
that there are no inaccuracies in the raw data produced. Further, the Fast Fourier
Transform method used to derive the frequency data is beyond doubt. Though this
analysis is not presented here, the data from the control group were used to calculate
the peak frequency of tremor activity. Results from this analysis were consistent with
those from other studies of normal tremor (1.3.1.3.2), indicating a peak of activity
with the 8-13 Hz frequency range.
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It would have been desirable to have included a Parkinson's disease group for
comparison but this did not prove possible. It was originally proposed that a group of
untreated PD patients could be recruited. However, in Edinburgh there is no central
service for Parkinson's disease and newly-diagnosed patients are usually prescribed
L-dopa by GPs. L-dopa, like antipsychotic medication affects a multitude of different
systems and disparate physical features. There is as yet no evidence concerning its
specific effects on tremor characteristics. Given the difficulties involved in recruiting
a group of Parkinson's disease uncontaminated by L-dopa these plans were
abandoned.
The resting tremor frequency construct, like the constructs tapped by the other
measures, needs to be fully investigated. Predictions were made earlier that an
elevated proportion of low frequency tremor would be associated with increased
severity of global parkinsonism, based on similar findings in the literature (Arblaster
et al., 1993). It was hoped that the frequency ratio could function as a marker of the
presence of sub-clinical parkinsonism. However, there is no evidence from this study
to support this prediction. In fact, there is little evidence of slowed tremor frequency
in the patients tested. The proposed association between a slow resting tremor and
the presence of parkinsonism is central to the hypothesised role of instrumented
tremor assessment. However, the characterisation of tremor (3.9) found that though
symptomatic tremor was present in a large proportion of patients it was a postural
tremor of relatively high frequency.
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The failure to link changes in tremor frequency with ratings of parkinsonism or with
typical antipsychotic medication brings into question the role of instrumentation, or
at least of this form of instrumentation, in the assessment of tremor. If it is accepted
that the failure to detect a slow resting tremor in the patients tested reflects a genuine
absence of this form of tremor in the patient group tested it is necessary to consider
why the studies in the literature did find this form of tremor. These studies may differ
in the participating patients or in the medication received by those patients.
Some groups of patients can be more susceptible to parkinsonism, particularly older
patients (Ayd, 1961), or those with chronic deficit forms of schizophrenia (Prosser et
al., 1987). The mean age of the patient group in this study was 36.1 years. This was
lower than the mean age in two studies which found evidence of parkinsonian resting
tremor in DIP: 44.2 (Caligiuri et ah, 1991) and 54.3 (Arblaster et ah, 1993). In the
light of findings that older patients are more susceptible to developing DIP, and that
age-related changes in tremor frequency characteristics may parallel those seen in
parkinsonism, it may be that these findings cannot be generalised to younger groups
of patients. Further, the group assessed by Caligiuri et al. (1991) had been selected
on the basis of their displaying other signs of EPS (TD) and thus cannot be regarded
as being representative of all psychiatric patients.
In addition, Arblaster et al. (1993) found that in the patients exhibiting raised a low
tremor frequency subsequent clinical assessment revealed previously unnoticed DIP.
This parkinsonism predated the study and was apparently detectable by observer
ratings though it had previously gone unnoticed. The findings indicate not so much
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that the instrumented assessment had great sensitivity but that the patients involved
in the study had not been adequately monitored for the development of DIP. Further,
they suggest that the overall prevalence of parkinsonism in the group of Arblaster et
al. was higher than in the cohort of patients involved in this study.
4.1.8 Tremor
In the literature, analysis of tremor frequency promises most as an indicator of global
severity of parkinsonism. However, in this study the resting tremor frequency ratio
was unrelated to ratings of global severity. If the instrumentation of resting tremor
frequency cannot be validated as an indicator of parkinsonism, is there a role for
other tremor quantification techniques, such as those using postural tremor amplitude
(which was demonstrated to be closely correlated with ratings of tremor severity)?
An earlier section (4.1.6) considered the importance of an accurate measure of
tremor amplitude. It was noted that tremor amplitude varies greatly in the normal
population and is affected by a number of variables, most of them unrelated to
psychosis or antipsychotic medication. Tremor amplitude is of importance only as it
affects activities of daily living or becomes socially embarrassing. To a great extent
both of these factors, especially the latter, depend on patient perceptions of the
tremor. What is a minor inconvenience to one individual may be greatly distressing
to another. There seems little need for, or justification for the use of, a highly
accurate measure of tremor amplitude when it is the consequences of the tremor that
are meaningful.
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Overall, there is apparently little use for accelerometry techniques in clinical practice
though a simple method of objectively measuring the consequences of tremor for
performance of activities of daily living can have relevance (e.g. the glass of water
technique noted earlier). Within the research environment, the use of accelerometry
and frequency analysis techniques may have some benefits in distinguishing tremors
with different frequency compositions (e.g. 3.9).
4.1.9 Summary of the role of instrumentation in the assessment of DIP
In brief, both measures of bradykinesia proved to be valid assessors of this feature.
Accuracy was high, particularly in the case of the Jebsen test evaluated in a single
case study. The positive feedback device provided a reasonably valid measure of
rigidity though accuracy was not high. Difficulties with the method stemmed from
both the awkward nature of the device itself and the problems for participants of co¬
operating with the procedure. A highly accurate assessment of tremor characteristics
was obtained via accelerometry, quantifying tremor amplitude and frequency
characteristics. However, there are problems with the constructs used. Though the
instrumentation generally provided valid measures of the features concerned, in all
cases questions were raised concerning the need for greater accuracy than is provided
by observer ratings. This issue is addressed more closely later (4.6).
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4.2 Bradykinesia is the predominant feature of DIP
The arguments to be proposed in the examination of this hypothesis were touched
upon in the previous section. In addressing the first hypothesis, that instrumentation
has a role in the assessment of DIP, the relative importance of measuring accurately
the different features of parkinsonism was discussed. This is dependent, in part, upon
the predominance or otherwise of those features, it being of greater importance to
assess accurately a major feature than a minor one.
The literature suggests that upper-body parkinsonism is the cardinal sign of
Parkinson's disease (Quinn, 1995), and clinical experience suggests that this is even
more the case in DIP. The most obvious means of identifying a predominant feature
is to note the measures, be they observer-ratings or instrumental assessments, on
which the greatest proportion of patients fall outside the normal range.
On the basis of the observer-ratings, symptomatic tremor is present in a greater
number of patients than is the case for any of the other features of parkinsonism.
However, tremor may have many causes other than parkinsonism, including other
forms of medication, such as antidepressants, lithium, or clozapine, and this analysis
must exclude all those patients. Within the group of patients treated with typical
antipsychotic medication only, tremor is less prevalent.
However, there are some receiving typical antipsychotic medication only do exhibit
noteworthy levels of tremor. A higher frequency postural tremor has been noted in
PD (Findley et al., 1981) but is less commonly described than the resting tremor.
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This may account for the tremor seen in the typical antipsychotic group but without a
Parkinson's disease comparison group it is difficult to be certain.
Of the other features of parkinsonism, severe levels of rigidity were rarely found and
even mild rigidity was not common. Bradykinesia is exhibited by many more
patients than is rigidity, and it is present to a severe degree in some. However, many
other patients are rated as exhibiting only minimal levels or none at all.
When the results of instrumentation are used, comparisons may be made with a
control group and it is possible to consider directly the proportion of patients who
fall outside the normal range. When a bradykinetic group was identified using the
Jebsen hand function test, a threshold value of 2 SDs above the mean of the control
group was used to identify an 'abnormal' group of similar size to that identified
using the observer ratings. In the evaluations of the other instrumental assessment
procedures a threshold value of 1SD above the mean of the control group was used.
This evidence may support the hypothesis that bradykinesia is the predominant
feature of DIP, i.e. that severity relative to the control group is greater in this feature
than in others. Alternatively, it may indicate merely that the relative sensitivity of the
Jebsen test is greater than of the other tests.
Further evidence to support the hypothesis may be obtained by examining the
relationship between bradykinesia and other features of parkinsonism. If one feature
of a syndrome is more strongly associated with the presence of other features of the
syndrome than a second, the former may be regarded as being a more central feature
265
of the syndrome. In terms of DIP, if bradykinesia is more strongly associated with
the presence of other features of parkinsonism than is tremor, this will support the
hypothesis that bradykinesia is the primary feature of DIP.
In fact, evidence does exist linking the presence of bradykinesia with other features
of parkinsonism. In the literature, bradykinesia has been found to be associated with
the non-physical features of parkinsonism, and to a lesser degree with rigidity
(Mortimer et al., 1982). In this study the presence of the motor planning impairment
was associated with significantly higher levels of bradykinesia.
On the basis of these associations, Mortimer et al. (1982) postulated the existence of
two forms of Parkinson's disease: one predominantly tremulous, and characterised
by preservation of intellectual abilities, the other predominantly bradykinetic in
which cognitive impairments and rigidity are both present to a significant degree.
This latter form more closely resembles clinical impressions of bradykinesia.
However, few authors have adopted this concept, the varied clinical presentation of
Parkinson's disease, and all other forms of parkinsonism, being best accommodated
within a syndrome.
The finding that a particular feature of parkinsonism predominates in DIP has
implications for the clinical assessment of the disorder, rating scale design etc. A
number of scales, still widely used, place their emphasis on features of parkinsonism
other than bradykinesia. For example, rigidity was not present to any great degree in
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this patient group yet rigidity-related items form the major part of the Simpson-
Angus scale (Simpson & Angus, 1970).
The ESRS (Chouinard et al., 1980) is a more modern scale, designed with input from
neurology and featuring a novel dual axis rating scheme for tremor. Yet there is
perhaps too great an emphasis on tremor in the context of DIP. Though there are a
number of bradykinesia-related items (e.g. gait and posture) they make less
contribution to total variance than the tremor items.
Though tremor is common in psychiatric patients, and a frequent source of
complaints when of large amplitude, its role in DIP is unclear. It is not associated
with the other physical features of parkinsonism, nor with the presence of cognitive
deficits. Further, the difficulty of accommodating different forms of tremor (low
frequency resting tremor vs. high frequency postural tremor) within a rating scale is
yet to be satisfactorily resolved, despite the innovative rating guidelines used in the
ESRS.
That tremor may result from factors other than parkinsonism is a another source of
confounding. Other classes of medications such as lithium or antidepressants may
exacerbate tremor, and the prevalence of multiple drug therapy in this cohort was
high. The literature indicates that this is far from uncommon, many studies finding
the prevalence of multiple drug therapy to be higher than was found here (Burke et
al., 1996).
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If it can be satisfactorily demonstrated that bradykinesia is the cardinal sign of
parkinsonism, then this feature must account for the greatest proportion of variance
in ratings of parkinsonism. Further reasons why bradykinesia must be emphasised in
ratings of parkinsonism will follow from the next section, the consideration of the
third hypothesis.
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4.3 Cognitive and subjective features of parkinsonism are present in DIP
This hypothesis will be addressed under two headings: subjective features and
objective impairment.
4.3.1 Objective features - motor planning impairment
The methodology for this analysis uses the results from the CANTAB reaction time
test. The results of two response conditions are compared. The two conditions are
similar in the form of stimulus presented and the response required. However, they
differ in the extent of information-processing required. This paradigm has been used
to demonstrate impairments in motor planning (Evarts et al., 1981; Flowers, 1978)
and in cognition (Rogers et al., 1987).
In this study, the results from the CANTAB reaction time test are used to
demonstrate the presence of an impairment in motor planning. In the SRT condition
the form of response required can be known prior to the presentation of the stimulus.
In the CRT condition the form of response cannot be known until the stimulus is
presented. Normal subjects use this prior knowledge of the response form to pre-plan
the movement to be made; this acts to decrease response latency. If SRT response
latency is subtracted from CRT response latency, the remainder is the information-
processing latency - the time taken to plan the response movement in the CRT
condition.
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It has been demonstrated that Parkinson's disease patients do not show this increase
in reaction latency in the CRT condition over the SRT condition: information-
processing time is apparently shorter than in normal control groups. Analysis reveals
a selective increase of SRT reaction latency, attributed to a failure to make use of
available information to pre-plan the response movement.
Though the motor planning impairment is present in a significant proportion of
Parkinson's disease patients, its presence has not previously been demonstrated in
DIP. In Parkinson's disease the presence of this motor planning impairment (and
equally of other cognitive impairments) is associated with greater severity of
bradykinesia. It is the association with more severe bradykinesia which can confirm
that the impairment is parkinsonian in nature.
The results from the CANTAB reaction time test confirm the presence of the motor
planning impairment in a group of patients. This group, termed the 'deficit group'
did not show the normal increase in response latency in the CRT condition over the
SRT condition, indicating a failure to pre-plan response movements. The severity of
bradykinesia in the deficit and non-deficit groups was compared. Observer-ratings of
bradykinesia were higher in the deficit patient group than in the non-deficit patients.
Instrumented measures of slowing indicated that the deficit group was significantly
slower than the non-deficit group. On one measure (Jebsen) the non-deficit group
was found to be slowed relative to the control group though less slowed than the
deficit group. This association between the presence of the motor planning
impairment and greater severity of bradykinesia confirms that the impairment is a
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feature of parkinsonism. No other significant differences were found between the
two groups.
4.3.2 Subjective features
Subjective sensations were assessed primarily using the visual analogue scales and
the SWN. The BDI provided a criterion of subjective depression.
4.3.2.1 Visual analogue scales
A number of notable findings were obtained from the visual analogue scales. Firstly
the subjective experience of slowing was only weakly related to either observer-
ratings or objective measures of slowing, and similarly, the subjective experience of
restlessness showed little association with an observer rating of restlessness. These
findings indicate that patients are not aware of the severity of the physical features of
parkinsonism. Or, to emphasise that the subjective features may themselves be
features of parkinsonism, that the subjective features of parkinsonism are not related
necessarily to the objective features.
It should be noted that it is not unknown for experimenters to use patients' subjective
ratings of their EPS as indicators of severity. Though subjectively slowed patients
may indeed be bradykinetic the low level of correlation between subjective and
slowing, consistent with other studies of the subjective experience of treatment
(Gerlach & Larsen, 1999), cannot support this methodology.
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The subjective ratings were not unrelated to other measures. Links were found with
other indicators of subjective state and subjective slowing in particular was very
closely associated with depression. As psychomotor slowing is a frequent major
component of depression this is not a surprising finding.
The inclusion of the subjective sedation scale was intended to provide an insight into
the extent to which patients were able to distinguish slowing from sedation, two
phenomena easily misinterpreted by the observer. However, none of the observer
rating scales used included an item for sedation, and this hope was further
confounded by the failure of the slowing scale to provide a valid indicator of
slowing. However, the results of the two scales do indicate a strong correlation
between sensations of slowing and sedation. This may suggest either that the two are
both induced by the medications received. Or alternatively, that patients experience
the two phenomena as subjectively very similar and are as unable to distinguish them
as are raters.
Significant correlation was also found between ratings of slowing and restlessness.
This finding was unexpected, but may be accounted for by associations between
slowing and restlessness, and depression and anxiety, respectively. The relationship
between slowing and depression was noted above, subjective restlessness is a
common feature of anxiety, and depression and anxiety frequently co-vary.
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Perhaps the most important finding from the visual analogue scales was the lack of
subjective restlessness found in the clozapine group relative to the typical
antipsychotic group. Significantly increased levels of restlessness relative to the
control group were found in all other patient groups. That a patient group reported
normal levels of restlessness indicates that the increased levels of restlessness in the
other patient groups were related to medication rather than features of psychosis.
These findings will be addressed further in a later section (4.5.2).
Finally, the use of the scales must be considered. The visual analogue scales proved
very simple to use. Patients found completion of these scales easy and intuitive.
Responses were supplied rapidly and without the impression that patients felt the
scales an imposition (not the case with all the self-ratings administered, 4.3.2.2). A
wide range of scores was achieved amongst the patient group, increasing the validity
of the analysis; clustering of scores was seen only in the control group.
4.3.2.2 SWN
A very high level of inter-correlation was found between the sub-scales so the SWN
total score was used in analysis. The results from this analysis were disappointing.
The literature states that the SWN is highly sensitive to the effects of typical
antipsychotic agents, and is capable of distinguishing the effects of typical
antipsychotics from those of other classes of psychoactive agents including atypical
antipsychotics. However, when patient medication groups were compared, SWN
total score did not indicate any differences in group mean score between the patient
groups. All patient groups tended to exhibit higher mean scores than did the control
273
group; this tendency was not limited to groups receiving typical antipsychotic
medication. The scale did not differentiate antipsychotic treated patients from non-
antipsychotic treated patients or typical antipsychotic treated patients from non-
antipsychotic treated patients.
The reasons for this apparent failure must be examined. There are three possible
causes for this pattern of results:
1) The SWN is an inaccurate scale (i.e. criterion validity is low);
2) The SWN does not measure the phenomenon it purports to measure (i.e.
construct validity is low);
3) The patient medication groups do not differ significantly on the axis measured by
the SWN (the null hypothesis).
Total SWN score was found to show a very high level of correlation with BDI score.
The strength of this relationship indicates that the SWN exhibits a high level of
criterion validity as a measure of depression. In consequence, the first of the possible
causes (that the scale is simply an inaccurate measure) may be rejected. Two
alternative accounts remain: that the SWN is measuring some phenomenon other
than that which it purports to measure, and that there are no differences between the
patient medication groups.
The association with the BDI scores has further consequences for the evaluation of
the SWN. If the SWN is a valid measure of depression it implies that, if the SWN is
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indeed sensitive to the effects of typical antipsychotics, that the effects of these
agents include depression.
The SWN was developed on an empirical basis, the items used being selected from a
larger battery for their sensitivity to the effects of typical antipsychotics. That these
effects are closely related to depression is a common theme in literature concerned
with subjective experience of antipsychotics (Bandelow et al., 1992; Van Putten &
May, 1978; 1.2.4). This evidence suggests that if any differences exist between the
patient medication groups then they may be as likely to be detected by the BDI as the
SWN. In fact, the BDI results do not show any significant differences in mean score
between the patient medication groups. This may be interpreted as evidence
supporting postulated cause three, that the SWN did not find significant differences
between the patient medication groups because the groups do not differ on the axis
measured.
It was not expected that large differences in SWN scores would be found between
the groups. The severity of the physical features of DIP was low in almost all
patients, and there is some evidence for associations between the physical features of
EPS and subjective experiences (Casey, 1994) though it was found in this study that
the relationship is not a necessary one. Though the associated features (e.g.
bradykinesia and feelings of lethargy and a lack of psychic energy) do not co-vary
perfectly in terms of severity, it seems unlikely that very severe negative subjective
experiences would be present in a group of patients in whom severe parkinsonism
was rare. However, it must be noted that differences in subjective experience of
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medication between the patient medication groups were found. The visual analogue
scale for restlessness found significantly lower levels of subjective restlessness in the
clozapine group than in the typical antipsychotic group.
There are two remaining possible causes of the apparent failure of the SWN to detect
the effects of typical antipsychotic medication, namely that the construct validity of
the scale is low, and that no differences exist. The first of these accounts is supported
by the finding of increased levels of subjective restlessness associated with typical
antipsychotic medication. It is possible that the most comprehensive account
comprises a combination of these two versions. The SWN appears to be a valid
measure of the construct it taps, a construct comprising aspects of antipsychotic
associated dysphoria similar in nature (subjective experience and superficial
appearance) to depression. However, the construct does not include sensations of
restless, a major component of the typical antipsychotic experience. Though effects
of medication group were found on subjective ratings of sensations of restlessness
similar effects were not found on depression-related sensations. This suggests that
the 'failure' of the SWN has two contributory causes:
1) construct validity - the SWN does not tap sensations of restlessness;
2) null hypothesis - the groups do not differ in severity of depression.
In use, the SWN was unpopular with patients, unlike the visual analogue scales.
Complaints focussed mainly on the questions being difficult to understand. The
language of the questionnaire is complex and abstruse, perhaps a consequence of its
translation from the original German. Many patients needed help from an
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investigator to understand what the questions were asking of them. Further, the
searching nature of the questions and the degree of introspection needed to answer
them was often felt to be an imposition. Those patients being assessed on a repeat
basis objected to repeating this questionnaire though not the other parts of the
assessment. In addition, the sheer number of items present in the scale makes it time-
consuming and arduous to complete, this being the case even for the control group.
4.3.2.3 Summary of subjective features of parkinsonism
The results of the measures of subjective experience (visual analogue scales) provide
clear evidence of the presence of subjective restlessness associated with typical
antipsychotic medication. However, the evidence is more equivocal on the presence
of other aspects of subjective experience of antipsychotics. Though some patients'
scores on the SWN indicated a lack of subjective well-being, these included patients
who were not receiving antipsychotic medication, either typical or atypical. Scores
were not higher in patients receiving typical antipsychotics than in other medication
groups. Further, there was a very high level of correlation between scores on the
SWN and self-ratings of depression, suggesting that the lack of well-being may be
disease-related depression rather than medication-induced.
The results also indicate that patients are relatively unaware of the severity of their
physical parkinsonism. Ratings of the subjective sensation of slowing are associated
with depression rather than objective evidence of slowing, and ratings of subjective
restlessness are only weakly related to observer ratings of restlessness.
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In terms of the evaluation of the assessment methods the findings were similarly
mixed. The visual analogue scales proved to be sensitive markers of the severity of
subjective sensations. Combined with their simplicity and ease of use this makes
them a powerful tool. In contrast, the SWN proved ineffective at distinguishing the
effects of medication from features of psychosis. Though criticism is made of the
limited construct employed in the scale, the results emphasise the similarity of the
effects of medication to features of psychosis and the difficulties patients as well as
physicians have in distinguishing the two types of phenomena.
4.3.3 Summary of the prsence of cognitive and subjective features of parkinsonism
in DIP
The evidence examined in this section demonstrates the presence of non-physical
features of parkinsonism and other subjective effects of antipsychotic medication in
the patient group. It must be noted that not all the adverse effects of typical
antipsychotics are parkinsonian: for example, though akathisia has been described as
a component of parkinsonism, it may occur in the absence of parkinsonism.
The evidence from the CANTAB reaction time test demonstrates unequivocally the
presence of a non-physical feature of parkinsonism. An impairment in motor
planning was found in a significant proportion of patients. The presence of this
impairment was associated with greater severity of bradykinesia; it is this association
with bradykinesia which confirms that the impairment is parkinsonian. Though the
presence of the impairment and the association with bradykinesia had been
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demonstrated in Parkinson's disease (Evarts et al., 1981; Flowers, 1978), they had
not previously been demonstrated in DIP.
Evidence was found of subjective sensations of slowing in all patients; these
sensations were associated with depression. Though depression has been described in
Parkinson's disease, it may be due to other causes. Some of the patients assessed in
this study were treated for depression as a major affective disorder (many of whom
were in the typical antipsychotic medication group) and depression has been
described as a feature of schizophrenia (Knights & Hirsch, 1981).
It is difficult for the assessor to determine which of these possible mechanisms is
responsible for the depression observed in an individual patient. However, when
groups of patients are contrasted the comparison between patient medication groups
may be informative. Despite the use of this comparison no differences were found
between patient medication groups in the extent of either depression or subjective
slowing. A similar pattern of results was found in ratings of subjective sedation
which correlated closely with both subjective slowing and depression. Though these
findings do not conclusively demonstrate the absence of medication-related sedation,
slowing and depression, they provide no evidence that the presence of these
sensations was related to medication.
Though the patient medication groups did not differ in the levels of slowing or
sedation reported, differences were found in levels of subjective restlessness. Mean
levels of restlessness were higher than in the control group in all patient groups
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except for the clozapine group. The mean level in the clozapine group did not differ
from that in the control group and was significantly lower than in the typical
antipsychotic group.
The demonstration of subjective effects associated with medication indicates the
validity of the visual analogue scales. This provides confidence that the apparent lack
of differences between the patient medication groups in terms of ratings of slowing
and sedation represents a genuine lack of medication group effects rather than a lack
of discriminatory power in the analysis, and that the levels of slowing and sedation
(and associated depression) are not related to medication factors.
The results of the SWN did not demonstrate any significant effects of medication
group. Scores on the scale correlated closely with scores on the BDI, indicating that
the construct tapped by the SWN is very similar to depression. The patient
medication groups did not differ in subjective ratings of depression.
In summary, the results provide a demonstration of the presence of a
characteristically parkinsonian motor planning impairment and of sensations of
restlessness which may be a component of DIP.
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4.4 Appraisal of the study
The hypotheses set out in the introduction have been addressed using the results from
the clinical and instrumental assessments. However, it is necessary to evaluate how
successfully the questions posed have been answered, and examine the validity of the
process as a whole. Were the instrumental methods chosen, the patient group
recruited, the data collected, and the forms of analysis used appropriate to allow the
hypotheses to be confirmed?
4.4.1 Patients recruited
The patients were recruited mostly from acute wards and outpatients clinics. They
represented a typical cross-section of patients seen in psychiatric practice. This has
benefits in the extent to which results from this study may be generalised to the wider
population of psychiatric patients. However, there are disadvantages in terms of
research methodology in that care must be taken to avoid problems of confounding
by diagnosis within medication groups or vice versa. The patient groups used in
analyses are frequently heterogeneous. The medication groups tend to contain
patients with varying diagnoses, diagnosis groups contain patients receiving a variety
of agents.
Further, the prevalence of multiple drug therapy is high (2.5.5) with a majority of
patients receiving more than one psychoactive agent. This form of prescribing may
be intended to alleviate side effects of primary treatment agents, to improve response
to primary treatment agents, or to treat comorbid states for which a single agent is
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not effective (Dufresne, 1995). Supplementary medications in the typical anti¬
psychotic groups included additional typical antipsychotics, lithium carbonate,
tricyclic antidepressants, SSRIs, carbamazepine, and anti-parkinsonian agents
(procyclidine). Even in the clozapine group, half of the group were receiving
supplementary medication including SSRIs, other antidepressants, and even a small
regular dose of a typical antipsychotic (2.5.1 and 2.5.5).
In terms of research methodology, the use of treatment groups in which patients are
receiving varied supplementary medications is undesirable. However, it is a common
feature of prescribing practice in psychiatry and the figures for multiple drug therapy
in this study were in fact lower than in other, similarly diagnosed cohorts. In the
study of Burke et al. (1996) up to one third of schizophrenia inpatients were
receiving 4 or more medications. Within the context of an observational study,
treatment regimes cannot but reflect the high prevalence of multiple drug therapy in
clinical practice.
Efforts to recruit patients receiving relatively pure treatment regimes had adverse
consequences for the size of the patient groups. Though ideally larger groups with a
more homogenous composition would have been recruited, it proved difficult to
identify sufficient numbers of suitable patients. Limited group sizes had a
detrimental effect on the analytical power of the study, reducing the significance
level of group effects. It should be noted that few patients who had been asked to
take part refused to do so, and no patients withdrew from the instrumented stage of
the assessment.
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At the top of this section it was noted that the patients recruited comprised for the
most part a cross-section of patients in acute wards and outpatient clinics, and the
heterogeneity of the patient groups discussed. Both of these factors may have
affected the extent to which some of the results from this study could be compared
with those from other studies. Failures to demonstrate the existence of certain
features of parkinsonism, or other medication-related phenomena in this patient
group have been described elsewhere (slow resting tremor under typical
antipsychotic medication, 3.9.3.1; slow resting tremor under lithium therapy,
3.9.3.2). Possible accounts for this failure were suggested earlier, focussing on
differences between the patient groups involved in this study and the others, and
differences in prescribing practices. It is known that patients who are older or whose
symptomatology is more chronic in nature, are more susceptible to parkinsonism. In
addition, many studies are conducted using patient groups in which high potency
high dose medication regimes are the norm. Both of these factors may have acted to
reduce the likelihood of finding evidence of the above phenomena in this patient
group.
4.4.2 Criteria
When the accuracy of a new measure is to be evaluated a Gold Standard criterion is
used to establish validity. The worth of the evaluation, and hence the extent to which
the validity of the measure can be established, is dependent upon the accuracy of the
criterion.
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The use of observer-ratings as criteria has significant weaknesses. Though intra-rater
and inter-rater reliability is high for the scales used, they are dependent upon the skill
and experience of the rater, and cannot be truly objective. The ordinal nature of the
ratings also affects accuracy. The limited number of possible responses tends to
increase the apparent reliability of the assessments when inter- or intra-rater
reliability is evaluated, though the sensitivity of the measure to small changes in
condition is reduced. Floor effects may also occur where severe dysfunction is rare.
A further consequence of an ordinal response paradigm for the statistical analysis is a
detrimental effect on the power to detect effects of medication group due to the need
to use non-parametric statistical tests.
The weaknesses of some ratings were made apparent when their ability to detect
minor differences between medication groups in the severity of slowing was
contrasted with that of the Jebsen test (3.10.1.4). In this evaluation the accuracy of
the Jebsen test proved greater than that of the TAKE and ESRS single-item ratings of
bradykinesia.
Further, there are difficulties with the constructs used to assess some features. This
applies particularly to rigidity (4.1.4), though to some extent tremor too (4.1.6 and
4.1.7). If the criterion to be used is felt to be inaccurate, the investigator must rely




The accuracy of the instrumental measures was evaluated relative to the observer-
ratings criteria. The analysis included calculation of the correlation between the
measures and the criteria, and the relative sensitivity and specificity of the measures.
These latter two properties indicate respectively the ability of the measure to
successfully identify patients who exhibit the disorder and to reject those who do not.
Within the limitations of the other factors affecting the study these means of analysis
were the most appropriate, allowing the accuracy of the measures to be quantified
relative to that of existing criteria and the validity of the measures to be established.
4.4.4 Instrumentation selected
The instrumentation methods used in the study were selected examples of particular
genres of objective assessment. It was necessary to determine whether the methods
used were valid and then to consider to what extent the findings could be generalised
to other instrumental measures of the same features.
4.4.4.1 Jebsen
The Jebsen test was selected because it provides a comprehensive assessment of
motor performance. It has been demonstrated to be accurate and reliable, and its
results do not exhibit practice effects (Jebsen et al., 1969). However, the test is
dependent upon cumbersome equipment and its comprehensive nature makes it time-
consuming to complete.
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To investigate the role of performance measures in DIP it was necessary to use a test
known to possess good properties and validated in a number of different patient
groups. It could then be ensured that a failure to demonstrate validity of the measure
was an indication that performance measures were an inappropriate means of
assessing bradykinesia rather than simply that an inaccurate measure had been used.
In order to investigate construct validity it must be ensured that a lack of criterion
validity may be discounted as a possible source of invalidity.
The suggestion was made that comparable information to that obtained from the
Jebsen might be achieved using simpler and quicker performance tests; such tasks
would be more suitable for clinical use. Numerous suitable tasks exist, some having
been previously used in Parkinson's disease where the Jebsen has not. However the
accuracy and reliability of these tests have not been investigated to the same degree
as the Jebsen test. Any such measures would need to be validated individually,
possibly against the objective criterion of the Jebsen test. However, the validity of
performance measures as assessors of bradykinesia has been demonstrated in
principle.
4.4.4.2 CANTAB
The CANTAB battery is even better validated in the literature than the Jebsen test. It
provides timing of movement speed to a greater accuracy than can be obtained using
manual timing (e.g. in the Jebsen test). As with the Jebsen test as an example of a
performance measure, it was vital to ensure that failure to demonstrate validity in the
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use of a reaction time test as a measure of bradykinesia was not the result of an
inaccurate measure but attributable to a lack of construct validity.
The construct validity of the CANTAB reaction time test was demonstrated though it
may be of a lower level than that of the Jebsen test. As a means of evaluating the role
of reaction time measures in assessing bradykinesia the CANTAB test proved very
appropriate. It allowed the comparison of this type of measure with performance
measures such as the Jebsen test. The very simple construct underlying reaction time
tests means that the findings obtained using the CANTAB test may be generalised to
any accurate reaction time test.
4.4.4.3 Rigidity
The positive feedback device had been used previously and validated in other patient
groups. Unlike other methods of rigidity instrumentation reviewed in the introduction
it is theoretically sound. The validity of this device in this patient group was
examined earlier. The positive feedback device demonstrates a reasonable level of
validity; though it is perhaps less accurate than the bradykinesia instrumentation
used, this may be due in part to floor effects (severe rigidity was very rare). There
were also problems with subject compliance (not specific to patient groups) with the
demands of the assessment.
As with the instrumentation methods selected to assess other features of DIP it was
essential to select a well validated measure of rigidity. The theoretical construct
validity of the positive feedback device makes it a more appropriate choice than
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other existing methods of rigidity instrumentation. However, the failings of the other
methods make it difficult to generalise from the results obtained in this study.
4.4.4.4 Tremor
The principle methods of tremor transcription via accelerometry and analysis of
tremor frequency composition using FFT are well established in the literature.
Accelerometry is an accurate modern method of transcribing tremor activity. Unlike
other older methods it is non-intrusive, relying upon a small lightweight electronic
sensor fastened to the finger by a velcro strap rather than fastening the patient to a
mechanical device. The interface and software used in this study were new but are
standard procedures. There is little consistency in the literature over the optimal
method of quantifying differences in tremor frequency composition but the algorithm
used in this study had been previously validated in studies which found positive
results (Caligiuri et al., 1989b; Caligiuri et al., 1991; Caligiuri & Lohr, 1993); there
is no indication from other authors that it is invalid.
The two quantification procedures used must be considered separately, as they were
analysed earlier. The criterion validity of the postural tremor amplitude method was
demonstrated but it is unclear whether the construct has much relevance to other
measures of treatment success. Specifically, the procedure may not be worthwhile to
achieve the extra accuracy gained over simpler methods of assessment.
No evidence was found of an association between resting tremor frequency ratio and
other measures of parkinsonism. As there were no indications of failings in the
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instrumentation and the tremor frequency characterisation analysis had found
evidence of medication group differences in tremor frequency composition this was
attributed to characteristics of the patient group.
The methods selected for the study were highly appropriate for their purpose.
Accelerometry, the FFT algorithm, and the quantification procedures used (postural
tremor amplitude and resting tremor frequency ratio) are all well supported in the
literature. The findings, as they pertain to the constructs examined, may be
generalised to other valid instrumentation procedures. However, it is worth noting
the comments made above concerning the possibility that particular characteristics of
the patient group in this study may have contributed to the apparent failure to
replicate previously published findings.
4.4.5 Hypotheses
This section considers the hypotheses used, how appropriate they were and how well
they were addressed.
4.4.5.1 Instrumentation has a role in the assessment of DIP
This hypothesis was at the heart of the project. Instrumentation to assess the features
of parkinsonism has been investigated in many other studies but, the majority of
these studies have focussed on a single feature of parkinsonism (and a single method
of instrumentation). All of these studies have addressed simply the validity of the
particular method and not considered whether there is a meaningful role for the
procedure question. The role of instrumentation as a whole was a question which had
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not previously been addressed explicitly, and one which deserved this degree of
attention.
4.4.5.2 Bradykinesia is the predominant feature of DIP
The predominance of bradykinesia in Parkinson's disease was noted often in this
work. Clinical experience suggests that it predominates to an even greater degree in
DIP. However, this question had not previously been addressed in a systematic
fashion. This hypothesis was phrased in a manner that enabled the issue to be
addressed using quantitative techniques.
4.4.5.3 Cognitive and subjective features of parkinsonism are present in DIP
The difficulties of distinguishing the superficially similar phenomena of DIP and
deficit symptoms of psychosis were discussed in the introduction. It was also
suggested that the boundary between these two domains of symptomatology was
central to treatment success and a major issue in modern psychiatry. This hypothesis
provided a means of empirically demonstrating that some deficits, externally similar




Results from the tremor instrumentation frequency analysis were used to characterise
the form of tremor found in patient medication groups relative to normal physiologic
tremor in the control group.
4.5.1.1 Results from this study
Medication group Tremor properties
Typical
antipsychotics
Non-significant increase in high frequency tremor activity in
posture.
Lithium Increase in postural tremor amplitude particularly in the high
frequency band.
Clozapine Increase in postural tremor amplitude in both high and low
frequency bands. Non-significant increase in resting tremor
amplitude particularly in the low frequency band.
Antidepressants Increase in resting tremor amplitude particularly in the high
frequency band
4.5.1.2 Results from the literature




Faster postural tremor (Lance et
al., 1963).
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DIP Slow resting tremor (Arblaster Resting tremor peak below 7 Hz
et al., 1993). (Arblaster et al., 1993), due to
Faster postural tremor; slow increased amplitude at lower
resting tremor may be rare in frequencies (Caligiuri et al.,
DIP (Owens, 1999). 1991).
Lithium Fine postural tremor, possibly Acute lithium tremor is of
related to essential tremor, increased amplitude; frequency
distinct from resting tremors composition is unchanged
(i.e. parkinsonism) and other (Pullinger & Tyrer, 1983).
postural tremors (Gelenberg & Chronic lithium tremor exhibits
Jefferson, 1995). lower peak frequency and is
possibly extrapyramidal. (Tyrer
et al., 1981).
Clozapine No work concerned with the properties of tremor under clozapine
could be found.
4.5.1.3 Comparison
The comparisons will be considered by medication group commencing with the
typical antipsychotic group, the primary focus of this study.
In the typical antipsychotic groups, the results of this study are inconsistent with the
published literature as they do not indicate the stereotypical slow resting tremor of
Parkinson's disease found by other authors (Caligiuri et al., 1991; Arblaster et al.,
1993). The reasons for this result are considered earlier (4.5.1.3). In essence it is
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believed to arise either from differences in the characteristics of the patients tested or
the medication regimes used in the different studies.
The pattern of tremor seen in the lithium-treated patients in this study is consistent
with descriptions of lithium tremor as a fine postural tremor (Gelenberg and
Jefferson, 1995). Some indications were noted of increases in low frequency
amplitude though not to the extent found by Tyrer et al. (1981). As with the absence
of slow resting tremor in the typical antipsychotic group the lack of slow resting
tremor may result from differences in the patient groups tested, some patients being
more susceptible to developing EPS than others.
No studies of instrumented tremor under clozapine therapy were found. However, the
increased amplitude of postural tremor is consistent with informal observations.
4.5.2 Clozapine and other atypical antipsychotics
The development of clozapine and its benefits over typical antipsychotics were
examined in the introduction. It was noted that clozapine is found to be highly
effective in the management of positive psychotic symptomatology yet is
significantly more tolerable than typical antipsychotic agents and has increased
efficacy in treatment-resistant cases. The relevant findings from this study involve
both objective and subjective indicators of tolerability and re-emphasise the
differences between clozapine and typical antipsychotics.
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It should be noted that the clozapine group is not in way a specially selected group.
Rather, this group of patients could be said to be 'negatively selected'. Clozapine is
prescribed at the Royal Edinburgh Hospital to two categories of patients. The first of
these categories comprises patients who have failed to respond to typical
antipsychotics, those with treatment-resistant schizophrenia. The second comprises
patients unable to tolerate typical antipsychotics, who exhibit severe levels of EPS
even with minimal doses. It would be reasonable to expect greater levels of
bradykinesia in a group consisting of patients who are likely to be receiving
relatively high equivalent doses, and patients likely to exhibit more severe adverse
effects relative to their antipsychotic dose. However, despite the selection bias, the
clozapine group demonstrated clear advantages over typical antipsychotics.
Firstly, the Jebsen test results (3.10.1) indicated that unlike all other patient groups,
and particularly the typical antipsychotic group, the clozapine group was not
significantly slowed relative to the control group. Psychomotor slowing may be a
feature of both DIP and psychosis (negative symptoms of schizophrenia and
depression), yet this patient group were unimpaired relative to the controls.
The predominant role of bradykinesia in DIP was fully discussed earlier, as was its
relationship to deficit symptoms of schizophrenia and global functioning including
psychosocial competence. The value of an antipsychotic agent which is effective
even in treatment-resistant schizophrenia yet has a low liability to cause DIP cannot
be over-emphasised.
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The second notable difference involved subjective experiences of medication. Levels
of sensations of restlessness, as indicated by the visual analogue scale were
significantly lower in the clozapine group than in the typical antipsychotic group, and
were not significantly higher than those in the control group (3.10.2). Subjective
restlessness is frequently associated with akathisia, and has been found to be a major
factor in non-compliance with medication (1.2.4).
Also discussed in the introduction was the development of other atypical
antipsychotics. These proposed successors to clozapine are hoped to provide all the
benefits of clozapine in terms of efficacy and neurological tolerability yet without the
dangerous adverse effects of clozapine. A small group of patients receiving these
'New Generation' antipsychotics were included in this study. The results from this
group must be viewed with extreme caution in light of the inadequate patient
numbers (see below), however the New Generation atypical antipsychotics appeared
to have a degree of tolerability midway between those of typical antipsychotics and
clozapine. This finding is consistent with the literature (Miller et al., 1998).
The small size of the New Generation group is in part due to the manner in which the
medication groups were recruited. It was originally intended to use a single atypical
antipsychotics group consisting of patients receiving either clozapine or one of the
New Generation atypical antipsychotics. However, preliminary results indicated that
though results of the clozapine group tended to form a cluster distinct from results of
the typical antipsychotic group, results of the New Generation group were midway
between the clozapine group and the typical antipsychotic group. To address this
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problem attempts were made to recruit more patients to both the atypical
antipsychotic groups. Though the clozapine group reached sufficient numbers it did
not prove possible to recruit more patients to the New Generation group within the
time available. The size of this group has adverse consequences for the power of all
statistical analyses involving this group. It is also necessary to note the presence of
different atypical antipsychotic agents within this group: it cannot be assumed that
there are not significant differences in the tolerability profiles of these different
drugs.
Despite these caveats, the findings appear to reinforce suggestions (Miller et al.,
1998) that clozapine is still unique in its level of tolerability.
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4.6 Implications for research and/or clinical practice
The primary thrust of this study was to investigate the role of instrumentation in the
assessment of DIP, hypothesising that such a role existed. The evidence collected
indicates that though instrumented assessment has a part to play this role may be
limited.
The assessment methods used were generally inconvenient and impractical for
regular use, relying upon awkward, cumbersome and often expensive equipment.
Though the literature indicated that information concerning tremor frequency
composition not available from observer ratings might mark global parkinsonism this
was not the case in this patient cohort.
Further, there is little evidence to suggest that accuracy is substantially greater than
with observer ratings. It was only with the use of performance measures to
instrument bradykinesia that greater accuracy could be demonstrated (3.10.1). Nor is
there much evidence to suggest a need for greater accuracy than can be obtained
using well-designed rating scales (though a case may be made for bradykinesia, see
next paragraph). The routine use of instrumentation would be justified only on
finding a method of instrumentation which is not only as accurate as observer ratings
but simple to use, cheap and portable.
The central role of deficit symptomatology in predicting treatment outcome was
noted in the introduction (1.1.3), as was the fact that these symptoms may occur as
features of both psychosis and parkinsonism. The great superficial similarities in
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some aspects of these disorders make it difficult to determine whether deficits
observed are features of psychosis or the adverse effects of medication (though some
investigators have suggested that this is possible on a longitudinal basis (Amador et
al., 1999; Carpenter et al., 1988)).
The association between cognitive deficit features of parkinsonism and bradykinesia
was also noted earlier. This link has been demonstrated in Parkinson's disease
(Mortimer et al., 1982) and now in DIP (3.6.2 - 3.6.3). It is proposed that assessment
of the severity of bradykinesia may allow an indirect monitoring of the severity of
parkinsonian deficits, free from confounding by features of psychosis.
However, as demonstrated earlier the accuracy of the performance measures of
parkinsonism was only moderate in the cross-sectional analysis. The procedures are
inadequate to accurately identify the presence of parkinsonism in a one-off
assessment. In the single case serial assessment (3.8) a number of observations were
made of clinical state using both observer-ratings and instrumental measures. In this
longitudinal follow-up situation the degree of correlation between the Jebsen test and
observer-ratings of bradykinesia indicated a very high level of accuracy in the results
of the test.
The routine use of performance measures of bradykinesia may be recommended as a
means of indirectly monitoring the development of non-physical features of
parkinsonism. These deficits may be identified as resulting from adverse medication
effects rather than features of psychosis and may thus be treated appropriately.
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